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THE ROLE OF GENETIC ALTERATIONS IN TUMOR INITIATION, 
PROGRESSION AND TRANSFORMATION 
Weiwei Zhang, Ph.D. 
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Supervisor: Wing C. Chan, M.D. 
Follicular lymphoma (FL) is the second most common lymphoma in the United States. 
Although it is generally an indolent lymphoma, FL is not curable, and, in about 30% of patients, 
the FL undergoes transformation into an aggressive lymphoma (tFL) with marked worsening of 
prognosis. To identify mutations preferentially present in tFL, we performed whole exome 
sequencing (WES) on paired FL and tFL arising in the same patients and developed a mutational 
analysis pipeline. After we identified potentially important genes that have been found to be 
mutated in our paired FL and tFL study, we constructed a custom capture platform including 
these genes as well as other genes known to be mutated in B-cell lymphomas. We were able to 
use this focused sequencing platform to analyze additional samples at greater sequencing depth. 
Clonal architecture and evolution can be readily identified; however, the DNA samples were 
fragmented using restriction enzymes, which compromised duplicate analysis.  We developed a 
new approach with a statistical model to solve the problems. Samples from uninvolved tissue of 
the same patients are commonly used to distinguish germline variants from somatic mutations; 
however, the germline DNA was often not available for our samples. , We designed a filtering 
based method to limit the number of germline variants that would be mistakenly called somatic 
mutations and validated this approach using a dataset with paired normal samples. We also 
introduced a novel idea based on machine learning to predict somatic mutations from paired FL 
and tFL samples without healthy tissue. Five machine learning algorithms were tested in 
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datasets with known somatic mutations, and their performance was evaluated by statistical 
measures. The results indicated somatic mutations can be reliably predicted. In order to provide 
complementary information, we integrated our mutation data with copy number abnormality 
data and found genes more frequently mutated in tFL cases. The recurrently mutated genes are 
often involved in epigenetic regulation, the JAK-STAT or the NF-κB pathway, immune 
surveillance, and cell cycle regulation, or are transcription factors involved in B cell development. 
As no entirely tFL specific mutations are found, the transformation event needs to cooperate 
with pre-existing alterations and future studies will focus on identifying cooperative mutations 
for FL transformation.  
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A. Lymphoma biology 
Lymphomas are tumors derived from lymphatic cells. Lymphomas have many subtypes, with 
the two main categories being Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). NHL 
contains approximately 90% of lymphomas, and the majority of NHL is derived from B-
lymphocytes at various stages of B cell differentiation (Table 1-1). A small percentage is derived 
from T-lymphocytes, and rarely from natural killer (NK) cells and dendritic cells1. The tumor 
behavior varies significantly, from indolent, e.g. Follicular Lymphoma (FL), to aggressive, e.g. 
Diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL). According to Revised 
European-American Lymphoma (REAL), DLBCL (31%) and FL (22%) are the two most common 
lymphoid neoplasms in the United States and Western Europe2. 
 
Table 1-1. WHO classification of mature B-cell neoplasms1. 
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A.1. Structure of the lymphoid system 
The lymphoid system plays a vital role in defense against pathogens from viruses to 
parasites.  It is comprised of lymphoid tissue and recirculating lymphocytes. 
Lymphoid tissue has two major forms, central (primary) lymphoid tissue and peripheral 
(secondary) lymphoid tissue (Figure 1-1). The bone marrow and thymus are the two organs of 
the central lymphoid system. They are the sites of B and T cell maturation respectively. The 
matured B and T cells express different antigen receptors and migrate into the peripheral 
lymphoid tissue to defend against pathogens invading the body. Cellular and humoral immune 
responses take place in the peripheral lymphoid tissue, which includes spleen, bone marrow, 
tonsil, mucosa-associated lymphoid tissues and lymph nodes. The spleen responds 
predominantly to blood-borne antigens. The bone marrow is both a central and a peripheral 
lymphoid organ because it gives rise to B and NK cells. The tonsil and mucosa-associated 
lymphoid tissues react to antigens entering via the surface mucosal barriers.  Lymph nodes 
mount immune responses to antigens or antigen presenting cells (APCs) entering through the 
afferent lymph vessel. Lymph nodes are major sites of B, T and other immune cells and provide 
sites for interaction of the lymphocytes, APCs and other cells. Lymph nodes are composed of 
three major areas, the cortex, paracortex and medulla (Figure 1-2). The cortex contains primarily 
B cells, some of which aggregate in primary follicles. When an immune response occurs, the 
follicles develop a central area, with large proliferating cells, termed a germinal center (GC). The 
paracortex contains primarily T cells and many antigen presenting cells. The medulla contains 
both T and B cells and many plasma cells and scavenger phagocytic cells.  Lymphocytes and 
antigens enter the cortex through the afferent lymphatic vessel and filter down through the 
paracortex and into medulla before leaving the lymph node via the efferent lymphatic vessel 
and moving on. 
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Figure 1-1. Major lymphoid organs and tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. Schematic structure of the lymph node. 
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A.2. B cell differentiation 
B cell differentiation in the central and peripheral lymphoid tissues involves epigenetic and gene 
expression changes. In general, B cell differentiation and migration occur through multiple 
stages, associated with changes in the immunoglobulin (Ig) gene loci, expression of cytokine and 
receptors and Ig protein (Table 1-2, Figure 1-3). A cluster of genes encoding the Ig heavy chain is 
located on chromosome 14. It includes a series of variable (V) genes, joining (J) genes, diversity 
(D) genes and C genes. Clusters of genes encoding the B cell receptor light chains are located on 
chromosome 2 and chromosome 22, respectively. Each cluster includes a series of V genes, J 
genes and one or more C genes, and only one of the light chains is used to construct the Ig 
molecule. DNA rearrangement generates a diverse array of antigen-specific molecules by 
shuffling, cutting and recombining individual V, D, and J segments into a heavy chain and similar 
recombination of individual V and J segments for the light chain immunoglobulin molecule. Two 
heavy chain and two light chain molecules transcribed from the rearranged IgH and IgL (Ig kappa 
and Ig lambda ) of a cell will be assembled into a full immunoglobulin molecule to attack one 
particular antigen without attacking the body itself during the B cell differentiation3. The first 
stage of differentiation starts when the hematopoietic stem cells in the bone marrow receive 
signals from bone marrow stromal cells and begin B cell development. The second stage is the 
CD34+ progenitor B cells express some B cell characteristic markers and initiate IgH 
rearrangement. The Ig gene recombination is initiated by the recombination-activating gene 1 
(RAG1)-recombination-activating gene 2 (RAG2) protein complex (Figure 1-4). At the third stage, 
the progenitor B cells differentiate into precursor B cells. The early precursor B cells involve the 
recombination of the D and J segments of the IgH. The late precursor B cells involve the 
rearrangement of the V segment to previous recombined DJ segments. This stage results in the 
complete rearrangement of the IgH gene. IgL rearrangement takes place only after the IgH gene 
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arrangement. It occurs in a similar manner to the rearrangement of IgH. In contrast to the IgH, 
the IgL does not possess D segment. Therefore, it only takes one step to form a V J segments. At 
the fourth stage, the precursor B cells differentiate into immature B cells. The light chain 
arrangement results in the expression of an IgM protein on the cell surface. At this stage, the 
immature B cells haven’t encountered any antigen yet and they are also unable to initiate an 
immune response to foreign antigens. At the fifth stage, the immature B cells leave the bone 
marrow and migrate to peripheral lymphoid tissues. With the expression of IgM and IgD 
together, the immature B cells give rise to mature naïve B cells. The mature naïve B cells have 
the capability of responding to antigen.  At the sixth stage, some of the mature naïve B cells 
encounter antigens and transform to extrafollicular B blasts, and later to short-lived plasma cells 
or primed B cells. Other mature naïve B cells form primary follicles. The primed B cells migrate 
into primary follicles with cognate T-cells and differentiate into centroblasts (CBs) with rapid 
proliferation. In this stage, somatic hypermutation occurs and provides additional variation that 
may improve the antibody responses to antigens as advantageous mutations lead to increasing 
affinity to antigen. The whole process is called affinity maturation. CBs may move to the light 
zone of the GC and become centrocytes (CC).  CC with advantageous mutations survive and 
differentiate into long-lived plasma cells or memory B cells. At the seventh stage, the memory B 
cells with IgM protein migrate to marginal zone. CC can undergo further DNA rearrangement to 
change the class of the Ig through isotype switching. Long-lived plasma cells with IgG, IgA and 
IgE predominantly stay in the bone marrow. As a result of B cell development, naïve mature B 
cells, GC B cells, memory B cells and long-lived plasma cells are the four major forms of mature B 
cells. FL s are at the developmental stage of GC B cells.  
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Table 1-2. B cell development and the corresponding lymphoma2. 
 
 
Figure 1-3. Events in B cell development2. 
 
8 
 
 
Figure 1-4. RAG protein involvement in the rearrangement of immunoglobulin gene segments4. 
RAG protein complexes are illustrated as light purple and light orange colored domes even 
though all RAG protein complexes are identical. This complex breaks double-stranded DNA 
between the B cell receptor coding segments and recombination signal sequences during the 
process of VDJ recombination. A ubiquitously expressed set of non-homologous end joining 
proteins repairs and joins the cleaved DNA ends afterwards. 
  
A.3. FL 
FL, the second most common histologic subtype of NHL in North America, arises from the 
proliferation of malignant germinal center B cells (Table 1-2). Despite the fact that FL is generally 
slow-growing, it is still not curable and it becomes less sensitive to chemotherapy when relapse 
happens. Up to 90% of FL cases have a translocation between chromosomes 14 and 18 leading 
to the overexpression of BCL2 in germinal center B cells (Figure 1-4). The BCL2 gene is normally 
found on chromosome 18q21, and the translocation moves the gene near to the 
immunoglobulin heavy chain enhancer element on chromosome 14. t(14;18) is the classical 
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cytogenetic aberration in FL, but there are other translocations of chromosome 18, such as 
t(2;18) or t(18;22), which juxtapose BCL2 to the loci of the IgL chain (κ or λ), which also result in 
BCL2 overexpression5,6. However, the translocation alone is insufficient for the establishment of 
FL but it provides a survival advantage for the cell in the germinal center microenvironment, 
where the cell can accumulate additional abnormalities. Clearly, these secondary events are 
necessary to contribute to disease progression.  
A.4. Transformed follicular lymphoma (tFL) 
FL can transform into an aggressive lymphoma with poor prognosis. There are two main 
types of tFL, DLBCL and Burkitt-like lymphoma (BLL). DLBCL is the most frequent tFL; gene 
expression profiling studies have demonstrated that DLBCL consists of two major distinct 
molecular subtypes, germinal center B-cell like (GCB) DLBCL and activated B-cell like (ABC) 
DLBCL. GCB DLBCL arises from normal germinal center B cells whereas ABC DLBCL arises from 
postgerminal center (Post GC) B cells and has significant lower overall survival rate than GCB 
DLBCL. BLL is currently known as unclassifiable B cell lymphoma with features that are between 
DLBCL and BL.  
In most cases, tFL emerges from the FL clone by acquiring additional abnormalities that give 
it a growth advantage and make it more aggressive and able to grow without the GC 
microenvironment. In a few instances, however, the DLBCL appears to arise from the emergence 
of an unrelated second lymphoma. It is very important to identify the transformation because it 
represents a change in the biology of the disease and in the patient’s clinical course. After FL 
transformation, the patient has a more rapidly progressing disease and short survival, commonly 
less than 2 years. Occasionally, tFL is found at the presentation of the lymphoma and this type of 
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tFL may be biologically distinct from the usual type that arise later in the course of a FL and has 
better prognosis7. 
B. Genetic abnormalities 
B.1. Genetic abnormalities that contribute to the development of FL 
The t(14;18) is considered as the first hit in FL development (Figure 1-5). It causes 
dysregulation of tumor cell apoptosis, but it is not sufficient to result in clinical disease. 
Therefore lymphomagenesis requires a number of additional genetic and cytogenetic events. 
These later events change the biological and clinical behavior of the clone, and finally generating 
the FL. Aberrant BCL2 overexpression allows the survival of the abnormal GCB cells in the GC 
microenvironment where continuous somatic hypermutation or recombination activity in class 
switch increase the instability of the genome and probability of second hits that promote the 
formation of FL. A number of secondary chromosomal alterations have been reported, for 
example, the most common alterations are the partial trisomies of chromosomes 1q, 7, 8 and 
18q, and 1p and 6q deletion. Deletion in 6q usually follows by the deletion of 1q5. Some genetic 
abnormalities are associated with late disease or transformation8,9. In rare case, the histologic 
progression of FL involves MYC rearrangements10. 
BCL6 translocation is also common in FL and can occur in cases with or without the classical 
BCL2 rearrangement. Constitutive overexpression of BCL6 may be an important mechanism is 
the pathogenesis of FL11,12. 
With next generation sequencing (NGS), many mutations have also been recently identified 
in multiple studies (Figure 1-5), for example, KMT2D (MLL2), EZH2, and CREBBP are often 
mutated in early FL8,13-16. 
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Figure 1-5. Model of B cell NHL histogenesis and pathogenesis2.  
 
B.2. Genetic and cytogenetic abnormalities that drive transformation 
DLBCL is considered de novo if it develops in the absence of a precursor malignancy such as 
FL. In contrast, when a person is diagnosed with DLBCL but he previously or concurrently had FL 
diagnosis, then it may represent a tFL. If the DLBCL and the FL share a common precursor, they 
should share many of the copy number abnormalities (CNAs) and mutations, thus supporting 
the idea that they are clonally related and not independent tumors. FL is usually indolent, but 40% 
of patients will develop tFL with poor prognosis. There must be secondary genetic and 
cytogenetic abnormalities that drive the transition from an indolent to an aggressive stage. 
Identification of these abnormalities that drive transformation is critical for a better 
understanding of the progression and evolution of tFL. 
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To date, studies of the genetic abnormalities in de novo DLBCL have revealed a large 
number of findings, for example: chromosome alterations affect 3q27 recurrently in DLBCL. This 
region includes BCL6, a transcriptional repressor that belongs to the family of transcription 
factors containing zinc-fingers and is required for GC formation and B cell immune response. 25% 
of GCB DLBCL cases have chromosomal rearrangements of BCL2. It is possible that some such 
cases may actually represent transformation of a clinically inapparent FL.  
Current concepts describe the transformation as the result of heterogeneous genetic and 
cytogenetic abnormalities. The genetic abnormalities in transformation have been represented 
in four models8. The four models are grouped into 2 categories, linear evolution from FL and 
divergent evolution from a preclinical progenitor. In fact, transformation is all linear. The 
divergent model is a sampling artifact because the tumor sampled does not contain the direct 
precursor of the transformed tumor. However, the precursor clone for the transformed tumor 
may be a minor subclone at the time of sampling and it is very informative to identify these 
subclones in the study of clonal evolution in transformation.  
Multiple studies suggest several discrete mechanisms are involved in driving transformation 
from FL. These mechanisms include TP53 mutations9 and deletions, inactivation of p16 and 
dysregulation of MYC17.  
DLBCL molecular subtypes have been reported to have different oncogenic pathways. SPIB 
gain or amplification, deletion of CDKN2A tumor suppressor locus and trisomy 3 happen more 
commonly in ABC DLBCL whereas amplification of mir-17-92 and loss of the tumor suppressor 
PTEN are only recurrent in GCB DLBCL18. Similarly, mutations affecting the NF-kB pathways are 
much more prevalent in the ABC subtype.  It would be highly interesting to compare the copy 
number variation (CNV) and mutation profiles of tFL with these DLCBL subtypes. 
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C. CNV analysis   
CNV refers to gain or loss of chromosomal regions in the genome. CNV regions vary from 
kilobase range change to gain or loss of entire chromosomes. Most CNV is stable and heritable. 
CNV can cause disease, affect gene expression level and change phenotype. CNV analysis can be 
used to detect chromosomal abnormalities that contribute to lymphoma. 
C.1. CNV general technology 
Techniques to identify cytogenetic aberrations have changed drastically in the past decade. 
Fluorescent in situ hybridization (FISH), comparative genomic hybridization (CGH) and array 
comparative genomic hybridization (aCGH) are three technologies that have been widely used in 
molecular cytogenetics. FISH is based on the capability of a fluorescent–labeled single stranded 
DNA to hybridize to its complementary DNA sequence19. FISH is often used to identify 
chromosomal rearrangement including translocations, inversions, etc. but CNVs can also be 
detected. CGH is designed for CNV detection. It can efficiently compare two genomic DNA 
samples by competitive hybridization to normal metaphases19. Normal genomic DNA serves as 
the standard for comparison of the test DNA. Compared to standard FISH, which can only test 
one or several genes at a time, CGH is able to detect gains or losses genome wide. aCGH utilizes 
the same principles as traditional CGH but has tremendously higher resolution. Hybridizing is 
performed on a high density DNA array format and able to detect small CNVs in the genome20. 
C.2. Single-nucleotide polymorphism array analysis procedure 
In our previous study, DNA from FL and tFL tumors was hybridized to high-resolution 
GeneChip Human Mapping 250K Nsp single-nucleotide polymorphism (SNP) arrays. In contrast 
to aCGH, which uses competitive hybridization of fragmented tumor DNA and control DNA 
labeled with different fluorophores to a microarray platform to detect CNAs, SNP array contains 
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oligonucleotide probes that interrogate both copy number (CN) and SNP sites. Therefore, SNP 
arrays are able to detect both DNA CN and SNP-based genotypes at submegabase resolution, 
including loss of heterozygosity (LOH), and uniparental disomy21. 
A circular binary segmentation algorithm22 was used to analyze the resulting data. This 
algorithm segmented chromosomes into similar log2 ratios and connected the change point to 
the locations of regions with aberrant DNA copy numbers. Therefore, it identified regions of CN 
gain or loss. Minimal common regions (MCRs) were determined for recurrent CNAs (rCNAs) in all 
samples.  
D. NGS analysis 
NGS, also known as high throughput sequencing or massively parallel sequencing, has 
dramatically changed the way scientists extract genetic information from biological systems 
(Table 1-3). These technologies help us to develop great insight into the abnormalities affecting 
the genome, transcriptome and epigenome through DNA sequencing of genomic DNA, cDNA 
and bisulfite treated DNA with cheaper cost. NGS allows us to discover point mutations as well 
as structural alterations such as indels, inversion and translocations that contribute to diseases. 
Sequencing of the transcriptome provides us the capability to identify changes of gene 
expression, alternative splicing, gene fusions, mutations and non-coding RNA species. 
Sequencing after Bisulfite treatment can be used to determine the global cytosine methylation 
status of DNA. 
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Table 1-3. Multilevel high throughput NGS23. 
 
D.1. NGS: general technology 
There are multiple platforms for performing NGS and the Illumina platform is one of the most 
commonly used technologies. It has been reported to have high sensitivity and reliability in DNA 
mutation detection. It is a sequencing method based on engineered polymerases and reversible 
terminator bases. Under the catalysis of the polymerase, the DNA templates are copied base by 
base using the deoxyribonucleotide triphosphates which are fluorescently-labeled and reversibly 
terminated. During each cycle, the fluorescence signal is captured by a build-in camera at the 
point of incorporation and the nucleotides are identified. After that, the fluorescence label and 
the blocking group are removed allowing the addition of the next bases. The critical difference 
NGS extends this process across millions of DNA fragments in a massively parallel fashion 
instead of sequencing a single DNA fragment.  
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D.2 Whole exome sequencing (WES) analysis procedure 
WGS sequences all DNA sequences in an organism’s genome, and has more uniform quality 
for the identification of variants as well as large insertions and deletions and other structural 
alterations.  On the other hand, WES is an efficient strategy to selectively sequence the exome. 
The exome include all regions in genes that are translated into protein including also splice 
junctions and some regions important in regulating transcription. Since the exome constitutes 
only about 1% of the human genome, WES is more cost efficient and less computationally 
intensive than WGS. Sequencing depth can generally be higher.   
E. Custom capture panel 
To obtain mutations preferentially present in FL and tFL, we performed WES on paired FL 
and tFL arising in the same patients and developed a mutational analysis pipeline. Even if the 
cost of sequencing decreases a lot, it is still expensive to sequence a large number of samples. It 
is also time-consuming to analyze the huge amount of data, especially since the mutated genes 
that contribute to the disease are limited in number. Therefore, once we identified potentially 
important genes that are mutated from WES studies, a focused sequencing platform to analyze 
genes of interest can be constructed. This platform can analyze a large number of samples at 
greater sequencing depth and less cost to identify transformation associated mutations and 
their possible cooperation in the transformation process.  
F. Application of genetic abnormality analysis in cancer research  
Gains and losses of CN can range in size from thousands to millions of bases. For large CNAs, 
it can be difficult to determine which genes contribute to cancer.  It is possible that multiple 
genes in these regions are contributing.  Examining GEP and mutations may help to identify the 
target genes in these regions.  
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NGS provides a great opportunity to exam the genetic mutations at a genome-wide level. 
We are able to go through the mutations in coding regions and splice sites, and have a view of 
the mutational landscape of FL and tFL, and figure out the alterations that cause transformation. 
We incorporate CNV data into mutation studies so that the combination of the two approaches 
can provide a comprehensive view of genetic abnormality. The integrated data help us to 
identify the abnormalities associated with transformation of FL and characterize the progression 
of FL. 
G. Overview of this dissertation 
The motivation of the study is to identify genetic changes that would provide important 
insight into the mechanisms of FL tumorigenesis and transformation; however, there are a 
number of obstacles. One obstacle is the shortage of matching normal samples in FL research. 
The normal sample is currently the only way to confidently filter out all germline variants but it 
is difficult for researchers to collect normal samples in the FL field. Another difficulty is the 
limited number of cryopreserved or fresh tumor samples available for analysis.  There are also 
computational challenges to overcome such as removal of passenger mutations and duplicate 
analysis. 
In this study, we applied a variety of statistical methods to improve the performance of the 
analysis. We introduced a binomial distribution based statistical model to estimate duplicate 
ratio in custom capture panel that uses restriction enzymes to capture the genes of interest. 
Instead of applying typical log-rank in survival analysis, advanced test statistics with different 
weights were provided based on abnormalities that occur in the early or late stage of FL 
development. We developed a variety of mutation detection pipelines for different NGS 
platforms and sample combinations. We applied a two-step filtering method to identify somatic 
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mutations based on the biological features of FL to provide potential driver mutations that 
contribute to the disease. We also proposed a novel computational model using the machine 
learning concept to distinguish the germline variants from somatic mutations without 
corresponding normal samples in sequencing analysis.  
The rest of this dissertation is organized as follows. In chapter 2, we introduce the pipelines 
on which the methods were built and evaluated. We also describe the samples to which our 
methods were applied and the datasets in which our methods were validated. In chapter 3, we 
report the initial results and validation results of the methods applied in the analysis. In chapter 
4, we associate the CN abnormalities with our mutation data, integrate our mutation data with 
other two datasets, combine the studies with other biological analysis, and generate more 
comprehensive understanding of FL initiation and progression. In chapter 5, we describe the 
future study in identifying epigenetic alterations, contributions of mutations in regulatory region 
and non-coding regions, functional study of the individual mutated genes in FL and 
transformation, extending our current pipelines to FFPE samples, and improving features 
applied in machine learning models. In chapter 6, we summarize how the pipelines and 
approaches designed in this thesis significantly improve the data analysis, provide reliable 
results, and detect novel abnormalities in FL and tFL research.  
 
 
 
 
 
19 
 
 
 
 
 
 
 
CHAPTER II 
METHOD 
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A. WES and data analysis 
A.1. WES dataset 
We obtained 12 paired FL and tFL frozen tissue samples from the same patients before and 
after transformation. The samples were provided by the University of Nebraska Medical Center 
(UNMC), Lymphoma/Leukemia Molecular Profiling Project (LLMPP), or Aarhus University 
Hospital. This study was approved by the UNMC institutional review board.  
A.1.1. Sample and patient materials 
The time between the FL diagnosis and transformation varied from 1 year to 9 years. The tFL 
samples were all diagnosed as DLBCL by a panel of LLMPP hematopathologists. Our previous 
gene expression profiling (GEP) analysis had classified the tFL samples as activated B-cell (ABC)-
like, unclassifiable (UC), or germinal center B-cell (GCB)-like tFL. The clonal relationship between 
the biopsies was confirmed by comparing the genetic profile based on clinical data, SNP array 
and/or sequencing to confirm that there was close similarity between pairs. When BCL2 status 
was unknown, BCL2 rearrangement was assessed by PCR to determine if the frequency of 
t(14;18) positivity expected for an FL dataset was observed in the tFL dataset. We did PCR with 
primer that prime in 3 places where the break point often occurs, major breakpoint region, 
minor cluster region and intermediate cluster region (Table 2-1). 
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Table 2-1. Sample and patient information for WES. 
 
A.1.2. Library preparation 
Library preparation was performed according to the manufacturer’s protocol using 
Illumina’s TruSeq DNA sample prep kits. Exome capture was performed according to the 
manufacturer's protocol using either Illumina's TruSeq exome enrichment kit (11 paired samples) 
or Agilent's SureSelect exome enrichment kit (1 paired sample). 1 µg of DNA per sample was 
used for capture, and the equivalent of 1 to 3 samples was sequenced per lane on an Illumina 
HiSeq2000 or HiSeq2500 sequencer.  
To prepare the samples using the Illumina’s TruSeq exome enrichment kit, DNA was sheared 
into 100-300 base-pair long fragments using a Covaris sonicator. After fragmentation, ends were 
repaired, A-overhangs were added at the 3'-end of the DNA fragment, and adaptors were 
ligated to both ends of the DNA fragments. These DNA fragments were then denatured into 
single-stranded DNA and hybridized to biotin-labeled DNA probes (Truseq) or biotin-labeled RNA 
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probes (SureSelect) specific for the targeted regions. After enrichment using streptavidin beads, 
the enriched DNA fragments were eluted from the solution. After amplification, the DNA 
molecules were ready for cluster generation and subsequent sequencing. 
A.2. Pipeline for calling variants in WES 
As shown in Figure 2-1, the pipeline is as follows: After sequencing, the raw read quality was 
first evaluated by FastQC (v0.10.1), and then mapped to human reference genome hg19 using 
the Burrows-Wheeler Aligner (BWA) (0.7.5a-r405). Genome Analysis Toolkit (GATK) (v3.1-1-
g07a4bf8) was used for local realignment and base quality recalibration. Duplicate marking was 
done with Picard (v1.115). Variant calling was performed with VarScan2 (v2.3.6). Basic filtering, 
including base quality, total read depth, read depth supporting the reference sequence, read 
depth supporting the variant sequence, forward read depth supporting variant and reverse read 
depth supporting variant, was applied to filter out unreliable variants. The variants were then 
annotated using ANNOVAR24. We filtered out known germline variants (single-nucleotide 
polymorphisms [SNPs] and indel polymorphisms) based on dbSNP138 and only selected 
mutations that were nonsynonymous, stop gain, stop loss, insertion or deletion in the coding 
region or splice sites. Since we have paired FL and tFL samples, we categorized our mutations 
into three types: FL-unique mutations indicated mutations only detected in the FL sample not 
the paired tFL sample; tFL-unique mutations indicated mutations only detected in the tFL 
sample not the paired FL sample; and shared mutations indicated mutations detected in both 
paired FL and tFL samples. 
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Figure 2-1. Pipeline designed for WES with paired sample. 
 
A.3. WES performance analysis 
In order to evaluate the performance of WES, we applied sequence performance analysis 
(Figure 2-2) to check the total number of reads used for the alignment, the number of reads that 
were successfully mapped to the reference, the number of aligned reads that were mated with 
their paired reads, the fraction of duplicates in the sequenced reads, the regions in the 
reference that were aligned by the reads, the depth of each position in the aligned region, and 
the coverage and depth of coding regions and splice sites. 
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Figure 2-2. Pipeline designed for WES performance evaluation. 
 
A.4. Pipeline validation 
Sanger sequencing is an accurate analysis method for variants validation when the variant 
frequency presents at 20% or greater in the samples. We applied Sanger sequencing to validate 
50 variants to confirm the reliability of the WES pipeline. 
B. Custom capture panel sequencing and data analysis 
B.1. Custom capture panel dataset 
Samples included in the custom capture panel pipeline were all frozen tissues including 7 
pairs of FL and tFL samples, 4 triplets with a tFL and two FL samples, and 15 single tFL samples. 
The 7 pairs of FL and tFL samples were obtained at FL diagnosis and at later transformation 
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diagnosis.3 out of these 7 pairs of FL and tFL samples were performed by WES earlier and 
resequenced for the performance comparison. The 4 sample triplets were obtained along with 
the disease progression. The samples were provided by the UNMC, the LLMPP, or Aarhus 
University Hospital. This study was approved by the UNMC institutional review board. 
B.1.1 Sample and patient materials 
The time between the FL diagnosis and transformation varied from less than 1 year to 7 
years. The tFL samples were diagnosed as DLBCL by a panel of LLMPP hematopathologists. Our 
earlier GEP analysis had assigned the tFL samples as ABC-like, UC and GCB-like. When BCL2 
status was unknown, BCL2 rearrangement was assessed by PCR to determine if the frequency of 
t(14;18) positivity expected for an FL dataset was observed in the tFL dataset. We did PCR with 
primer that prime in 3 places where the break point often occurs, major breakpoint region, 
minor cluster region and intermediate cluster region (Table 2-2). 
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Table 2-2. Sample and patient information for custom panel sequencing. 
 
B.1.2. Custom capture panel design 
The potentially interesting genes that were included in the custom capture panel were 
selected based on the preliminary analysis of some of our WES analysis and previously published 
lymphoma sequencing studies. The custom capture panel allows us to sequence genes of 
interest in a large number of samples at greater sequencing depth. We expected the custom 
capture panel to allow us to evaluate clonal architecture and evolution. The criteria for selection 
included: 
1. B-cell expressed genes25 that were recurrently mutated in the 11 initial WES cases, 
2. Classic cancer genes (http://cancer.sanger.ac.uk/cancergenome/projects/classic),  
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3. Genes frequently mutated in lymphomas according to the Catalog of Somatic Mutations in 
Cancer (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) or  
4. Genes recurrently mutated in previously published B-cell lymphoma sequencing studies8,26-29. 
496 genes potentially involved in the FL and tFL disease process were included in the custom 
panel (Table 2-3).  
ABCA7 4 CDT1 3 FCGBP 3 JAK3 2 NPR2 3 SGK1 3 
ABCB1 3 CELSR1 3 FGFR1 1 KANSL2 3 NRAS 3 SHKBP1 3 
ABL1 4 CENPE 3 FGFR4 3 KDM2B 3 NTN3 3 SHPRH 3 
ACACB 3 CEP350 3 FLNC 3 KIAA0100 3 NUMA1 3 SIDT2 4 
ACSF3 4 CHD2 3 FLYWCH1 1 KIAA0430 3 NUP98 4 SIN3A 3 
ACSS1 3 CHD3 3 FNDC3B 3 KIAA1109 3 NVL 3 SMAD4 2 
ACTB 3 CHD8 4 FOLH1 3 KIAA1211 3 ODF2 3 SMARCA4 2 
ACTG1 3 CHTF18 3 FOXO1 5 KIAA1551 3 OFD1 2 SMARCB1 2 
ACVR1B 2 CIC 3 FOXO4 3 KIF1B 1 OGT 4 SMG7 3 
ADAMTS18 3 CIITA 5 FRG1B 1 KIF4A 3 P2RY8 4 SNRNP200 3 
ADRBK1 3 CLASP1 3 FRYL 3 KLF2 2 PABPC1 1 SNX19 3 
AFF1 4 CLEC16A 3 FTCD 3 KLHL6 4 PACS1 3 SOCS1 4 
AFF4 3 CLSTN3 3 FTH1 2 KMT2A 5 PALD1 3 SPEN 4 
AKAP13 3 CLUH 3 FUBP1 5 KMT2C 6 PASD1 2 SPG11 3 
AKAP8 2 CNOT1 5 GAK 3 KMT2D 7 PASK 3 SPTBN1 3 
AKAP9 4 CNOT3 3 GAS7 3 KMT2E 3 PAX5 2 SPTBN5 5 
AKT1 1 COL7A1 3 GATA2 1 KNTC1 3 PAXIP1 3 SRSF2 1 
ALMS1 3 CREB3L2 3 GATA3 1 KPNA5 3 PBRM1 6 STAT3 5 
ANKLE2 3 CREBBP 9 GCN1L1 4 KRAS 4 PCBP1 1 STAT6 4 
ANKRD12 3 CRTC1 3 GGA1 3 KTN1 3 PDCD11 1 STK11 1 
ANKRD17 3 CRTC2 0 GIGYF2 4 LAMP1 3 PDE4DIP 3 STK4 4 
ANXA1 3 CSNK1D 3 GNA11 2 LCP1 3 PDS5B 4 SYK 4 
APC 5 CSRP2BP 3 GNA13 4 LILRB1 3 PGAP2 1 SYNE1 8 
ARHGAP30 3 CTBP2 1 GNAS 1 LRBA 4 PHF3 3 TAF1 4 
ARHGEF12 3 CTCF 3 GOLGA3 3 LRCH4 3 PHF6 3 TAGLN 3 
ARHGEF2 4 CTNNA1 1 GOLGA4 3 LRP10 4 PHKA2 3 TARSL2 3 
ARID1A 4 CTNNB1 3 GPR82 3 LRRC7 2 PHRF1 3 TBL1XR1 4 
ARID1B 3 CUL7 4 GRB2 2 LRRK1 5 PICALM 3 TBP 2 
ARRDC2 3 CXCR5 3 GSE1 3 MACF1 3 PIK3CA 3 TCF3 4 
ASPM 3 CYLD 4 GTPBP8 3 MALT1 3 PIK3R1 5 TDG 2 
ASXL1 4 CYP1A2 1 GTSE1 2 MAP2K4 1 PIM1 6 TET2 4 
ATAD3B 3 DARS2 3 GYS1 3 MAPK1 1 PKD1 3 TIGAR 3 
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ATF7IP 3 DAXX 1 HCK 3 MBTPS1 3 PLCG2 4 TINF2 2 
ATM 4 DAZAP1 3 HDAC7 3 MCTP2 3 PLEKHA5 3 TMC8 3 
ATP10A 3 DDX3X 4 HEATR5B 3 MDN1 4 PMS1 3 TMEM30A 5 
ATRX 5 DDX56 4 HELZ 3 MED12 4 POU2F2 1 TNFAIP2 3 
AXIN1 1 DENND5A 3 HERC1 2 MED26 3 PPP2R1A 2 TNFAIP3 6 
B2M 6 DEPDC5 3 HIST1H1B 3 MEF2B 5 PPP2R3C 3 TNFRSF14 6 
BAP1 1 DGKZ 3 HIST1H1C 5 MEN1 2 PPP2R5A 1 TNK2 3 
BAZ2A 3 DHX15 4 HIST1H1D 7 MET 2 PRDM1 3 TOPBP1 3 
BBS10 3 DIAPH1 1 HIST1H1E 4 METTL9 3 PRDM15 2 TP53 9 
BBX 3 DIP2A 3 HIST1H2AC 4 MGA 3 PRKAR1A 1 TPR 3 
BCL10 7 DMD 4 HIST1H2AG 3 MIA3 3 PRKDC 5 TRAF3 4 
BCL11A 5 DMXL1 3 HIST1H2BC 5 MICAL3 3 PRMT6 3 TRIP11 4 
BCL2 7 DNM2 5 HIST1H2BG 2 MKI67 3 PTCH1 3 TSC2 4 
BCL2L10 1 DNMBP 3 HIST1H3B 1 MLH1 2 PTEN 6 TSC22D1 2 
BCL6 5 DNMT3A 2 HIST1H3H 3 MLLT10 5 PTPN11 2 TSPAN32 1 
BCLAF1 1 DOCK11 3 HIVEP2 3 MON2 3 PTPRH 3 TTC27 3 
BCOR 4 DOT1L 3 HIVEP3 3 MS4A1 3 PUM1 3 U2AF1 1 
BCR 5 DPF2 3 HLA-A 2 MSH2 3 PXDN 3 U2AF2 4 
BIRC6 4 DPYD 3 HLA-B 2 MSH6 4 RAPGEF1 4 UBAP2 4 
BLM 3 DTX1 3 HLA-C 2 MST1 4 RAPGEF2 3 UBC 3 
BOD1L1 3 DYNC1H1 3 HLA-DMB 2 MTG2 3 RASGEF1A 1 UBE2A 2 
BRAF 3 DZIP3 3 HMGB1 1 MTR 3 RB1 4 UBR4 4 
BRCA1 3 EBF1 4 HNF1A 1 MUC4 4 RBM15 3 UBR5 3 
BRCA2 5 EDEM3 3 HPS3 3 MUM1 3 RBM39 3 UPF1 3 
BRD2 3 EGFR 4 HPS5 3 MYBL2 3 RBMX 3 UPF2 3 
BRD4 4 EGLN1 3 HRAS 2 MYC 5 REV1 3 USP10 3 
BRD8 3 EIF4A2 3 HSPA8 3 MYD88 7 REV3L 1 USP19 3 
BTAF1 3 ELP2 2 HTT 3 MYH11 3 RFTN1 5 USP34 3 
BTBD3 3 EML4 4 HUWE1 4 MYH9 3 RFX7 4 VHL 2 
BTG1 4 EP300 7 HVCN1 3 MYO18A 2 RFXAP 3 VPS13C 3 
BTG2 4 EP400 3 ICE1 3 MYO1G 2 RGS12 3 WDR76 4 
BUB1B 4 EPHA7 3 ID3 1 MYRIP 3 RHOH 1 WDR90 1 
CALR 1 ERAP1 1 IDH1 4 NBAS 3 RLTPR 3 WHAMM 1 
CAMTA1 4 ERICH1 3 IDH2 1 NBEAL2 3 RNF103 3 WHSC1L1 3 
CARD11 8 ERMARD 3 IFI16 3 NCOR1 3 RNF213 7 WRN 3 
CARS 4 ETS1 2 IGF1R 3 NCOR2 2 RNF40 3 XPO1 4 
CASC5 4 EWSR1 3 IGFN1 2 NF1 4 ROBO1 4 YY1AP1 2 
CBL 2 EXOC4 3 IGLL5 2 NF2 1 ROCK2 3 ZC3H18 3 
CCDC94 3 EXOSC6 1 IKZF1 2 NFE2L2 2 RPN2 3 ZMYM3 4 
CCND3 6 EZH2 7 IKZF3 5 NFKB2 4 RRP1B 3 ZNF142 3 
CCNH 3 FAM186A 1 IL7R 2 NFKBIA 3 RTTN 3 ZNF500 3 
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CD22 3 FANCA 4 INO80 4 NIN 4 RUNX1 3 ZNF521 6 
CD36 7 FANCD2 3 INPP5D 3 NISCH 3 S1PR2 3 ZNF600 3 
CD58 5 FANCE 3 INTS10 3 NKAP 3 SAMD9 3 ZNF608 3 
CD70 3 FANCF 3 IQGAP1 3 NOA1 1 SCAPER 3 ZNF708 3 
CD74 5 FAS 4 IRF4 4 NOC2L 3 SEC23IP 3 ZNF830 1 
CD79B 7 FASN 4 IRF8 4 NONO 3 SENP6 4 ZNF85 1 
CDAN1 3 FBLN2 3 ITPKB 3 NOTCH1 6 SETD2 3 ZRSR2 1 
CDC73 2 FBXO11 3 ITPR2 4 NOTCH2 3 SETDB1 4 ZWILCH 1 
CDH1 2 FBXO31 2 JAK1 2 NPIPB15 1 SF3A2 3 
  CDKN2A 3 FBXW7 6 JAK2 2 NPM1 1 SF3B1 5 
  
Table 2-3. Genes selected in custom capture. Note: The number indicates the recurrence of 
each gene was reported by different resources. 
B.1.3. Library preparation 
Agilent’s Haloplex custom gene enrichment panel was designed using Agilent’s SureDesign 
software. 200 ng of DNA per sample was used for capture, and 10-12 samples were sequenced 
per lane.  
To prepare the samples, we first used restriction enzymes to fragment the DNA samples. 
After DNA denaturation, the biotinylated HaloPlex probes guided the targeted fragments to 
form circular DNA molecules. These biotinylated HaloPlex probes were specifically designed to 
hybridize to both ends of the fragmented DNA samples. Sample barcodes were incorporated in 
the DNA sample at the same time. Afterwards, magnetic streptavidin beads were used to 
retrieve perfectly hybridized DNA fragments. The circular DNA molecules were then closed by 
ligation and amplified by PCR. After amplification, the DNA molecules were ready for sequencing. 
B.2. Pipeline for calling variants in custom capture panel sequencing 
Since we had cases with either one, two, or three samples, the pipelines were designed 
slightly differently (Figure 2-3, Figure 2-4 and Figure 2-5). In general, after sequencing, the raw 
read quality was first evaluated by FastQC (v0.10.1), and then the raw reads were mapped to 
human reference genome hg19 using BWA (0.7.5a-r405). GATK (v3.1-1-g07a4bf8) was used for 
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local realignment and base quality recalibration. Variant calling was performed with VarScan2 
(v2.3.6). Basic filtering was performed as described above for the WES samples. The variants 
were then annotated using ANNOVAR24. We filtered out known germline variants (SNPs and 
indel polymorphisms) based on dbSNP138 and only selected mutations that were 
nonsynonymous, stop gain, stop loss, insertion or deletion in the coding region or splice sites. 
Since we had sample pairs and triplets, we categorized our mutations into three types: FL-
unique; tFL-unique; and shared mutations as described above for the WES samples. 
 
Figure 2-3. Pipeline designed for custom capture panel with paired sample. 
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Figure 2-4. Pipeline designed for custom capture panel with single sample. 
 
 
 
Figure 2-5. Pipeline designed for custom capture panel with tripled sample. 
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B.3. Custom capture panel performance analysis 
We applied custom capture panel performance analysis (Figure 2-6) to check the total 
number of reads used for alignment, the number of reads that were mapped to the reference 
and the number of aligned reads that were mated with their paired reads.  
 
Figure 2-6. Custom capture panel evaluation pipeline. 
 
B.4. Pipeline validation 
We selected 3 samples that were previously sequenced by WES and applied custom capture 
panel sequencing to them again to evaluate the performance of the custom capture panel.  
We made two mutation lists from the 3 samples: one for WES, and the other one for custom 
capture panel sequencing. The mutations were chosen in the regions covered by both WES and 
custom capture panel sequencing. The overlap of the two mutation lists, the variant frequency, 
mutation depth, and overall coverage were compared in the 3 samples. The previous Sanger 
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sequencing results that we did in the 3 paired overlap samples were used again to validate the 
mutations detection accuracy in the custom capture panel sequencing. KARPAS422 is a cell line 
with known mutations. We sequenced the cell line by custom capture panel and checked if it 
detected the known mutations in the cell line. 
C. Binomial distribution model for estimating the duplicate ratio 
The restriction enzyme based custom capture panels select genes at exactly same start and 
end positions. Because of this, the well-known duplicates marking program Picard cannot 
identify duplicates. This duplicate generation is due to the amplification by PCR causing multiple 
reads to be derived from a single initial molecule. We designed a binomial distribution statistical 
model to estimate the duplicate ratio (the average number of reads per initial molecule). The 
model is based on the variant frequency of heterozygous germline variants being approximately 
50% and the p-values from the statistical test for each heterozygous germline variant should be 
uniformly distributed. 
C.1. Data preprocess 
After basic filtering, the variants have balanced reads supporting alternative alleles and 
good base quality. We then used dbSNP to annotate the heterozygous germline variants by 
using our own scripts instead of annotation programs as we were only interested in 
heterozygous germline variants. We also checked the distribution of the variant frequency, total 
read number and the number of reads supporting the alternative allele to avoid bias or outliers 
that might potentially affect the estimation. 
C.2. Estimating the duplicate ratio 
For each sample, we generated the p-values for each heterozygous germline variant based 
on the binomial test with 50% probability of success. We only used the p-values between 0.1 
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and 0.9. The reason that we did not use p-values <0.1 is that sequencing errors introduced many 
apparent variants with low variant frequencies that fortuitously matched dbSNP, the p-values 
close to zero were overrepresented and rejected the null hypothesis (probability to get reads 
supporting one allele is 50%). The reason we didn’t use p-values >0.9 is the majority of total 
reads are assigned equally in heterozygous germline variants so that the p-values were close to 
1 and did not reject the null hypothesis. We then selected an alpha value which makes the slope 
of the regression model fitting the frequencies of the p-values to the p-value close to 0. The 
alpha value is the estimated PCR-duplicate ratio that can adjust the slope of the linear 
regression model to the uniformly distributed pattern.  
C.3. Model validation 
We simulated a dataset based on the real total number of reads in our samples and assigned 
a duplicate ratio equal to 1, 2 and 4 to confirm the patterns of the p-values from the binomial 
test. If there are no duplicates, most of the hypotheses will not be rejected; the majority of the 
total reads are assigned equally; therefore, there should be a big peak on the far right of the 
histogram of p-values; and the rest of the p-values are uniformly distributed. If there are PCR-
generated duplicates, most of the hypotheses will be rejected; a majority of total reads are 
assigned unequally; and p-values close to zero should be overrepresented. As there is a bigger 
PCR-duplicate ratio, the peak close to zero is expected to be more exaggerated. We also did 
10,000,000 simulations based on a real number of reads from all of our samples with duplicate 
ratio equal to 1 to confirm the binomial distribution model. We should see the trend be flat 
except the p-values close to 1, which confirms that the p-values from the binomial test will be 
uniformly distributed if there are no duplicates. 
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D. Filtering method for removing germline variants 
The variants called by either the WES or custom capture panel sequencing pipelines include 
two groups, germline variants and somatic mutations. Germline variants are heritable variations 
that are present in the germ cells and can pass to all cells in the body of the progeny. In contrast, 
somatic mutations are not inherited from a parent and cannot be transmitted to offspring. The 
conventional mutation analysis requires paired normal and tumor samples to distinguish 
germline variants from somatic mutations. The general idea is that the variants that are 
detected in both normal and tumor samples are germline variants, and conversely, the variants 
that are only found in the tumor sample are considered somatic mutations. We were interested 
in detecting somatic mutations that drove transformation, but our samples lacked 
corresponding normal samples to filter out germline variants that were absent from dbSNP, 
which are predominantly SNPs present at very low population frequency (private SNPs). A 
filtering based method was used to filter out germline variants and keep the somatic mutations. 
The filtering method is based on the biological understanding of FL. The mutations that drive 
transformation or contribute to FL often: occur recurrently; associate with critical CNAs and 
oncogenes; have an impact on amino acid structure and function of protein. Because FL is a B 
cell lymphoma, the mutated genes have to be expressed in B cell to be able to play roles in FL 
development. Datasets from reliable organizations provide comprehensive information to help 
filter out false positive mutations. As examples, there are common errors that may occur in 
sequencing technology or variants that are reported in dbSNP. 
D.1. Databases collection 
Multiple databases were collected or constructed to help sort out germline variants and 
somatic mutations. The databases are listed as following: 
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1. List of genes expressed in B cell. Genes that were expressed in B cells based on our previous 
GEP analysis and whole transcriptome sequencing data from lymphoma cell25. Genes were 
considered not significantly expressed in B-cells if their maximum FPKM value was less than 1 of 
5 naïve B-cell samples, 4 germinal center B-cell samples, and 5 DLBCL samples that include both 
GCB and ABC subtypes. For a few genes not included in this dataset, our Affymetrix dataset of 
normal B-cell and DLBCL samples was used to determine expression and a maximum log2 value 
of 8.5 was set as the threshold of expression; 
2. Sanger cancer gene list (http://cancer.sanger.ac.uk/cancergenome/projects/classic); 
3. Cosmic cancer gene list (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/); 
4. List of apparent recurrent mutations in 13 normal samples. Mutations that were detected in 
normal samples were considered as private SNPs or sequencing artifacts; 
5. List of mutated genes from previous published lymphoma sequencing studies8,26-29; 
6. dbSNP138; 
7. Annotation databases from ANNOVAR (http://annovar.openbioinformatics.org/en/); 
8. Paralog gene list (http://massgenomics.org/2013/06/ngs-false-positives.html). The paralog 
gene list is used to avoid 2 types of false positive variants. One is from genes that are physically 
large so that they tend to accumulate a lot of mutations. The other is from the misalignment to 
a paralog, in which case the reads supporting the variant allele were originally from another part 
of the genome. 
D.2. Data preprocessing 
Each database we used in the filtering method has its own specific format. Some databases 
include extremely comprehensive formats. We extracted the information and parsed it to a 
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simple version so that we can easily apply it to future interaction. We also preprocessed the 
format of our variant list in order to connect it to various databases. 
D.3. Germline variant filtering  
To obtain a confident somatic variant list, a filtering process was applied. This pipeline 
generated a mutation list with two tiers of confidence and one rescued tier. First, variants were 
excluded if they met specified criteria from the following: 
1. Existed in the dbSNP database (dbSNP138) with same orientation; 
2. Synonymous mutations; 
3. Found in a set of 13 unrelated normal samples as SNPs or artifacts; 
4. Shared by samples from six or more cases or 50% of total samples unless they are from a gene 
known to have frequent mutations at the site (such as EZH2);  
5. Found other variants in closely neighboring positions; 
6. Mutations in intergenic regions, introns, and 5’ or 3’ untranslated regions (UTR); 
7. Genes previously reported as frequently showing false positive mutations 
(http://massgenomics.org/2013/06/ngs-false-positives.html). 
Second, the remaining variants were considered as candidate somatic mutations (CSMs). 
Mutations were included in our list only if they met specified criteria from the following: 
1. Not being found in all samples from the same patient and cannot be explained by copy 
number (CN) abnormality; 
2. Previously identified in a B-cell lymphoma genome; 
3. Being a truncating mutation; 
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4. Previously identified in a non-B-cell-lymphoma cancer genome; 
5. Identified in a gene from the Cancer Gene census list; 
6. Having a reduced variant frequency which cannot be explained by CN abnormality. 
Based on these 6 criteria above, the reported variants were classified into two tiers. 
Mutations satisfying one of the first three conditions, or two of the other three conditions were 
classified as high-confidence Tier 1 mutations; mutations that met only condition 6 were 
classified as less confident Tier 2 mutations. Because we used very strict filtering criteria to try 
to ensure that we did not include germline variants (private SNPs) in our mutation data, we may 
have filtered out some true mutations. To avoid underestimation of prevalence of important 
genes, other CSMs in B-cell expressed, recurrently mutated genes assigned to Tier 1 and 2 lists 
were rescued and designated Tier R. All the other mutations were considered as likely germline 
variants, and were thus excluded from the following analysis. 
D.4. Filtering method validation 
To validate the performance of the pipeline for filtering out germline variants, we applied 
the pipeline to a published FL sequencing dataset. This dataset has FL, tFL and normal samples 
from the same patient so that we can use the normal samples for filtering. 6 WGS samples with 
matched FL, tFL and normal samples were downloaded from a published paper9. We generated 
two somatic mutation lists. One somatic mutation list was generated using our WES pipeline 
(Figure 2-1) and did not utilize the matched normal data. The other somatic mutation list was 
generated using the standard somatic calling pipeline VarScan2 taking into account the normal 
data. This somatic mutation list did not include germline variants. We then compared the two 
somatic mutation lists at each criterion and validated the filtering method. 
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E. Machine learning model for removing germline variants 
Predictive modeling is a concept of building a trained model that learns certain features 
from a training dataset and then applying the trained model to make predictions from other 
datasets. Typically, there are two main categories of predictive modeling. One is able to predict 
continuous outcomes and is based on the relationships between attributes and trends. This is 
called a regression model. The other one is capable of predicting discrete outcomes and is based 
on grouping the attributes. This is called pattern classification which can be divided into two 
types: supervised and unsupervised learning. Supervised learning uses the known discrete 
outcomes in the training dataset to train the model. In unsupervised learning the outcomes in 
the training dataset are not known, therefore, the program tries to find unknown information 
from the attributes in the dataset. In our study, we used supervised learning modeling to predict 
germline variants in pairs of FL and tFL samples without normal samples.  
E.1. Dataset preprocessing 
We collected two published sequencing datasets9 that have FL, tFL and normal samples from 
the same patients so that we can use one as the training dataset and the other one for the 
testing dataset. We first applied a standard somatic calling pipeline using VarScan2 and 
generated variants. The variants were classified into germline variant and somatic mutation 
groups by comparing with their corresponding normal samples. We then annotated the variants 
with well-known prediction scores by ANNOVAR24. The variants were variant call format, which 
packs information in couple columns. We parsed the information into a more organized and 
convenient format for the models to do the training and testing. The parsed format separated 
the packed information into individual columns, reorganized the columns, and only kept the 
information we need for next steps. 
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E.2. Model training 
We applied 5 robust machine learning algorithms to our training dataset. These were SVM, 
recursive partitioning (RP), Breiman and Cutler’s random forests (RF) for classification and 
regression, classification and regression tree (TR) and feed-forward neural networks (NNET). We 
used R (statistical language) package e1071, rpart, randomForest, tree, and nnet for each of the 
respective models listed. The features that we used for training were the variant frequency of 
the FL sample, variant frequency of the corresponding tFL samples, dbSNP, and SIFT score. SIFT 
score is a score that can predict amino acid changes that affect protein function; the smaller the 
score is, the more deleterious the variant. We applied two sets of features. One set is called a 
basic feature set; it includes variant frequency for FL, variant frequency for tFL, and dbSNP. All 
our variants have the information for the basic feature set. Therefore, all of them were included 
in the training dataset. The other set is called a complex feature set, this set added the SIFT 
score as the extra feature. SIFT fails to provide a score for a very small number of the variants in 
the datasets. The machine learning algorithms do not work with missing data; therefore, we 
only used the mutations that have SIFT score information for our complex feature set. We 
trained all the 5 models with two feature sets in Okosun’s dataset and tested them in 
Pasqualucci’s dataset with statistical measures individually. ROCR30 is another R package for 
evaluating the performance of classifiers. We used it to evaluate the performance of our models. 
We used 5 different R packages, each of them has its own design. Therefore, when we applied 
the statistical measures to the tested models, we made 5 different scripts to retrieve 
information required by the calculation.  
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E.3. Model selection and validation 
We applied the 5 different models to the two published datasets. The statistical values, 
sensitivity, specificity, area under the receiver operating characteristic (ROC) curve (AUC), and 
false discover rate (FDR), were calculated for each model based on its performance in the 
testing dataset. We also applied the trained models to one of our own sequencing samples. 
These samples had the best coverage and depth. As we mentioned earlier, our own sequencing 
data does not have corresponding normal samples to remove germline variants, but we applied 
a filtering based method to effectively remove most of the germline variants. Therefore, the 
somatic mutations predicted by the machine learning models should have decent overlap with 
the results generated by our filtering based method. The best machine model was selected by 
considering all the statistical results. 
F. Data integration for downstream analysis 
To have a more comprehensive view of the genomic alterations and to use the CNV data to 
assist the analysis of mutation data, we integrated our mutation data with our previous 
corresponding CNV data and other two sequencing data to investigate the genetic landscape of 
the disease. 
F.1. Integration of mutation and CNA datasets 
Integration of the mutation data with CNA data can provide complementary information for 
us to examine their association with FL transformation. In our CNV analysis, a circular binary 
segmentation algorithm was applied to segment chromosomes into regions of similar CN log2 
ratio. It translated noisy intensity measurements into regions of equal CN log2 ratios and 
connected the change point to the locations of regions with aberrant DNA CNs and thereby 
identified regions of CN gain and loss. Each chromosome in each sample was divided into many 
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segments with similar CN. These segment files were used to assign the CN for each mutation in 
our analysis. We also identified mutated genes that were included in the regions of each rCNA 
for data interaction. 
F.2. Integration of mutation datasets  
In order to enhance the investigation of the genetic events that drive the transition from FL 
to tFL, we integrated other two published mutation datasets and identified recurrent mutations.  
For each dataset, we first retrieved the mutations with their original sample name, mutation 
positions, variants, mutation types, and gene names. Then we classified each mutation as FL-
unique, tFL-unique or shared. All the 3 datasets were then combined into a comprehensive 
matrix. In this matrix, the rows included all the gene names that had been detected in any of the 
3 datasets, the columns included all the paired samples that had been used for mutation 
detection. Additionally, 5 columns were added: FL-unique mutation frequency, tFL-unique 
mutation frequency, shared mutation frequency, genes expressed in B cell, and genes selected 
in our custom capture panel. For each sample and each gene, mutation types were annotated; 
some of them had more than one type. We classified them as genes with only shared mutation, 
genes with only FL-unique mutation, genes with both FL-unique and shared mutations, genes 
with tFL-unique mutation, genes with both shared and tFL-unique mutations, genes with both 
FL-unique and tFL-unique mutation, genes with FL-unique, shared and tFL-unique mutations, 
and genes with CNV. We tallied the frequencies for sorting the mutations conveniently. We also 
identified mutations that were involved in potentially important domains and pathways from 
the combined dataset. We also identified mutations that were detected in FL samples at low 
levels but had increased variant frequency in the tFL for clonal analysis.  
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G. Survival analysis 
Most standard statistical models require a normal distribution and cannot be applied in 
survival analysis because the time to the event occurrence is rarely normally distributed and we 
often lack follow-up information on the patients. For an example of the latter, logistic regression 
can study how risk factors are associated with disease or affect the time to the disease, but 
patients may drop out of the study or fail to develop a disease before the end of the study. All 
these realities make logistic regression unfit for survival analysis. The Kaplan-Meier (KM) 
method uses information from the dropout patients, rather than simply throwing it away, to 
estimate the survival probability at a given time.  
The log-rank test is a widely used hypothesis test in survival analysis. It is applied to 
compare the survival distributions of two groups of patients. One group includes patients with a 
factor, and the other group includes patients without the factor. After the test, we can come up 
with a conclusion about whether the two groups (with and without the factor) have identical 
survival functions. The log-rank test works well when the factor has the exact same weight or 
influence at each observed event time. The majority of the situations in the biological field are, 
however such that the characteristics of the factors do not always have exactly the same impact 
during the disease development. For example, loss on 9p21.3 occurring early in FL 
development31 has more influence on patients’ early overall survival. If we use a log-rank test, 
we will easily miss the biological abnormality information that can improve the analysis. 
Therefore, in our study, we designed a survival analysis that associated an understanding of how 
the abnormalities contribute to FL development and provided a more accurate and 
comprehensive test.  
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Statistical Analysis System (SAS), a professional software suite for statistical analysis that is 
flexible to select the test that matches the biological property, is convenient to navigate to 
different analysis parts, and facilitates the display and retrieval of integrated information, was 
applied to our survival analysis. 
G.1. Dataset description 
The samples that were used for the survival analysis were obtained from the LLMPP or the 
UNMC Pathology/Oncology Database. This study was approved by the UNMC institutional 
review board and conducted in accordance with the declaration of Helsinki. Diagnoses were 
confirmed by a panel of LLMPP hematopathologists.  
We originally performed CN analysis using the high-resolution GeneChip Human Mapping 
250K Nsp SNP array (Affymetrix) on 225 FL and 84 tFL samples. After preliminary analysis, 198 FL 
and 79 tFL samples had sufficient quality and were kept for rCNA identification. The method for 
rCNA identification was described in a previous published paper31. In general, the raw CEL files 
were imported into Genotyping Console 4.1 software (Affymetrix) generating SNP genotypes 
and probe-intensity log2 ratios (relative to 48 normal controls provided by Affymetrix). A 
DNAcopy R package from Bioconductor was applied to segment probe values and estimate CN. 
The recurrent abnormalities, represented as rCNAs, were then identified.  
We had clinical data for 149 FL cases and 21 tFL cases. These tFL samples were defined as 
DLBCL that occurred in patients diagnosed with FL. Since we had a very small number of tFL with 
clinical data, we only applied the survival analysis to FL cases. 
G.2. Applying KM method 
In survival analysis, the time variable was survival time, and the event was death. Censoring 
is the key analytical problem in survival analysis; it occurs when we have the individual true 
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survival time interval, but it is unknown most of time. Most survival time intervals are right-
censored, because the survival time has been cut off before the true survival time, in other 
words, the observed survival time is shorter than the true survival time. Our goal is to use the 
right-censored observed survival time in FL patients to suggest the true survival time. The KM 
method was applied to estimate the survival probability at a given time. We made use of a risk 
set at a given time. By risk set, we mean the information we have on the individuals who have 
survived at that given time. We also used the information we have on censored people up to the 
time of censorship instead of discarding the information. The KM survival curves were plotted to 
interpret the survival data.  
We examine CNVs as factors that potentially influence the patients’ survival time. We used 
them to divide the clinical data into two groups for future survival comparison. For each group, 
we applied the KM method to the FL clinical data. The number of censored patients, deceased 
patients and living patients were all calculated at the time point that patients either dropped or 
deceased in the study. A survival curve was generated by the KM method for each group for 
future survival curves comparison. 
G.3. Applying log-rank test 
The log-rank test is the most popular method for testing whether two KM curves are 
statistically equivalent. The null hypothesis is that there is no overall difference between the 
two survival curves. In our study, the null hypothesis was that there is no overall difference 
between the group with the abnormality and the group without the abnormality. Under this null 
hypothesis, the log-rank test used a chi-square distribution to test a statistic with one degree of 
freedom. The categories of the outcomes were defined by each of the ordered failure times for 
the entire set of data and the statistics used the categories of the outcomes to calculate the 
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observed cell counts versus expected cell. The expected cell count (Equation 2-1 and Equation 2-
2) was the proportion of the number of patients in one group out of the total patients in both 
compared groups at risk at time j (Equation 2-3) multiplied by the total number of deaths at 
time j in both groups (Equation 2-4). The log-rank test statistic (Equation 2-5) divided the square 
of the sum of the observed counts (𝑚𝑖𝑗) minus expected counts (𝑒𝑖𝑗) over all failure times for 
either one of the two comparing groups by the variance of the sum of the observed counts 
minus expected counts over all failure times for either one of the two comparing groups. A p-
value for the log-rank test was determined from the chi-square distribution tables. We used the 
p-value to conclude whether or not this abnormality affects the survival. 
Equation 2-1: 𝑒1𝑗 = (
𝑛1𝑗
𝑛1𝑗+𝑛2𝑗
) × (𝑚1𝑗 + 𝑚2𝑗) expected cell count for group 1 at jth failure  
Equation 2-2: 𝑒2𝑗 = (
𝑛2𝑗
𝑛1𝑗+𝑛2𝑗
) × (𝑚1𝑗 + 𝑚2𝑗) expected cell count for group 2 at jth failure  
Equation 2-3: 𝑛𝑖𝑗/(𝑛1𝑗 + 𝑛2𝑗 ) proportion of patients at jth failure, i=1, 2 represents the group 
number 
Equation 2-4: (𝑚1 𝑗 + 𝑚2 𝑗) the total number of deaths at jth failure, 1 and 2 represent the 
group 1 and group 2 
Equation 2-5: 
(∑  (𝑚𝑖𝑗−𝑒𝑖𝑗)𝑗 )
2
𝑣𝑎𝑟(∑  (𝑚𝑖𝑗−𝑒𝑖𝑗)𝑗 )
 i=1, 2 represents the group number, j is the order of failure time 
G.4. Applying alternatives to the log-rank test 
To test the null hypothesis that two survival curves are statistically equivalent, there are 
several alternatives to the log-rank test as shown in Table 2-4. The main difference in the 
methods is the weights at the jth failure time in test statistic (Equation 2-6). The log-rank test 
uses the summed observed minus expected failures in each group to form the test statistic. This 
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simple sum gives the same weight to each failure time when combing observed minus expected 
failures in each group. In contrast, the alternative tests apply different weights at the jth failure 
time. Take the Wilcoxon test as an example. It places more emphasis on the information at the 
beginning of the survival curve where the number at risk is large allowing early failures to 
receive more weight than later failures. This type of weighting is often used if a factor related to 
survival has stronger effect in the earlier phase and tends to be less effective over time. 
Therefore, if the CN abnormality occurs in the early stage of FL, the Wilcoxon test will be a 
better choice than the log-rank test. Similarly, the Tarone-Ware test weights the early failure 
time more heavily, but the weight is between log-rank and Wilcoxon. Prentice32 illustrated that 
the Tarone-Ware test is always superior to either the log-rank test or Wilcoxon test. The Peto 
test weights the jth failure time by the survival estimate?̂?(𝑡𝑗); it gives more weight for the 
earlier survival time as well. The Fleming-Harrington test has the most flexibility in terms of the 
choice of weights in the test. We can choose the values for parameters p and q. For example, if 
p=1 and q=0, then 𝑤(𝑡) = ?̂?(𝑡𝑗−1)
𝑃[1 − ?̂?(𝑡𝑗−1)]
0 = ?̂?((𝑡𝑗−1) giving more weight for the earlier 
survival times when ?̂?(𝑡𝑗−1) is close to one. In contrast, if p=0 and q=1, then 𝑤(𝑡) =
?̂?(𝑡𝑗−1)
0[1 − ?̂?(𝑡𝑗−1)]
1 = 1 − ?̂?((𝑡𝑗−1), I giving more weight for the later survival times when 
?̂?(𝑡𝑗−1). If p=0 and q=0, then 𝑤(𝑡) = ?̂?(𝑡𝑗−1)
0[1 − ?̂?(𝑡𝑗−1)]
0 = 1; thus, it reduces to the log-
rank test. Selecting the appropriate weighted test according to the property of the abnormality 
can provide more accurate analysis. 
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Table 2-4. Weights in alternative test statistics. 
Equation 2-6: test statistic= 
(∑ 𝑤(𝑡𝑗)(𝑚𝑖𝑗−𝑒𝑖𝑗)𝑗 )
2
𝑣𝑎𝑟(∑ 𝑤(𝑡𝑗)(𝑚𝑖𝑗−𝑒𝑖𝑗)𝑗 )
 i=1,2 represents the group number, j is the 
order of failure time, 𝑤(𝑡𝑗) weight at jth failure time. 
From our previous study, we had the average number of abnormalities associated with each 
rCNAs calculated to model the progression of rCNAs with FL development31. We can estimate 
the temporal order of the rCNA in the disease from this calculation. According to the published 
study, samples with abnormalities that occur in the early stage of FL are expected to have 
generally a low number of abnormalities, whereas samples with abnormalities that occur late in 
the disease are expected to have a high number of abnormalities. Therefore, early rCNAs would 
be expected to have a lower average number of other abnormalities and we should select a test 
statistic that puts more weight for the earlier survival time. In contrast, test statistics that put 
more weight on the later survival time could be applied to rCNAs that tended to occur late. 
G.5. Applying survival analysis by SAS 
The SAS programming language is specifically designed for statistical analysis. It can also 
retrieve and manipulate data from various sources. We applied the KM method and the 
alternative tests by using SAS and generated a comprehensive result including survival estimates 
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in different failure times with the survival standard error, number of failure patients and 
number of risk patients, summary statistics for our time variable, a summary of censoring, 
survival curves with confident intervals, marked time and survival probability of censored 
patients, and multiple weighted alternative tests. 
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CHAPTER III 
INITIAL RESULTS AND DISCUSSION 
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A. WES analysis 
A.1. Introduction  
To identify the genetic changes that drive the transformation and contribute to its biological 
and clinical behavior, we sequenced 12 pairs of FL and tFL cases and applied a WES pipeline 
specifically designed for paired FL and tFL samples to identify mutations in the dataset. We then 
evaluated the performance of the WES by calculating the mapping condition, percentage of 
duplicates, coverage, and depth in annotated coding regions and splice sites of the samples. To 
confirm the reliability and capability of the WES mutation detection pipeline, Sanger sequencing 
was applied to validate the accuracy of the variant identification. 
A.2. Sequencing performance  
There were 12 pairs of FL and tFL samples sequenced by WES.  In general, the WES had very 
good performance (Table 3-1). Most of the reads were pair mapped (range: 96.23%-98.85%, SD: 
0.69%, Figure 3-1). The average percentage of duplicates was 34.41% (range: 19.44%-56.91%, 
SD: 11.57%, Figure 3-2). The average depth of bases at coding regions was 90 (range: 30-199, SD: 
37, Figure 3-3). The average depth of bases at splice sites was 73 (range: 26-180, SD: 32, Figure 
3-6). The average coverage of coding regions was 94.44% (range: 90.96%-99.67%, SD: 2.09%, 
Figure 3-4). The average coverage of coding region with at least 10 reads was 87.64% (range: 
75.71%-94.85%, SD: 5.34%, Figure 3-4). The average coverage of splice sites was 96.81% (range: 
94.50%-99.85%, SD: 1.36%, Figure 3-4). 
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Cases Total Reads  Duplicates %Duplicates 
Pair-
Mapped 
Reads  
Pair-Mapped 
Bases  
FL-1 237,590,222 74,826,008 31.49% 233,505,162 23,584,021,362 
tFL-1 266,693,964 71,921,285 26.97% 256,652,884 25,921,941,284 
FL-2 167,722,410 95,443,258 56.91% 163,370,368 16,500,407,168 
tFL-2 151,505,060 81,911,778 54.07% 147,515,422 14,899,057,622 
FL-3 173,523,760 71,057,500 40.95% 170,494,962 17,219,991,162 
tFL-3 102,426,766 48,077,593 46.94% 100,197,678 10,119,965,478 
FL-4 78,691,960 38,993,802 49.55% 76,703,946 7,747,098,546 
tFL-4 160,164,134 68,724,439 42.91% 157,400,100 15,897,410,100 
FL-5 95,405,906 42,166,753 44.20% 93,430,749 9,436,505,649 
tFL-5 112,526,146 57,537,049 51.13% 110,389,686 11,149,358,286 
FL-6 140,051,736 49,327,829 35.22% 137,578,938 13,895,472,738 
tFL-6 76,965,874 26,150,440 33.98% 74,417,132 7,516,130,332 
FL-8 138,771,418 45,034,843 32.45% 136,867,478 13,823,615,278 
tFL-8 161,157,660 48,874,483 30.33% 158,777,402 16,036,517,602 
FL-9 153,123,582 30,802,959 20.12% 151,108,590 15,261,967,590 
tFL-9 145,388,704 28,812,740 19.82% 143,571,681 14,500,739,781 
FL-10 145,153,806 29,265,025 20.16% 143,360,954 14,479,456,354 
tFL-10 106,939,220 22,798,673 21.32% 105,289,995 10,634,289,495 
FL-11 141,973,378 27,596,351 19.44% 140,231,461 14,163,377,561 
tFL-11 125,551,362 26,238,424 20.90% 123,869,734 12,510,843,134 
FL-12 172,894,910 54,648,179 31.61% 170,898,776 17,260,776,376 
tFL-12 182,211,848 58,432,593 32.07% 180,015,195 18,181,534,695 
FL-22 144,067,832 45,448,865 31.55% 141,669,627 14,308,632,327 
tFL-22 144,306,904 45,991,619 31.87% 142,075,691 14,349,644,791 
max 266,693,964 95,443,258 56.91% 256,652,884 25,921,941,284 
min 76,965,874 22,798,673 19.44% 74,417,132 7,516,130,332 
mean 146,867,023 49,586,770 34.41% 144,141,400 14,558,281,446 
median 144,730,355 47,034,606 31.97% 142,718,323 14,414,550,573 
SD 43560873 19772323 11.57% 42352468 4277599295 
Cases 
CDS 
covered 
CDS 10X 
covered 
CDS average 
DP 
Splice 
covered 
Splice average 
DP 
FL-1 98.74% 94.85% 199 99.31% 180 
tFL-1 99.67% 94.04% 155 99.85% 138 
FL-2 93.30% 82.78% 79 95.55% 65 
tFL-2 93.58% 83.47% 75 96.03% 61 
FL-3 93.80% 88.25% 92 96.70% 77 
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tFL-3 92.40% 81.74% 45 95.45% 39 
FL-4 90.96% 75.71% 30 94.71% 26 
tFL-4 93.74% 86.92% 75 96.34% 64 
FL-5 92.11% 79.83% 44 95.26% 37 
tFL-5 93.22% 83.81% 47 95.95% 41 
FL-6 93.30% 86.50% 86 95.93% 73 
tFL-6 91.40% 78.70% 43 94.50% 37 
FL-8 92.73% 84.63% 86 95.78% 69 
tFL-8 92.67% 84.88% 96 95.80% 76 
FL-9 95.67% 92.11% 112 97.75% 87 
tFL-9 95.44% 91.36% 95 97.67% 74 
FL-10 95.79% 92.38% 123 97.84% 95 
tFL-10 95.38% 90.89% 83 97.31% 64 
FL-11 95.72% 92.11% 109 97.80% 86 
tFL-11 95.70% 91.37% 92 97.70% 73 
FL-12 95.59% 92.25% 107 97.64% 78 
tFL-12 95.26% 92.10% 108 97.52% 79 
FL-22 95.09% 91.35% 95 97.46% 70 
tFL-22 95.21% 91.30% 94 97.51% 70 
max 99.67% 94.85% 199 99.85% 180 
min 90.96% 75.71% 30 94.50% 26 
mean 94.44% 87.64% 90 96.81% 73 
median 94.44% 89.57% 92 97.00% 72 
SD 2.09% 5.34% 37 1.36% 32 
 
Table 3-1. General statistical information of 12 pairs of FL and tFL WES sequenced samples. 
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Figure 3-1. Numbers of reads in 12 pairs of FL and tFL WES sequenced samples. 
 
 
 
Figure 3-2. Percentage of duplicates in 12 pairs of FL and tFL WES sequenced samples. 
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Figure 3-3. Read depth at coding regions and splice sites for 12 pairs of FL and tFL WES 
sequenced samples. 
 
 
 
 
Figure 3-4. Coverage of coding regions and splice sites in pairs of FL and tFL WES sequenced 
samples. 
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A.3. Validation of the WES mutation detection pipeline  
Sanger sequencing was applied to evaluate the capability of variant identification in the WES 
pipeline. 50 variants were selected from a confident variant list in Table 3-2. 47 out of 47 
variants were confirmed, and the primers in the other 3 variants did not work.  
Gene 
aa. 
change 
Chr Pos Ref Var Case Type 
Confirmed 
by sanger? 
ADCY9 C->S chr16 4164141 A T 5-tFL snp YES 
ANKRD12 S->T chr18 9255822 T A 5-tFL snp YES 
CLSTN3 A->V chr12 7287964 C T 5-tFL snp YES 
HMGN5 T->R chrX 80371830 G C 5-tFL snp YES 
IL4R Y->N chr16 27363936 T A 5-tFL snp YES 
LTBP1 P->R chr2 33623527 C G 5-tFL snp YES 
OR13H1 - chrX 130678922 G -A 5-tFL indel YES 
PTGES V->M chr9 132502006 C T 5-tFL snp YES 
ROBO1 L->F chr3 78987869 T A 5-tFL snp YES 
SDK1 D->A chr7 4011182 A C 5-tFL snp YES 
TP53 D->V chr17 7577598 T A 5-tFL snp YES 
TP53 M->V chr17 7577545 T C 5-tFL snp YES 
ZNF302 V->L chr19 35175831 G C 5-tFL snp YES 
ZNF594 K->R chr17 5085165 T C 5-tFL snp YES 
CDH23 N->H chr10 73544792 A C 6-tFL snp YES 
FUBP1 K->E chr1 78435630 T C 6-tFL snp YES 
GRIP1 D->H chr12 66786109 C G 6-tFL snp YES 
MYST1 H->Q chr16 31142184 C G 6-tFL snp YES 
SLC7A14 W->L chr3 170218933 C A 6-tFL snp YES 
SPEN - chr1 16256410 C +A 6-tFL indel YES 
TATDN3 Q->P chr1 212977991 A C 6-tFL snp YES 
TNFAIP3 Q->E chr6 138200146 C G 6-tFL snp YES 
ABCA12 - chr2 215901791 T A 9-tFL snp YES 
AKAP13 - chr15 86123376 A 
-
CCACAG 
9-tFL indel YES 
BCL9L G->D chr11 118779065 C T 9-tFL snp YES 
CDH7 T->M chr18 63547760 C T 9-tFL snp YES 
LOC643677 Q->H chr13 103393996 C A 9-tFL snp YES 
PGLYRP3 V->A chr1 153274966 A G 9-tFL snp YES 
PIK3R1 P->T chr5 67576825 C A 9-tFL snp YES 
SLITRK5 D->E chr13 88330325 C A 9-tFL snp YES 
SPATA20 G->R chr17 48628075 G C 9-tFL snp YES 
WNT3A V->G chr1 228210442 T G 9-tFL snp YES 
TBP - chr6 170871046 A - 7- indel YES 
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CAGCAG
CAG 
tFL* 
RRAGC I->F chr1 39322649 A G 6-FL snp YES 
RRAGC I->F chr1 39322649 A G 6-tFL snp YES 
RRAGC I->F chr1 39322697 T A 8-FL snp YES 
RRAGC I->F chr1 39322697 T A 8-tFL snp YES 
TPR R->Q chr1 186291702 C T 4-tFL snp YES 
SLC35F5 I->T chr2 114493380 A G 4-tFL snp YES 
SLC35F5 A->T chr2 114493426 C T 4-tFL snp YES 
MIR142 V->A chr17 56408621 A G 4-tFL snp YES 
MIR142 V->A chr17 56408621 A G 8-FL snp YES 
MIR142 V->A chr17 56408621 A G 8-tFL snp YES 
MIR142 S->G chr17 56408625 T C 9-tFL snp YES 
MIR142 V->A chr17 56408657 A G 11-FL snp YES 
MIR142 V->A chr17 56408657 A G 
11-
tFL 
snp YES 
TMSB4X - chrX 12994363 A G 4-tFL snp YES 
DDX3X R->S chrX 41205842 C A 6-tFL snp 
primer 
failed 
MGAT4B S->T chr5 179226060 C G 6-tFL snp 
primer 
failed 
MYO16 - chr13 109704824 G T 9-tFL snp 
primer 
failed 
Table 3-2. Sanger sequencing validation in of 50 variants found in WES sequenced samples. 
Note: * sample removed from the final analysis.  
 
A.4. Mutations identified by WES  
We identified a total of 1191 mutations (in 666 different genes) in the 12 paired WES 
dataset (Table 3-3). 838 mutations (in 363 different genes) were detected in both paired FL and 
tFL samples (shared mutations). 446 out of the 838 mutations were in genes expressed in B cells 
(in 187 different genes). 114 were in the confident final list (28 different genes). 90 (89 different 
genes) were only detected in FL samples (FL-unique mutations). 51 out of the 90 mutations 
were in genes expressed in B cells (50 different genes). 13 were in the confident final list (12 
different genes). 263 (249 different genes) were only detected in tFL samples (tFL-unique 
mutations). 135 out of the 263 mutations were in genes expressed in B cells (121 different 
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genes), 31 were in the confident final list (23 different genes). The recurrent mutations 
identified in our dataset were highly concordant with previously published sequencing reports, 
affirming the effectiveness of our analysis pipeline. 
Type 
Sequence 
type 
Total 
T1+T2+TR
+express 
T1 T2 TR 
T1+express
+recurrent 
T1+T2+TR+
express+re
current 
share WES 838 446 178 252 16 98 114 
FL-unique WES 90 51 46 5 0 13 13 
tFL-unique WES 263 135 119 15 1 27 31 
 sum 1191 632 343 272 17 138 158 
Table 3-3. Number of mutations detected by WES in different mutation types and filtering. 
 
A.5. Discussion 
We were particularly interested in mutations that contributed to transformation. Therefore, 
we separated the mutations into FL-unique mutations, tFL-unique mutations, and shared 
mutations so that we can assess if some of them occurred more frequently in one of the groups. 
If the mutations occur more often in the tFL-unique group, we considered them to be more 
likely to be related to transformation. Similarly, if the mutations occur more often in the FL-
unique group, we considered them to be more likely contributing to FL development. When we 
had sequenced a decent number of samples, we noticed that several mutations of a gene can be 
found in one sample. For example, BCL2 mutations were detected as a FL-unique mutation and 
also a shared mutation in the exactly same sample but at different positions. This could indicate 
mutations of both alleles of BCL2 or there were subclones harboring different mutations. These 
mutations were very carefully noted for further integration.  
59 
 
B. Custom capture panel analysis 
B.1. Introduction 
We sequenced 7 pairs of FL and tFL samples, 4 triples of two FL samples and a tFL sample, 
and 15 single tFL samples, and applied various pipelines to analyze the sequencing data as 
described above. To confirm the reliability and capability of the custom capture panel mutation 
detection, we compared the variants detected using the custom capture panel with the variants 
detected by WES on three paired samples analyzed by both approaches. We also checked the 
known mutations in a sequenced cell line. After the mutation detection pipelines and custom 
capture panel were proved to be effective, a simulation was applied to the data from the 
reliable variants to confirm the approach for estimating the duplicate ratio (the average number 
of reads per initial molecule). We then estimated the duplicate ratio in samples sequenced by 
custom capture panel.  
B.2. Sequencing performance 
A total of 43 samples (3 paired samples were also sequenced by WES) were sequenced using 
the custom capture panel.  In general, the custom capture panel had very good performance 
(Table 3-4). Most of the reads were pair mapped (range: 82.41%-91.21%, SD: 1.94%, Figure 3-5). 
The average depth at coding regions was 982 (range: 491-1515, SD: 224, Figure 3-6) and the 
average depth at splice sites was 849 (range: 426-1317, SD: 194, Figure 3-6), both of which are 
much deeper than WES. The average coverage at coding regions was 95.31% (range: 88.25%-
99.77%, SD: 1.45%, Figure 3-7), and the average coverage at splice sites was 89.60% (range: 
83.16%-90.13%, SD: 1.01%, Figure 3-7). 
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Cases 
Total 
Reads  
Pair-
Mapped 
Reads  
Pair-Mapped 
Bases  
%Pair-
Mapp
ed 
Reads 
CDS 
ave 
DP 
Spli
ce 
ave 
DP 
CDS 
cov 
Splice 
cov 
FL-3 32,115,446 29,290,422 2,958,332,622 
91.20
% 
786 683 
95.43
% 
89.82
% 
tFL-3 31,611,696 28,753,286 2,904,081,886 
90.96
% 
757 655 
95.43
% 
89.91
% 
FL-5 39,545,852 35,684,534 3,604,137,934 
90.24
% 
1237 830 
99.77
% 
90.06
% 
tFL-5 42,809,742 38,735,308 3,912,266,108 
90.48
% 
975 853 
95.76
% 
90.13
% 
tFL-15 33,735,752 30,695,784 3,100,274,184 
90.99
% 
814 708 
95.56
% 
89.94
% 
tFL-16 40,419,724 36,422,198 3,678,641,998 
90.11
% 
930 813 
95.66
% 
90.09
% 
tFL-17 38,825,300 34,737,906 3,508,528,506 
89.47
% 
932 839 
88.25
% 
83.16
% 
tFL-18 33,919,492 30,732,778 3,104,010,578 
90.61
% 
843 724 
95.37
% 
89.92
% 
tFL-19 37,800,608 34,477,870 3,482,264,870 
91.21
% 
994 813 
99.70
% 
89.75
% 
tFL-20 42,563,636 38,736,302 3,912,366,502 
91.01
% 
1048 915 
95.35
% 
89.86
% 
tFL-21 31,746,862 28,752,256 2,903,977,856 
90.57
% 
773 680 
95.34
% 
89.87
% 
KARPA
S-422 
40,802,670 36,187,510 3,654,938,510 
88.69
% 
952 841 
95.50
% 
89.92
% 
FL-23-1 38,999,680 35,230,592 3,558,289,792 
90.34
% 
1000 837 
95.52
% 
89.90
% 
FL-23-2 40,960,006 36,782,770 3,715,059,770 
89.80
% 
1017 858 
95.33
% 
89.83
% 
tFL-23 36,783,674 33,217,988 3,355,016,788 
90.31
% 
941 799 
95.37
% 
89.86
% 
FL-24-1 25,211,878 22,258,334 2,248,091,734 
88.29
% 
603 536 
95.00
% 
89.66
% 
FL-24-2 36,757,574 32,288,728 3,261,161,528 
87.84
% 
873 778 
95.18
% 
89.73
% 
tFL-24 42,562,004 37,436,676 3,781,104,276 
87.96
% 
1012 885 
95.40
% 
89.92
% 
FL-25-1 32,177,034 28,231,026 2,851,333,626 
87.74
% 
784 660 
95.21
% 
89.70
% 
FL-25-2 29,521,614 24,330,136 2,457,343,736 
82.41
% 
605 529 
95.59
% 
89.99
% 
tFL-25 39,425,936 32,595,856 3,292,181,456 
82.68
% 
750 667 
95.70
% 
89.97
% 
FL-26-1 30,333,532 26,278,374 2,654,115,774 86.63 708 605 95.23 89.82
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% % % 
FL-26-2 32,761,944 28,522,064 2,880,728,464 
87.06
% 
821 690 
95.29
% 
89.79
% 
tFL-26 37,275,886 32,372,154 3,269,587,554 
86.84
% 
880 753 
95.42
% 
89.94
% 
FL-27 47,299,092 42,250,582 4,267,308,782 
89.33
% 
1146 
102
1 
95.25
% 
89.59
% 
tFL-27 51,565,566 46,014,100 4,647,424,100 
89.23
% 
1214 
108
6 
95.24
% 
89.65
% 
FL-28 44,351,228 40,003,606 4,040,364,206 
90.20
% 
1049 930 
95.09
% 
89.54
% 
tFL-28 46,206,520 40,649,858 4,105,635,658 
87.97
% 
1131 986 
95.21
% 
89.58
% 
FL-29 48,257,298 42,504,248 4,292,929,048 
88.08
% 
1216 
104
4 
95.13
% 
89.63
% 
tFL-29 28,674,836 25,401,852 2,565,587,052 
88.59
% 
700 613 
94.99
% 
89.48
% 
FL-30 51,330,246 45,304,466 4,575,751,066 
88.26
% 
1266 
110
9 
95.18
% 
89.57
% 
tFL-30 40,658,460 36,030,640 3,639,094,640 
88.62
% 
1003 869 
95.06
% 
89.44
% 
FL-31 33,138,820 29,408,576 2,970,266,176 
88.74
% 
818 709 
95.03
% 
89.52
% 
tFL-31 20,070,002 17,797,300 1,797,527,300 
88.68
% 
491 426 
94.85
% 
89.38
% 
tFL-32 54,421,832 46,090,264 4,655,116,664 
84.69
% 
1301 
111
9 
95.00
% 
89.53
% 
tFL-33 39,634,324 35,351,892 3,570,541,092 
89.20
% 
978 848 
95.01
% 
89.59
% 
tFL-34 53,733,670 48,043,530 4,852,396,530 
89.41
% 
1319 
115
9 
95.22
% 
89.61
% 
tFL-35 52,127,122 46,398,420 4,686,240,420 
89.01
% 
1314 
113
4 
95.21
% 
89.72
% 
tFL-36 61,553,502 54,997,112 5,554,708,312 
89.35
% 
1515 
131
7 
95.19
% 
89.69
% 
tFL-37 48,163,280 43,010,422 4,344,052,622 
89.30
% 
1192 
102
6 
95.19
% 
89.71
% 
tFL-38 50,147,304 45,078,500 4,552,928,500 
89.89
% 
1208 
106
1 
95.25
% 
89.68
% 
tFL-39 43,741,788 38,832,258 3,922,058,058 
88.78
% 
1056 946 
95.09
% 
89.57
% 
tFL-40 52,922,576 47,175,804 4,764,756,204 
89.14
% 
1281 
114
2 
95.18
% 
89.72
% 
max 61,553,502 54,997,112 5,554,708,312 
91.21
% 
1515 
131
7 
99.77
% 
90.13
% 
min 20,070,002 17,797,300 1,797,527,300 
82.41
% 
491 426 
88.25
% 
83.16
% 
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mean 40,384,312 35,883,170 3,624,200,156 
88.84
% 
982 849 
95.31
% 
89.60
% 
media
n 
39,939,521 35,724,863 3,608,211,163 
89.17
% 
979 840 
95.23
% 
89.72
% 
SD 8,677,316 7,751,512 782,902,664 1.94% 224 194 
1.45
% 1.01% 
Table 3-4. General statistical information for custom capture panel sequenced samples.  
 
 
Figure 3-5. Numbers of reads in 43 FL/tFL custom capture panel sequenced samples. 
 
 
Figure 3-6. Depth of coverage for coding regions and splice sites in 43 FL/tFL custom capture 
panel sequenced samples. 
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Figure 3-7. Coverage of coding regions and splice sites in 43 FL/tFL custom capture panel 
sequenced samples.  
 
B.3. Custom capture panel mutation detection pipelines validation 
We sequenced 3 of the paired cases for which we had WES data. After that we determined 
the number of overlapping variants with sufficient depth in both platforms. We confirmed that 
more than 98% of the variants that were detected by WES were successfully detected in the 
custom capture panel in all 3 paired cases (Table 3-5). We also reported all the known mutations 
in KARPAS-422. We then calculated the depth for mutations (mutations in Tier 1 and 2 in Table 
3-6) found in both platforms and compared their variant frequency. We confirmed that the 
mutation depth in custom capture panel was much deeper than WES and the majority of variant 
frequencies between the two platforms were similar (Table 3-6).  
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 Case 
Variants Found in 
WES 
Sufficient Custom Depth Validated Validate Rate 
FL-3 109,803 2,788 2,742 98.40% 
tFL-3 98,423 2,522 2,485 98.50% 
FL-5 96,326 2,544 2,492 98.00% 
tFL-5 99,221 2,789 2,742 98.30% 
FL-10 112,456 2,898 2,845 98.20% 
tFL-10 104,922 2,703 2,650 98.00% 
Total 621,151 16,244 15,956 
Table 3-5. Variant overlap for 3 paired cases sequenced by both WES and custom capture 
panel. Sufficient custom depth indicates that the mutations found in WES also had sufficient 
depth in custom capture panel for comparison. 
 
Case 
Chromosome| 
Position |Altered-
Base 
Gene 
 
 
WES data Custom-seq data 
Var 
Read 
Depth 
Total 
Read 
Depth 
Var 
Freq 
Var 
Read 
Depth 
Total 
Read 
Depth 
Var 
Freq 
FL-10 chr14|23345905|C LRP10 40 96 42% 547 1765 31% 
FL-10 chr1|85736474|T BCL10 125 193 65% 17 245 7% 
FL-3 chr1|110882568|G RBM15 12 21 57% 35 160 22% 
FL-5 chrX|41200829|C DDX3X 11 31 36% 35 81 43% 
tFL-10 chr4|40245479|A RHOH 72 146 49% 1740 3550 49% 
tFL-10 chr16|3786704|G CREBBP 24 29 83% 347 456 76% 
tFL-10 chr6|157528317|A ARID1B 46 89 52% 628 1653 38% 
tFL-10 chr3|187449624|A BCL6 20 58 35% 440 1047 42% 
tFL-10 
chr12|49433524|-
CT 
KMT2D(
MLL2) 
50 62 81% 203 244 83% 
tFL-10 chr17|80209332|A CSNK1D 57 153 37% 522 1213 43% 
tFL-10 chr13|31037742|A HMGB1 57 136 42% 44 295 15% 
tFL-10 chr21|44521518|A U2AF1 38 102 37% 28 172 16% 
tFL-3 chr17|62007128|T CD79B 6 30 20% 447 2236 20% 
tFL-3 chr4|3134324|A HTT 15 61 25% 60 334 18% 
tFL-3 chr15|42035019|A MGA 21 39 54% 101 146 69% 
tFL-5 chr16|3807881|A CREBBP 18 34 53% 658 1646 40% 
tFL-5 chr12|49438694|T 
KMT2D(
MLL2) 
17 32 53% 683 1484 46% 
tFL-5 chr12|49418731|A 
KMT2D(
MLL2) 
17 43 40% 546 1162 47% 
tFL-5 chr7|148508728|T EZH2 20 43 47% 317 857 37% 
tFL-5 chr17|7577598|A TP53 14 25 56% 3 28 11% 
tFL-5 chr12|7287964|T CLSTN3 26 60 43% 1021 2430 42% 
tFL-5 chr16|3808033|G CREBBP 6 18 33% 451 1074 42% 
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tFL-5 chr16|3807917|C CREBBP 25 47 53% 999 2379 42% 
tFL-5 chr12|57493137|C STAT6 50 57 88% 654 909 72% 
tFL-5 chr17|78269544|C RNF213 13 26 50% 297 874 34% 
tFL-5 chr16|3808046|G CREBBP 7 16 44% 451 1074 42% 
tFL-5 chr16|85936784|G IRF8 18 32 56% 328 820 40% 
tFL-5 chrX|39923127|G BCOR 9 19 47% 259 740 35% 
tFL-5 chr3|78987869|A ROBO1 24 52 46% 609 1449 42% 
tFL-5 chr16|3808030|C CREBBP 6 19 32% 451 1074 42% 
tFL-5 chr12|57493818|C STAT6 51 60 85% 836 1114 75% 
tFL-5 chr17|7577545|C TP53 14 37 38% 5 6 83% 
Table 3-6. Comparison of depth in genes found mutated by WES and custom gene sequencing. 
 
B.4. Mutations identified by the custom capture panel  
We identified a total of 484 mutations (134 different genes) in the custom capture panel 
dataset (Table 3-7). 169 were detected in single samples (74 different genes) and 80 were in the 
confident final list (42 different genes). 156 (in 61 different genes) were detected in both paired 
FL and tFL samples (shared mutations) and 66 were in the confident final list (27 different genes). 
19 (in 17 different genes) were only detected in FL samples (FL-unique mutations) and 8 were in 
the confident final list (8 different genes). 140 (in 84 different genes) were only detected in tFL 
samples (tFL-unique mutations) and 68 were in the confident final list (40 different genes).  
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Type 
Sequence 
type 
Total 
T1+T2+TR
+express 
T1+
expr
ess 
T2+
expr
ess 
TR+e
xpres
s 
T1+expre
ss+recurr
ent 
T1+T2+TR+e
xpress+recu
rrent 
single custom 169 157 91 40 26 80 129 
share custom 156 143 94 40 9 66 95 
FL- 
unique 
custom 
19 17 14 2 1 8 10 
tFL- 
unique 
custom 
140 130 98 27 5 68 88 
 sum 484 447 297 109 41 222 322 
Table 3-7. Number of mutations detected by custom capture panel in different mutation types 
and filtering. 
 
B.5. Validation of a binomial distribution model  
Because most of our tumor samples have a considerable admixture of normal cells, the true 
variant frequency for somatic mutations is expected to be less than 0.5, but the frequency for 
germline variants should equal 0.5. Thus, we wanted to be able to use a proportion test to 
determine the likelihood that a fraction of variant counts was significantly different from 0.5. 
We performed the proportion test on the data from the custom platform on heterozygous 
germline variants (SNPs). For almost all heterozygous germline variants, approximately 50% of 
reads should support each allele. Using dbSNP, a compendium of germline variants we can 
extract heterozygous SNPs from the variants called using the mutation analysis pipeline. 
Unfortunately, when we performed the proportion test on these known SNPs, many more than 
expected showed a significant difference from 0.5. One possible explanation is that multiple 
reads were derived from a single initial molecule due to the PCR step; the average number of 
reads per initial molecule was designated “the duplicate ratio.”  If there are no duplicates 
(duplicate ratio =1), p-values from the binomial test for each heterozygous germline variant will 
be uniformly distributed, and the slope of the regression model fitting the frequencies of the p-
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values to the p-value will be close to 0; however, if there are PCR-generated duplicate reads, p-
values close to zero will be overrepresented. We designed a binomial distribution statistical 
model to estimate the duplicate ratio. We estimated the duplicate ratio based on the slope of 
the linear regression model of p-values generated from binomial tests and frequencies of the p-
values.  
To validate the model, we extracted all the heterozygous germline variants from the 
mutation detection pipelines and did the duplicate ratio simulation based on the extracted real 
total reads to display the patterns of p-values and frequencies of the p-values with and without 
duplicates. Figure 3-8 displayed the patterns of no duplicates, duplicate ratio equal to 2 and 
duplicate ratio equal to 4. The number of total reads applied in Figure 3-8 was randomly 
selected from the real total reads of all the samples (range, 100-1200). According to the 
rationale for the binomial distribution model, if there are no duplicates, most of the null 
hypotheses, the probability that a read supports one allele is 0.5, will not be rejected, and the 
majority of total reads are assigned equally. That is why there was a big peak on the far right, 
whereas the rest of p-values were uniformly distributed in Figure 3-8 (No duplicates). If there 
are PCR-generated duplicates, most of the hypotheses will be rejected, implying that at the 
majority of sites, the total reads are assigned unequally, and p-values close to zero will be 
overrepresented. That is why there was a big peak on the left as displayed in Figure 3-8 
(duplicate*2 and duplicate*4). As the PCR-duplicate ratio increases, the peak close to zero 
becomes more exaggerated; therefore, when the PCR-duplicate ratio was 2, the frequency of p-
values close to 0 was a little bit over 1500 and it increased to over 3000 when the PCR-duplicate 
ratio reached 4 in Figure 3-8. From the results of the 10,000,000 simulations we did based on a 
real number of reads from all of our samples with duplicate ratio equal to 1, we can see the 
trend of the histogram was flat except the p-values close to 1 in Figure 3-9 as we expected, 
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which confirmed that the p-values from binomial test will be uniformly distributed if there are 
no duplicates. 
  
Figure 3-8. Patterns of different duplicate ratio. 
 
 
Figure 3-9. Pattern when the duplicate ratio is equal to 1. 
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B.6. Duplicate ratio estimation 
We applied the Binomial distribution model and estimated the duplicate ratio for all the 
samples sequenced using the custom capture panel (Table 3-8). The average duplicate ratio was 
3.3. We then adjusted the reads in the 3 paired cases for which we had WES data and custom 
capture panel with predicted duplicate ratio. With a few exceptions, the read depth in the data 
from the custom capture panel was still much deeper than from WES in genes found mutated in 
both platforms (Table 3-9). 
Case  
Duplicate 
ratio 
Case  
Duplicate 
ratio 
Case  
Duplicate 
ratio 
Case15 2.76 Case25FL2 2.28 Case31tFL 2.36 
Case16 2.98 Case25tFL 2.62 Case32 3.8 
Case17 3 Case26FL1 2.92 Case33 3.8 
Case18 2.2 Case26FL2 2.62 Case34 2.96 
Case19 2.26 Case26tFL 1.75 Case35 2.7 
Case20 2.879 Case27FL 12 Case38 2.96 
Case21 2.92 Case27tFL 2.82 Case39 3.2 
Case23FL1 2.78 Case28FL 4.8 Case3FLcustom 2.24 
Case23FL2 2.7 Case28tFL 6.7 Case3tFLcustom 2.4 
Case23tFL 2.3 Case29FL 3.26 Case40 13 
Case24FL1 2.28 Case29tFL 2 Case5FLcustom 2.74 
Case24FL2 2.76 Case10FLcustom 2.94 Case5tFLcustom 2.56 
Case24tFL 2.24 Case10tFLcustom 2.7 CaseKARPAS422 2.9 
Case25FL1 2.46 Case31FL 2.56   
Table 3-8. Estimated duplicate ratio in all samples sequenced by custom capture panels. 
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Case 
Chromosome| 
Position 
|Altered-Base 
 
 
WES Custom 
Adjusted 
custom 
Var 
Read 
Depth 
Total 
Read 
Depth 
Var 
Freq 
Var 
Read 
Depth 
Total 
Read 
Depth 
Var 
Freq 
Var 
Read 
Depth 
Total 
Read 
Depth 
FL-10 
chr14|23345905
|C 
40 96 42% 547 1765 31% 186 600 
FL-10 
chr1|85736474|
T 
125 193 65% 17 245 7% 6 83 
FL-3 
chr1|110882568
|G 
12 21 57% 35 160 22% 16 71 
FL-5 
chrX|41200829|
C 
11 31 36% 35 81 43% 13 30 
tFL-
10 
chr4|40245479|
A 
72 146 49% 1740 3550 49% 644 1315 
tFL-
10 
chr16|3786704|
G 
24 29 83% 347 456 76% 129 169 
tFL-
10 
chr6|157528317
|A 
46 89 52% 628 1653 38% 233 612 
tFL-
10 
chr3|187449624
|A 
20 58 35% 440 1047 42% 163 388 
tFL-
10 
chr12|49433524
|-CT 
50 62 81% 203 244 83% 75 90 
tFL-
10 
chr17|80209332
|A 
57 153 37% 522 1213 43% 193 449 
tFL-
10 
chr13|31037742
|A 
57 136 42% 44 295 15% 16 109 
tFL-
10 
chr21|44521518
|A 
38 102 37% 28 172 16% 10 64 
tFL-3 
chr17|62007128
|T 
6 30 20% 447 2236 20% 186 932 
tFL-3 chr4|3134324|A 15 61 25% 60 334 18% 25 139 
tFL-3 
chr15|42035019
|A 
21 39 54% 101 146 69% 42 61 
tFL-5 
chr16|3807881|
A 
18 34 53% 658 1646 40% 257 643 
tFL-5 
chr12|49438694
|T 
17 32 53% 683 1484 46% 267 580 
tFL-5 
chr12|49418731
|A 
17 43 40% 546 1162 47% 213 454 
tFL-5 
chr7|148508728
|T 
20 43 47% 317 857 37% 124 335 
tFL-5 
chr17|7577598|
A 
14 25 56% 3 28 11% 1 11 
tFL-5 
chr12|7287964|
T 
26 60 43% 1021 2430 42% 399 949 
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tFL-5 
chr16|3808033|
G 
6 18 33% 451 1074 42% 176 420 
tFL-5 
chr16|3807917|
C 
25 47 53% 999 2379 42% 390 929 
tFL-5 
chr12|57493137
|C 
50 57 88% 654 909 72% 255 355 
tFL-5 
chr17|78269544
|C 
13 26 50% 297 874 34% 116 341 
tFL-5 
chr16|3808046|
G 
7 16 44% 451 1074 42% 176 420 
tFL-5 
chr16|85936784
|G 
18 32 56% 328 820 40% 128 320 
tFL-5 
chrX|39923127|
G 
9 19 47% 259 740 35% 101 289 
tFL-5 
chr3|78987869|
A 
24 52 46% 609 1449 42% 238 566 
tFL-5 
chr16|3808030|
C 
6 19 32% 451 1074 42% 176 420 
tFL-5 
chr12|57493818
|C 
51 60 85% 836 1114 75% 327 435 
tFL-5 
chr17|7577545|
C 
14 37 38% 5 6 83% 2 2 
Table 3-9. Comparison of read depth in genes found mutated by WES and custom gene 
sequencing after duplicate ratio adjustment. 
 
B.7. Discussion 
We observed the depth in 2 mutations detected by custom capture was not as good as WES 
and the 2 mutations were very close to each other. These errors are probably due to the poor 
design of that specific region. The average duplicate ratio was 3.3, but there are four samples 
with a much larger estimated duplicate ratio than others. It is probably because the tumor 
genome in these four samples has CNAs that have a large fraction of the dbSNP SNPs, which are 
truly not equal to 0.5, these dbSNP SNPS would interfere with the approach used. 
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C. Somatic mutation filtering 
C.1. Introduction 
In order to remove germline variants from our mutation list, we applied different layers of 
filtering with a number of reliable datasets. We also validated our somatic mutation filters in 
samples with corresponding normal samples to ensure that our filtering method can exclude 
most germline variants from our list of likely somatic mutations. We set up two tiers of 
mutations, listed according to stringency. 
C.2. Positive and negative filtering validation 
We applied the filtering to a dataset that had paired FL and tFL samples with normal 
samples from the same patients. In Table 3-10, we listed the number of germline variants and 
somatic mutations in different layers of filtering. In negative filtering, we first removed 
synonymous mutations and mutations detected in intergenic and intronic regions, and 5’ and 3’ 
UTRs. The total number of mutations after this step was 51,685. Then dbSNP filtered out a 
majority of variants and left 4655 variants including 4038 germline variants and 617 somatic 
mutations. Mutations that are very close to each other were considered false positives and were 
removed; this step left 1390 mutations in the list including 877 germline variants and 513 
somatic mutations. The paralog gene database removed 141 apparent mutations and left 1249 
mutations for the next step. Mutations found in other unrelated normal samples were 
considered private SNPs or artifacts. This resulted in 1183 mutations remaining in the study 
including 709 germline variants and 474 somatic mutations. After this step, we checked the 
recurrence of these remaining mutations and removed the ones that had high frequency. In 
general, negative filtering removed 51199 variants and kept 943 variants with 485 germline 
variants and 458 mutations. The proportion of germline variants decreased in Figure 3-10. The 
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positive filtering filtered out 457 mutations and kept 486 mutations including 98 germline 
variants and 388 somatic mutations. Since mutations can fall in different categories among the 
positive filtering criteria, we made Table 3-11, Table 3-12 and Table 3-13 to give a specific look 
at the distribution of germline variants and somatic mutations, we also made Figure 3-11 to 
display the portion of germline variants and somatic mutations in different categories. The FDR 
of the filter set is 20.2%.  
 Total Germline Somatic 
non-protein-changing 51685 - - 
dbSNP 4655 4038 617 
Adjacent 1390 877 513 
paralog genes 1249 758 491 
Normal samples 1183 709 474 
Too Many Positive 943 485 458 
Positive Filtering 486 98 388 
Table 3-10. Evaluation of the somatic filters performance of the negative and positive filtering. 
 
 
Figure 3-10. Proportions of germline variants and somatic mutations at different stages of 
negative and positive filtering. 
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Categories 388 true somatic mutations identified by   
Intra-Case-Specific 30 
Intra-Case-Specific, Cancer-Gene 1 
Intra-Case-Specific, Loss-Of-Function, Reduced-VAF 5 
Intra-Case-Specific, Loss-Of-Function, Reduced-VAF, Cancer-Gene 1 
Intra-Case-Specific, Reduced-VAF 107 
Intra-Case-Specific, Reduced-VAF, Cancer-Gene 5 
Intra-Case-Specific, Reported-Site 1 
Intra-Case-Specific, Reported-Site, Cancer-Gene 2 
Intra-Case-Specific, Reported-Site, Loss-Of-Function, Cancer-Gene 1 
Intra-Case-Specific, Reported-Site, Reduced-VAF 4 
Loss-Of-Function, Cancer-Gene 3 
Loss-Of-Function, Reduced-VAF 31 
Loss-Of-Function, Reduced-VAF, Cancer-Gene 4 
Reduced-VAF 145 
Reduced-VAF, Cancer-Gene 15 
Reported-Site, Cancer-Gene 1 
Reported-Site, Loss-Of-Function 4 
Reported-Site, Loss-Of-Function, Cancer-Gene 1 
Reported-Site, Loss-Of-Function, Reduced-VAF 4 
Reported-Site, Loss-Of-Function, Reduced-VAF, Cancer-Gene 1 
Reported-Site, Reduced-VAF 16 
Reported-Site, Reduced-VAF, Cancer-Gene 6 
Table 3-11. True positive somatic mutations in positive filtering. 
 
Categories 98 false mutations belonged to   
Intra-Case-Specific, Reported-Site, Reduced-VAF 1 
Loss-Of-Function, Reduced-VAF 4 
Reduced-VAF 76 
Reduced-VAF, Cancer-Gene 2 
Reported-Site, Cancer-Gene 2 
Reported-Site, Reduced-VAF 12 
Reported-Site, Reduced-VAF, Cancer-Gene 1 
Table 3-12. False positive somatic mutations in positive filtering. 
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 Germline Somatic 
Intra-Case-Specific 1 157 
Reported-Site 16 41 
Reduced-VAF 96 344 
Loss-Of-Function 4 55 
Cancer-Gene 5 41 
Table 3-13. Evaluation of the performance of the somatic filters in positive filtering. 
 
 
Figure 3-11. Proportions of germline and somatic variants among different categories of 
positive filtering. 
 
C.3. Discussion 
We applied very strict filters to avoid mistakenly including germline variants in our reliable 
somatic mutation list. These strict rules might be too strict and let some real somatic mutations 
slip away. For example, some real somatic mutations might not fall into negative filtering but 
also not have enough strong positive signals to pass the positive filter either. For such mutations, 
we added one more rescue rule, that is, the variants that did not pass the positive filter but 
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were in genes recurrently mutated in other samples were considered potential somatic 
mutations and were not removed. 
D. Somatic mutation prediction by machine learning methods 
D.1. Introduction 
We applied various machine learning methods to two published datasets8,9 (Pasqualucci 
dataset and Okosun dataset) to provide straightforward predictions of somatic mutations 
instead of filtering by layers. Sensitivity, specificity, FDR (Table 3-14) and AUC were used to 
evaluate the performance. We also applied the trained models to our dataset and checked the 
consistence with our filtering based method. RF turned out to have had the best performance in 
general. 
 
Table 3-14. 2X2 contingency table to calculate sensitivity, specificity and FDR. TN indicates true 
negative, FN indicates false negative, FP indicates false positive, TP indicates true positive, and 
FDR indicates false discover rate. 
 
D.2. Machine learning validation 
We downloaded two published datasets which have pairs of FL and tFL with corresponding 
normal samples. We used one dataset as training data, and the other as testing data with two 
sets of different features to predict somatic mutations. We assigned one set of features with 
basic information and the other set with more complex information. We calculated 4 statistical 
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measures to evaluate the performance of the models. Sensitivity measures the proportion of 
successfully detected true somatic mutations out of all true somatic mutations. Specificity 
measures the proportion of successfully detected true germline variants out of all true germline 
variants. FDR measures the proportion of false predicted somatic mutations out of all predicted 
somatic mutations. AUC measures the area under the ROC curve. 0.90 to 1 is considered to be 
excellent; 0.8 to 0.9 is considered to be good; 0.7 to 0.8 is considered to be fair; 0.6 to 0.7 is 
considered to be poor; and 0.5 to 0.6 is considered failure. In general, all the models had very 
decent statistical measures (Table 3-15, Table 3-16): the specificity and AUC were excellent. The 
sensitivity and the FDR varied among the different models. Complex features were slightly 
better than basic features. Taking all of the measures into consideration, RF had the best 
performance; it had much lower FDR and very similar in sensitivity to the others. We also 
applied the trained models to our own dataset and checked the overlap with the filtering based 
method. The majority of the predicted somatic mutations were detected by positive and 
negative filtering method, which confirmed the machine learning model to be very robust. 
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Table 3-15. Performance of machine learning models with basic features. SVM indicates 
support vector machine, rp indicates recursive partitioning, rf indicates random forest, nnet 
indicates neural networks, AUC indicates area under curve, FDR indicates false discover rate, TN 
indicates true negative, FN indicates false negative, FP indicates false positive, and TP indicates 
true positive. 
 
 
 
Table 3-16. Performance of machine models with complex features. SVM indicates support 
vector machine, rp indicates recursive partitioning, rf indicates random forest, nnet indicates 
neural networks, AUC indicates area under curve, FDR indicates false discover rate, TN indicates 
true negative, FN indicates false negative, FP indicates false positive, and TP indicates true 
positive. Note: * one spot was removed because the training dataset does not have it covered. 
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D.3. Discussion 
SIFT score is the feature we added in the set of complex features. It predicts amino acid 
changes that affect protein function33. If a variant is a somatic mutation that contributes to the 
disease, SIFT should be more likely to predict it to be deleterious. Conversely, germline variants 
that exist in a normal sample are more likely to be functionally neutral with a benign prediction 
from SIFT. Therefore, SIFT score should be able to provide very useful information to improve 
the training models. From the results, we did see the models that were trained with complex 
features performed better than those trained only with basic features. SIFT does not assign a 
score to all the variants; therefore, we had to filter out those that do not have a SIFT score in the 
training data. This limited the size of the training data, which may explain why the complex 
feature did not improve the statistical measures a lot. We do not have normal samples in our 
own dataset, but our somatic mutation filtering is very reliable. The overlap of the two 
independent methods is strong evidence indicating that the machine learning model has the 
capability to predict somatic mutations. It also confirms our filtering method. 
E. CNA and patient outcome 
E.1. Introduction 
FL is indolent with about 8 to 10 years survival time. However, tFL progresses more rapidly 
with shorter survival, commonly less than two years. Therefore it is very important for us to 
accurately identify abnormalities that are associated with survival so that we can monitor the 
patients more closely and provide better treatment plans. Compared to standard survival 
analysis, our advanced survival analysis provided alternative tests that were able to put weight 
in different stages of the survival curve and chose the most accurate test based on the character 
of each individual rCNA.  
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E.2. Survival analysis for patients with different rCNAs 
In our previous study, we used a CNV analysis pipeline on high-resolution SNP array 
processed samples to identify abnormalities that contribute to FL transformation. For each rCNA, 
the average number of rCNAs present in cases with that rCNAs was calculated to model the 
progression of rCNAs in FL evolution. Abnormalities that occur in the early stage of FL are 
expected to have higher frequency and be found preferentially in tumors that have a lower 
average number of other abnormalities, whereas abnormalities that occur late in the disease are 
expected to be found preferentially in tumors that have a high average number of other 
abnormalities. 
In our survival analysis, we first inferred the temporal order of the rCNAs based on the 
average abnormality numbers in Figure 3-1231. For example, loss on 9p21.3 (rCNA402) and 
6q13-q15 (rCNA341) occurred early in FL development. We then put the weight in different 
stages of the survival curve based on the biological characters of the rCNAs to test the 
difference between the two overall survival curves.  
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Figure 3-12. Number of abnormalities associated with rCNAs31.  The av.abnl indicates the 
average numbers of abnormalities with a specific CNA. 
Our survival analysis generated pdf format output with convenient bookmarks (Figure 3-13). 
The results included survival estimation at different time points with the corresponding number 
of failures, the number of remaining patients in the study and number of censored patients, p-
values for all alternative tests, survival curves for the two compared groups (with and without 
the abnormality) with 95% confidence intervals and censored patients at different time points 
within the survival curves (Figure 3-14). For example, we had 5 patients who had rCNA402 
(Table 3-18). 4 of them died at different time points (0.734, 0.767, 1.792 and 9.949). One of 
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them was lost to follow-up at 5.8940. The probability that a patient is alive past time=0 is 100%; 
the probability that a patient is alive past time=0.734 (268 days) is 80%; and the probability that 
a patient is alive past time=0.7670 (280 days) is 60%, when it comes to time=9.949 (3631 days), 
the probability that a patient is alive is 0%. If we do not take the biological property into 
consideration and just use the log-rank test, the log-rank statistic is 5.5652 and the 
corresponding p-value is 0.0183 (Table 3-19) indicating that the null hypothesis (all survival 
curves are the same) should be rejected. We can therefore conclude that groups with and 
without rCNA402 have significantly different KM survival curves and that rCNA402 is associated 
with poor outcome in FL. However, according to the calculated average numbers of 
abnormalities (Figure 3-12), rCNA402 occurs quite early (8.3 in Figure 3-12) in the FL 
development; therefore, the Wilcoxon test is a much more appropriate test for rCNA402, which 
puts more weight on the earlier survival curve, and the p-value (0.0080) from Wilcoxon test 
shows a much more significant difference between groups with and without rCNA402 (Table 3-
19) than the p-value (0.0183) from log-rank test. We are also 95% confident that the entire 
survivor function fell within upper curve and lower curve as figure 3-3 shows. We applied the 
survival analysis to other rCNAs that appear to occur in the early stage of FL as the previous 
study mentioned, and showed that rCNA304 (p-value<0.0001 by Tarone-Ware test), rCNA341 
(p-value =0.05 by Tarone-Ware test), rCNA1013 (p-value =0.0457 by Tarone-Ware test) and 
rCNA818 (p-value=0.0469 by Tarone-Ware test) are associated with poor  survival for the 
patients (Figure 3-14 and Table 3-19).  
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Figure 3-13. pdf format output with bookmark. 
 
 
Table 3-17. Survival estimation at different time points in rCNA402.  
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                     rCNA402 (early)                                                     rCNA304    
 
 
 
                         rCNA341 (early)                                                  rCNA1013 (early) 
 
 
 
                           rCNA818 (late) 
Figure 3-14. Survival curves of rCNA402, rCNA304, rCNA341, rCNA1013 and rCNA818.  
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                     rCNA402 (early)                                                        rCNA304    
 
 
 
                     rCNA341 (early)                                                      rCNA1013 (early) 
 
 
 
                       rCNA818 (late) 
Table 3-18. Tests in rCNA402, rCNA304, rCNA341, rCNA1013 and rCNA818. 
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E.3. Discussion 
We collected a decent number of clinical samples but some of the abnormality groups had a 
very small number of patients. It could cause a large standard error or a situation where one or 
two patients’ failure makes a noticeable difference between the groups being compared.  
There are multiple tests for abnormalities occurring in the early stage of the disease, and 
each of them is slightly different. Compared to the log-rank test, the Wilcoxon test puts the 
most weight in the earlier phase of the disease. The Tarone-Ware test is more moderate, and 
the weight is between a log-rank test and the Wilcoxon test on the earlier phase. One study 
group proved that the Tarone-Ware test is better than both the log-rank test and Wilcoxon test, 
so if the rCNAs do not indicate that abnormalities occur in a very early stage, we chose Tarone-
ware test instead of other tests. We can also take all the p-values from the tests into 
consideration. The Fleming-Harrington test can be applied to both abnormalities occurring in 
the early or late stage depending on the parameters. It is a very flexible method, but there are a 
large number of combinations for the parameters. How the parameters are assigned can also 
make a difference. 
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CHAPTER IV 
DOWNSTREAM ANALYSIS AND DISCUSSION 
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A. Somatic mutation integration 
We integrated somatic mutations that were identified in WES and custom capture 
sequencing using strict positive and negative filtering and selected recurrently mutated genes in 
the combined WES and custom capture panel dataset. 50 recurrently mutated genes were 
identified in the combined dataset. The genes most frequently mutated in tFL included KMT2D 
(MLL2), CREBBP, BCL2, EZH2, MEF2B, and TNFRSF14 as noted in Figure 4-1. We also identified 
recurrent shared mutations, FL-unique mutations and tFL-unique mutations from WES and 
custom capture sequencing each individually for FL transformation and subclone analysis (Table 
4-1 and Appendix A). Mutations detected in single tFL samples (without a corresponding FL 
sample) also contributed to FL transformation analysis (Table 4-1 and Appendix A). 
89 
 
 
 
Figure 4-1. Genes found to be recurrently mutated in tFLs. Only genes with at least one Tier 1 
mutation found in a tFL/FL pair were selected. Its distribution in other situations is also shown 
with different colors representing different statuses of the individual cases. Blocks with 1 color 
indicate that one mutation was observed. Similarly, blocks with 2 colors indicate that more than 
one status was observed. Genes are also noted by copy number gain or loss in the tFL cases. 
Copy number data are not available for case 8, 22, and 31. Tier R mutations were “rescued” 
from the stringent filtering criteria associated with Tier 1 and Tier 2 mutations. 
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Class T1+T2+TR Genes 
FL-unique 2 KMT2D(MLL2), BCL2 
tFL-unique 10 
KMT2D(MLL2), CREBBP, BCL2, EZH2, CARD11, CCND3, SOCS1, TP53, 
KMT2C(MLL3), MYD88 
shared 16 
KMT2D(MLL2), CREBBP, BCL2, EZH2, MEF2B, TNFRSF14, CCND3, 
SOCS1, IRF8, HIST1H1D, ARID1A, BIRC6, MGA, MIR142, C10orf12, 
RRAGC 
single 22 
KMT2D(MLL2), CREBBP, BCL2, EZH2, MEF2B, TNFRSF14, CARD11, 
CCND3, HIST1H1E, SOCS1, TAF1, CD79B, IRF8, PIM1, EP300, 
HIST1H1C, KMT2C(MLL3), RNF213, STAT3, DTX1, HIST1H2AM, IL7R 
Table 4-1. Recurrent somatic mutations identified in WES and custom capture sequencing. 
Genes from Tier R are labeled in green. 
 
B. Somatic mutations within regions of rCNAs  
Using our previous CNA data, we identified the CN for the recurrent mutations (Appendix B) 
and listed the mutations within rCNAs in FL and tFL samples (Appendix C). The integration of 
mutation data with CNA data provided complementary information to investigate the role of 
genetic alterations in tumor initiation and progression. In Figure 4-1, genes with CNA were 
denoted as G (CN=3, CN gain), L (CN=1, CN loss), GG (CN>3, CN amplification) and LL (CN<1, 
double loss).  
TNFRSF14 is a likely driver gene in one of the most frequent rCNAs in FL and tFL (loss of 
1p36.33-p36.31, rCNA122 in Table 4-2). It was mutated in 20% (7/35) of cases. One of the 
mutations was a FL-unique mutation in a paired case (chr1|2493172|A in FL-6). This case also 
had a CN loss (CN=1) affecting the gene. Two of the mutations were shared mutations 
(chr1|2493112|C in case 5 and chr1|2493111|A in case 10). One of the two shared mutations 
was associated with a CN loss (case 5, CN=1). The rest of the mutations were all found in 
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unpaired single tFL cases. One of the single tFL cases (chr1|2492063|-C in tFL-35) had a CN loss 
(CN=1) affecting TNFRSF14. Thus, homozygous loss of wild-type TNFRSF14 is a relatively 
frequent event in FL and tFL. 
CARD11 is an important oncogenic gene with frequent CN gain. It was mutated in 17% (6/35) 
of cases. Two of the mutations were tFL-unique mutations (chr7|2979495|G in tFL-2 and 
chr7|2979501|G in tFL-23). Both of the tFL-unique mutations had a CN amplification (CN=4 in 
tFL-2 and CN=3 in tFL-23) affecting the locus. The other cases with mutations were all unpaired 
single tFL cases. Two of the single tFL cases (chr7|2984163|T in tFL-15, chr7|2979466|G in tFL-
15, and chr7|2977614|A in tFL-34) had CN gain (CN=3) affecting CARD11. The CARD11 locus is 
affected by gains in 24% of FL samples and 39% of tFL samples in our previous studies. All the 
evidence suggests that CARD11 may be activated by both CN gain and mutation, and coordinate 
the activation of the NF-κB pathway. 
HIST1H1E is another important oncogenic gene with frequent copy number gain34. It was 
mutated in 17% (6/35) of cases. Two out of three paired cases had tFL-unique mutations 
(chr6|26156911|A in tFL-20 and chr6|26156797|T in tFL-23). One of the two tFL-unique 
mutations also had a CN gain (CN=3). The other 3 cases of the 6 were all unpaired single tFL 
cases. Two (chr6|26156947|G in tFL-37 and chr6|26157271|G in tFL-38) out of the three single 
tFL cases also had CN gain (CN=3). The evidence suggests that HIST1H1E may be affected by 
both CN gain and mutation. 
EZH2 is a known mutated gene in FL and tFL. It inhibits genes responsible for suppressing 
tumor development, and blocking EZH2 activity may slow tumor growth. It was mutated in 46% 
(16/35) of cases. Most of the mutations were the two highly recurrent mutations 
(chr7|148508727|A and chr7|148508728|T) reported by other groups as well. Two mutations 
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were found in the same tFL case (chr7|148508745|C and chr7|148508763|A in tFL-34). One 
mutation was a tFL-unique mutation (chr7|148506437|A in tFL-11). These mutations were often 
shared FL/tFL mutations or found in single tFL samples with CN gains affecting the EZH2 gene. 
The EZH2 locus is involved in an rCNA that was affected by gains in 24% of FL samples and 39% 
of tFL samples in our previous studies (rCNA799 in Table 4-2). The CN gain and mutations in 
EZH2 could enhance histone methylation at H3K27 and turn off genes inhibiting cell proliferation 
and differentiation. 
Our previous study identified several recurrent losses where the likely driver genes were 
identified. In our previous study, we identified a region of homozygous loss on 6q that occurred 
in 10% of tFLs and included only TNFAIP3 (rCNA37 in Table 4-2). Forty three percent (15/35) of 
our samples had copy losses including this gene (Figure 4-1). Three mutations were found in 
TNFAIP3: one unpaired tFL mutation (tFL-21, chr6|138200194|G), one tFL-unique mutation 
(chr6|138192455|T in tFL-31), and a shared mutation (chr6|138200146|G in case 6) with a copy 
loss in its FL sample (Table 4-2). All the evidence suggests that TNFAIP3 may be inactivated by 
both CN loss and mutation. A larger heterozygous rCNA on 6q occurring in 10% of tFLs (rCNA340 
in Table 4-2) includes 102 genes including SGK1, and a recurrent mutation of the kinase SGK1 
(chr6|134495706|G in FL-27 and chr6|134495724|C in tFL-28) occurred in two paired samples. 
Thirty four percent (12/35) of our samples had copy losses of this gene (Figure 4-1). CREBBP is 
the second most frequently mutated gene in our study. Mutation occurred in 54% (19/35) of our 
cases. Most of the mutations in CREBBP were shared FL/tFL mutations; the rest of the mutations 
were detected in single, unpaired tFL samples. One case had a shared CREBBP mutation and a 
CNL affecting CREBBP in the tFL. A small loss on chr16 (in 5% of tFLs in rCNA564 in Table 4-2) 
encompasses CREBBP and 7 other genes, and is likely driven by CREBBP.  
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TP53 was recurrently mutated in tFLs with 14% (5/35) of cases in our sequencing study. A 
17p loss occurs in 9% of FLs and 18% of tFLs (rCNA593 in Table 4-2). One case had heterozygous 
CN loss affecting TP53 in both FL and tFL samples in our previous study, but the mutations were 
only detected in tFL samples. We had one mutation in an unpaired tFL sample 
(chr17|7578286|G in tFL-32) and four tFL-unique mutations (chr17|7577545|C and 
chr17|7577598|A in tFL-5, chr17|7577097|A in tFL-22, chr17|7578265|G in tFL-27, 
chr17|7576571|C and chr17|7577093|G in tFL-29). One tFL-unique mutation had a CN loss 
(CN=1) affecting TP53. It is probable that the TP53 expression is reduced by CN loss earlier in the 
disease, and the mutations occur later, as they were only found in tFLs. 
rCNA CNA band Type 
Freq 
in FLs 
Freq 
in tFLs 
Numbers 
of gene 
in rCNA 
Mutated Genes in 
Our Cases 
122 1p36.33-p36.31- Loss 25% 24% 51 TNFRSF14,  
343 6p22.2-p21.33- Loss 1% 1% 173 
HIST1H3A, HIST1H3B, 
HIST1H1C, HIST1H1E, 
HIST1H2BG, 
HIST1H1D, PRSS16, 
ZNF184, HIST1H2AM, 
ZKSCAN3, PPP1R10,  
799 7q+ Amp or Gain 24% 39% 739 
CD36, CACNA2D1, 
PCLO, ZNF804B, 
AKAP9, CYP51A1, 
RELN, CCDC136, 
PLXNA4, EZH2, MLL3,  
1191 18q+ (x2) Amp 5% 6% 242 
ESCO1, DSC1, EPG5, 
LOXHD1, CTIF, WDR7, 
PHLPP1, BCL2, 
CCDC102B, NETO1,  
37 6q23.3- (x2) dbLoss 6% 10% 1 TNFAIP3,  
340 6q23.2-q25.1- Loss 6% 10% 102 SGK1, TNFAIP3,  
564 16p13.3- Loss 3% 5% 8 CREBBP,  
593 17p- Loss 9% 18% 431 
ZNF594, TP53, PER1, 
ZNF18, CDRT1, 
NCOR1, C17orf51,  
Table 4-2. Mutations identified in rCNAs.  rCNAs refer to the abnormalities which were 
identified and described in Bouska et al, 2013. Red color indicates mutated genes. 
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C. Somatic mutations acquired during transformation of FL  
We analyzed paired samples to identify genes that are likely to contribute to transformation. 
The genes that are mutated preferentially in the tFL samples are considered likely drivers of the 
indolent FL into aggressive tFL. TP53 (Table 4-3) and USH2A were the only two recurrent tFL-
unique mutations that were found exclusively in our 12 paired WES samples. USH2A is probably 
not expressed in B cells based on our previous GEP analysis. To identify more somatic mutations 
acquired during transformation, we expanded the analysis to FL and tFL sample pairs sequenced 
using the custom capture panel and detected 2 additional genes that were recurrently mutated 
only in tFL samples. These two genes were CARD11 and KMT2C (MLL3). CARD11 was mutated in 
17% (6/35) of cases and also affected by CN gain (Table 4-3). KMT2C (MLL3) was mutated in 11% 
(4/35) of cases (Table 4-3). Two of the mutations were tFL-unique mutations 
(chr7|151873463|A in tFL-27 and chr7|152027794|-C in tFL-29). The other mutations were all 
found in unpaired single tFL cases. One single tFL sample had two mutations 
(chr7|151860157|G and chr7|151868408|T in tFL-19); the other single tFL sample had a 
mutation (chr7|151891609|G in tFL-33) and also had a CN gain (CN=3) affecting KMT2C (MLL3). 
We also identified a set of genes with tFL-unique mutations in 2 or more cases, including EZH2, 
CCND3 (Table 4-3), and MYD88 (Table 4-3). These mutations were not exclusive to tFL, and some 
of the mutations are actually known to occur early in the development of FL, but it is possible 
they can also be late mutations that cooperate with other mutations in transformation or 
mutations that are present in the subclones that transformed later. Comparing each gene to all 
the others, three of the 50 genes in Figure 4-1 showed a significant difference in the fraction of 
tFL-mutated paired cases that had a tFL-unique mutation. TP53 showed a significant increase 
(p= 0.024, two-sided Fisher's exact test), consistent with its importance in transformation. In 
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contrast, MLL2 and CREBBP showed a significant decrease (p=0.045 each), consistent with 
mutations in these genes being usually early events in FL. 
10 out of 20 paired cases had EZH2 mutations, all of which occurred in the SET domain. In 4 
of the cases (tFL-4, tFL-6, tFL-22 and tFL-29), the mutations were only present in the tFL sample. 
In 5 cases (cases 1, 5, 24, 25 and 28), the mutation was shared with the FL biopsy, and in 1 case 
(case 11) the mutation was detected at very low VAF (<4%) in the FL biopsy and became clonal 
in the tFL biopsy. 
Sample 
ID 
Chr|Pos|VarAllele Gene MutType 
Var 
Freq 
CN 
tFL-5 chr17|7577545|C TP53 nonsynonymous 0.378 2 
tFL-5-cus chr17|7577545|C TP53 nonsynonymous 0.833 NA 
tFL-5 chr17|7577598|A TP53 nonsynonymous 0.56 2 
tFL-5-cus chr17|7577598|A TP53 nonsynonymous 0.107 NA 
tFL-22 chr17|7577097|A TP53 nonsynonymous 0.176 NA 
tFL-27 chr17|7578265|G TP53 nonsynonymous 0.63 1 
tFL-29 chr17|7576571|C TP53 stopgain 0.469 2 
tFL-29 chr17|7577093|G TP53 nonsynonymous 0.511 2 
tFL-32 chr17|7578286|G TP53 nonsynonymous 0.371 2 
tFL-2 chr7|2979495|G CARD11 nonsynonymous 0.303 4 
tFL-15 chr7|2984163|T CARD11 nonsynonymous 0.47 3 
tFL-15 chr7|2979466|C CARD11 nonsynonymous 0.46 3 
tFL-19 chr7|2977613|T CARD11 nonsynonymous 0.32 2 
tFL-19 chr7|2979486|G CARD11 nonsynonymous 0.4 2 
tFL-23 chr7|2979501|G CARD11 nonsynonymous 0.13 3 
tFL-34 chr7|2977614|A CARD11 nonsynonymous 0.28 3 
tFL-40 chr7|2985468|T CARD11 nonsynonymous 0.41 2 
tFL-19 chr7|151860157|G KMT2C(MLL3) nonsynonymous 0.25 2 
tFL-19 chr7|151868408|T KMT2C(MLL3) nonsynonymous 0.341 2 
tFL-27 chr7|151873463|A KMT2C(MLL3) nonsynonymous 0.39 2 
tFL-29 chr7|152027794|-C KMT2C(MLL3) frameshift_deletion 0.34 2 
tFL-33 chr7|151891609|G KMT2C(MLL3) nonsynonymous 0.37 3 
tFL-12 chr6|41903688|G CCND3 nonsynonymous 0.437 2 
FL-12 chr6|41903688|T CCND3 nonsynonymous 0.31 2 
tFL-21 chr6|41903731|A CCND3 stopgain 0.099 2 
tFL-22 chr6|41903755|A CCND3 stopgain 0.25 NA 
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tFL-39 chr6|41903710|G CCND3 nonsynonymous 0.44 2 
FL-12 chr3|38182641|C MYD88 missense 0.401 2 
tFL-12 chr3|38182641|C MYD88 missense 0.833 2 
tFL-19 chr3|38182641|C MYD88 missense 0.81 2 
tFL-22 chr3|38182025|T MYD88 nonsynonymous 0.143 NA 
tFL-23 chr3|38182032|G MYD88 nonsynonymous 0.19 2 
Table 4-3. Mutations in TP53, CARD11, KMT2C (MLL3), CCND3, and MYD88.  
 
D. Genes mutated in ABC-like vs. GCB-like lymphomas 
We classified tFL as ABC-like, UC, or GCB-like based on the gene expression signatures using 
in our previous study. The classification information was available for 32 out of 35 samples. 
Unexpectedly, a substantial number of tFL cases are classified as the ABC type instead of GCB 
type. CD79B was mutated in 14% of cases (5/35), more frequently in ABC-like (4/10=40%) than 
in GCB-like tFL (1/21=5%) (p=0.0274, Fisher’s exact test in Table 4-4), consistent with findings in 
de novo DLBCL35. Interestingly, the mutations were clustered in the immunoreceptor tyrosine-
based activation motif (ITAM) domain.  
The NF-κB pathway plays an important role of ABC-like tFL. Therefore, we investigated the 
mutations that can activate this pathway in our data. CARD11 (6/35), MYD88 (4/35, 1 is a shared 
mutation), TNFAIP3 (3/35), and BCL10 (1/35) were found mutated (Table 4-5). CARD11 is 
affected by CN gains in FL (24%) and tFL (39%) (Table 4-6), and it also had CN gain in two 
sequenced samples which had tFL-unique mutations (CN=3 in tFL-2 and tFL-23). TNFAIP3 is 
affected by CN losses in FL (26%) and tFL (34%) (Table 4-6). CARD11 mutations (Table 4-5) 
occurred within or adjacent to the coiled-coil domain (CCD) in our case. These mutations likely 
disrupt binding of the CCD to the inhibitory domain (ID), allowing CARD11 to assume its active 
conformation even without phosphorylation, and consequently activating NF-κB in the absence 
of BCR engagement36,37. BCL10 mutation (R58Q) occurred in its CARD domain near the acidic 
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patch that binds to the basic patch of the CARD 11 CARD domain, and three acidic residues (E50, 
E53, and E54) were identified as important for binding38. The R58Q mutation substitutes a 
glutamine for the basic arginine, which could increase binding to CARD11 by increasing the net 
negative charge. The MYD88 was mutated in 11% (4/35, 1 case doesn’t have GEP data) of cases 
(Table 4-5), more commonly in the ABC-like (2/10) than in the GCB-like tFL (1/21). All of the 
mutations were in the Toll/interleukin-1 homology domain (TIR), including two cases with the 
most frequent mutation, L265P39.  
BCL2, KMT2D (MLL2), EZH2 and SOCS1 were mutated more frequently in GCB-like tFL (Table 
4-4) in our study. Of note, BCL2 and SOCS1 were only mutated in GCB-like tFLs, consistent with 
what has been reported in DLBCL8,40. 
Gene 
all mut 
freq 
(n=35) 
FL mut 
freq 
(n=20) 
tFL mut 
freq 
(n=35) 
tFL only 
mut freq 
(n=20)* 
ABC tFL 
mut freq 
(n=10) 
GCB tFL 
mut freq 
(n=21) 
p-values of 
ABC vs GCB 
tFL mutations 
BCL2 49% 45% 40% 5% 0% 48% 0.012 
CD79B 14% 10% 14% 0% 40% 5% 0.027 
IL7R 9% 5% 9% 0% 20% 0% 0.097 
HTT 6% 10% 6% 0% 20% 0% 0.097 
KMT2D(MLL2) 69% 65% 69% 5% 50% 81% 0.105 
EZH2 46% 30% 46% 20% 20% 52% 0.129 
SOCS1 17% 10% 17% 5% 0% 29% 0.141 
MYD88 11% 5% 11% 10% 20% 5% 0.237 
KLHL6 6% 5% 6% 5% 10% 0% 0.323 
AKAP13 3% 0% 3% 5% 10% 0% 0.323 
ANXA1 3% 0% 3% 5% 10% 0% 0.323 
ARID1B 3% 5% 3% 0% 10% 0% 0.323 
BCL10 3% 5% 3% 0% 10% 0% 0.323 
BCL11A 3% 0% 3% 5% 10% 0% 0.323 
BCL6 3% 5% 3% 0% 10% 0% 0.323 
CD58 3% 0% 3% 0% 10% 0% 0.323 
CSNK1D 3% 0% 3% 5% 10% 0% 0.323 
FTH1 3% 0% 3% 0% 10% 0% 0.323 
HELZ 3% 5% 3% 0% 10% 0% 0.323 
HMGB1 3% 5% 3% 0% 10% 0% 0.323 
HPS5 3% 5% 3% 0% 10% 0% 0.323 
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MIA3 3% 5% 3% 0% 10% 0% 0.323 
NOTCH2 3% 0% 3% 0% 10% 0% 0.323 
PHF6 3% 5% 3% 0% 10% 0% 0.323 
PRDM1 3% 0% 3% 0% 10% 0% 0.323 
RAPGEF2 3% 0% 3% 5% 10% 0% 0.323 
RHOH 3% 5% 3% 0% 10% 0% 0.323 
SETD2 3% 5% 3% 0% 10% 0% 0.323 
TBL1XR1 3% 0% 3% 5% 10% 0% 0.323 
TET2 3% 0% 3% 0% 10% 0% 0.323 
TINF2 3% 0% 3% 5% 10% 0% 0.323 
U2AF1 3% 5% 3% 0% 10% 0% 0.323 
UBAP2 3% 0% 3% 5% 10% 0% 0.323 
ZNF142 3% 0% 3% 0% 10% 0% 0.323 
TNFRSF14 20% 15% 17% 0% 30% 14% 0.358 
DMD 9% 5% 9% 0% 0% 14% 0.533 
ETS1 9% 5% 9% 5% 0% 14% 0.533 
TAF1 17% 5% 17% 5% 20% 10% 0.577 
EP300 11% 0% 11% 0% 20% 10% 0.577 
RNF213 11% 5% 11% 5% 20% 10% 0.577 
MEF2B 20% 15% 20% 5% 10% 24% 0.634 
Table 4-4. P-values of ABC vs GCB tFL mutations. *Only calculated the frequencies in paired 
cases. 
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Sample ID Chr|Pos|VarAllele Gene CN 
FL-10 chr1|85736474|T BCL10 2 
FL-10-cus chr1|85736474|T BCL10 2 
tFL-10-cus chr1|85736474|T BCL10 4 
tFL-2 chr7|2979495|G CARD11 4 
tFL-15 chr7|2984163|T CARD11 3 
tFL-15 chr7|2979466|C CARD11 3 
tFL-19 chr7|2977613|T CARD11 2 
tFL-19 chr7|2979486|G CARD11 2 
tFL-23 chr7|2979501|G CARD11 3 
tFL-34 chr7|2977614|A CARD11 3 
tFL-40 chr7|2985468|T CARD11 2 
FL-3 chr17|62007128|T CD79B 2 
FL-3-cus chr17|62007128|T CD79B NA 
tFL-3 chr17|62007128|T CD79B 2 
tFL-3-cus chr17|62007128|T CD79B NA 
tFL-8 chr17|62006836|T CD79B NA 
FL-8 chr17|62007129|T CD79B NA 
tFL-19 chr17|62006798|C CD79B 2 
tFL-21 chr17|62006799|C CD79B 2 
tFL-38 chr17|62007480|C CD79B 2 
FL-12 chr3|38182641|C MYD88 2 
tFL-12 chr3|38182641|C MYD88 2 
tFL-19 chr3|38182641|C MYD88 2 
tFL-22 chr3|38182025|T MYD88 NA 
tFL-23 chr3|38182032|G MYD88 2 
FL-6 chr6|138200146|G TNFAIP3 0 
tFL-6 chr6|138200146|G TNFAIP3 2 
tFL-21 chr6|138200194|G TNFAIP3 2 
tFL-31 chr6|138192455|T TNFAIP3 NA 
Table 4-5. Genes mutated in NF-κB pathway. The first Sample ID column indicates the samples 
in which the mutations were detected, the Chromosome| Position |Altered-Base column 
indicates the coordinates of the mutations, the Gene column indicates the genes of the 
mutations, the CN column indicates the CN estimated in this gene from our previous study, NA is 
noted if we don’t have the CN information. 
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Gene Samples 
%  
Loss/double 
Loss 
% 
Double 
Loss 
% 
Gain/Amplification 
% 
Amplification 
CARD11 
FL (n=198) 0.000 0.000 0.242 0.030 
tFL (n=79) 0.025 0.000 0.392 0.089 
TNFAIP3 
FL (n=198) 0.263 0.056 0.000 0.000 
tFL (n=79) 0.342 0.101 0.000 0.000 
Table 4-6. Frequency of CNAs affecting CARD11 and TNFAIP3 based on previously published 
data. 
 
E. Mutations affecting miRNA 
MicroRNAs are short non-coding RNAs that are involved in post-transcriptional regulation of 
gene expression. They affect both the stability and translation of mRNAs. The seed sequence is 
an essential region for the binding of the miRNA to the target mRNA. There are 422 microRNAs 
targeted by illumina’s TruSeq exome enrichment kit. We used the BED file provided by Illumina, 
which has details on all of the target microRNAs regions, and calculated the coverage and depth 
of all the microRNAs in all our WES samples to confirm the microRNA capture performance. The 
average coverage and depth for all microRNAs in all samples is 96.70% and 80 respectively. 
The only micro-RNA found to be mutated was miR-142, listed in Table 4-7. MiR-142 is a 
hematopoietic-specific micro RNA precursor whose 3p and 5p arms are both functional and 
expressed at similar levels41. MiR-142 was mutated in 3 of 12 tFL cases, two of which were 
shared with the corresponding FL and one was a tFL-unique mutation. Interestingly, all the 
mutations were located in the seed sequences (nucleotides 2-8) in Figure 4-2.  The mutation 
(chr17|56408621|G) that was identified in 2 cases and affects miR-142-3p, was also detected in 
DLBCL by another group42. The other shared mutation affecting miR-142-5p is a new finding. 
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SampleID Chr|Pos|VarAllele Gene VarFreq 
tFL-4 chr17|56408621|G MIR142 0.19 
FL-8 chr17|56408621|G MIR142 0.448 
tFL-8 chr17|56408621|G MIR142 0.471 
FL-11 chr17|56408657|G MIR142 0.086 
tFL-11 chr17|56408657|G MIR142 0.207 
Table 4-7. Mutations in miR-142. The first column (Sample ID) indicates the samples in which 
the mutations were detected, the second column (Chromosome| Position |Altered-Base) 
indicates the coordinates of the mutations, the third column (Gene) indicates the genes affected, 
the fourth column (Var Freq) indicates the variant frequencies of the mutations. 
 
Figure 4-2. Domains/regions affected by mutations for miR-142. 
F. Recurrently mutated genes in 3 datasets  
To increase our analytical power and to gain a more comprehensive view of the genes that 
likely drive transformation, we combined our data with two published datasets for further 
analysis (Figure 4-3). We identified additional genes that tend to be associated with 
transformation, including MYC, EBF1, IRF4, RPN1, SOCS1, SYNE1, SGK1, PIM1, EP300, BMP7, 
ETS1, SARDH, TAF1, FBXO11 and HIST1H1E summarized in Table 4-8 below. 
MYC had a tFL-unique mutation in only 1 of our samples but 4 samples in other datasets. 
EBF1 had 4 tFL-unique mutations (2 FL-unique mutations) in 4 samples in other datasets. IRF4 
had 3 tFL-unique mutations in 3 samples in another dataset. RPN1 had a tFL-unique mutation in 
only 1 of our samples and 2 samples in another dataset. SOCS1 had tFL-unique mutations in 2 of 
our samples (2 shared mutations) and 2 samples in other datasets. SYNE1 had a tFL-unique 
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mutation in only 1 of our samples (1 FL-unique mutation) and 2 samples in another dataset. 
SGK1 had a tFL-unique mutation in only 1 of our samples (1 FL-unique mutation) and 2 samples 
in another dataset. PIM1 had 4 tFL-unique mutations in 4 samples in another dataset (2 shared 
mutations). EP300 had 2 tFL-unique mutations in 2 samples in another dataset (1 shared 
mutaiton). BMP7 had 2 tFL-unique mutations in 2 samples in another dataset (1 shared 
mutaiton). ETS1 and TAF1 both had a tFL-unique mutation in 1 of our samples (1 shared 
mutation) and 1 sample in another dataset. SARDH had 2 tFL-unique mutations in 2 samples in 
another dataset. FBX011 had 2 tFL-unique mutations 2 samples in other datasets. HIST1H1E had 
1 tFL-unique mutation in 1 of our samples (1 shared mutation) and 3 samples in other datasets. 
Overall, the recurrent mutations (Figure 4-3) identified in our dataset were highly 
concordant (92%) with the other two datasets.  
103 
 
 
 
Figure 4-3. tFL-unique mutated genes found in more than two cases in 3 combined datasets. 
The data was summarized from a combine set of 42 FL and tFL paired samples. Only genes 
expressed in B cells are shown. Genes in bold were selected in custom capture panel. The color 
of each block represents the mutation type of the corresponding genes and cases. 
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Table 4-8. Additional genes that tend to be associated with transformation in combined 
datasets. 
 
G. Pathway analysis 
In addition to the NF-κB pathway described in ABC-like DLBCL, our previous CN analysis 
study revealed that the rCNAs affect in B-cell transcription factors, cell cycle regulation, and 
immune surveillance pathways in the transformation of FL.  
Similarly, we found that mutations also commonly target genes involved in these same 
pathways (Table 4-9). For example, several regions with small deletions or amplifications were 
likely driven by B-cell transcription factors. Recurrent mutations affecting B-cell transcription 
factors were also identified, including mutation of MEF2B. Four of the cases harbored previously 
described MEF2B mutations43 that block association with the co-repressor CABIN1, increasing 
transcriptional activity (3 cases, D83V; 1 case E73K; Figure 4-4). 
We applied David Bioinformatics Resources 6.7 to identify pathways significantly enriched 
for mutations in our tFL WES mutations. Table 4-9 shows BIOCARTA and KEGG pathways 
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enriched in our list of mutations. The top 3 enriched pathways involved B-cell receptor signaling, 
IL-7 signaling, and JAK-STAT activation.  
The Switch/Sucrose non-fermentable (SWI/SNF) is a nucleosome remodeling complex 
involved in chromatin remodeling. It is capable of altering the position of nucleosomes along 
DNA. In tFL, SWI/SNF members appear to be targets of both mutation and copy loss. ARID1A is 
mutated in 9% of tFL cases (3/35 in Table 4-10) and 15% of tFL cases (5/32) have a CNA affecting 
ARID1A including a small recurrent CN loss that encompassed ARID1A at 5% frequency (Table 4-
11). Additionally, 1/35 tFLs had an ARID1B mutation and 1/12 cases had ARID4B and ARID5B 
mutation (Table 4-10). A small, rare, recurrent CNA affected ARID1B, but almost 23% of tFLs had 
a larger loss on chr6 that included ARID1B (Table 4-11). In addition to SWI/SNF family members, 
many genes involved in chromatin organization and modification were mutated in our cases 
(Figure 4-3), as was also observed by others. EZH2 and MLL3 mutations were described above. 
We also identified frequent CNAs and mutations affecting genes that regulate B-cell 
migration and AKT/mTOR pathway activation. This pathway has recently been shown to be 
mutated in DLBCL and cell lines26,27,44,45 . Figure 4-5 depicts the pathway with S1P interacting 
with its receptors. S1PR2 (a G-protein-coupled receptor) signals through GNA13 (G-protein), 
which interacts with ARHGEF1 (a RHO guanine-nucleotide exchange factor) and RHOA. 
Interruption of this pathway promotes migration of B-cells out of the GC and activation of AKT. 
All three genes were mutated in our dataset (Table 4-12).  The effect of S1P signaling through 
S1PR1 is the opposite of S1PR2 signaling, and CD69 interacts with and inhibits S1PR1. No 
mutation in CD69 or S1PR1 was detected by us or others, but analysis of our CNA data indicated 
CNL involving CD69 in 7.6% of tFLs (Table 4-11), which could partially reduce the normal 
inhibitory influence on S1PR1. Indeed, copy loss affecting S1PR2, GNA13, ARHGEF1, P2RY8, 
and/or CXCR4 loci occurs more frequently in tFL compared to FL (21.5% vs 7.5% in Table 4-13). 
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There was a single case that had 3 separate FL-tFL shared mutations in ARHGEF1. A second case 
had a shared mutation in GNA13. Additionally, the Pasqualucci dataset identified GNA13 
mutations in 3 cases (2 tFL-unique mutations and 1 FL-unique mutation in Figure 4-3).   
AKT pathway activation can be enhanced by concurrently activating mutations affecting the 
mTOR pathway. Two cases harbored a shared FL-tFL mutation affecting conserved residues 
within the switch 1 region of RRAGC (Table 4-12), and other two studies identified mutations in 
3 cases (2 FL-unique mutations and 1 shared mutation in Table 4-14) affecting the same region. 
Additional genes that affect the PI3K/AKT/mTOR pathway were mutated in our dataset including 
TSC2, PIK3R1, and PTEN (Table 4-12). 
Category Term PValue Genes FDR (%) 
KEGG 
hsa04662:B cell 
receptor signaling 
pathway 
0.003698 
CARD11, CD19, FCGR2B, 
LILRB3, PPP3R1, CD79B, 
PIK3R1 
4.112991 
BIOCARTA 
h_il7Pathway:IL-7 
Signal Transduction 
0.011012 
NMI, BCL2, CREBBP, 
IL2RG 
12.26147 
KEGG 
hsa04630:Jak-STAT 
signaling pathway 
0.012082 
STAT6, IL2RA, CCND3, 
IL4R, CREBBP, IL2RG, PRL, 
PIK3R1, STAT2 
12.87195 
BIOCARTA 
h_pmlPathway:Regulat
ion of transcriptional 
activity by PML 
0.013431 CREBBP, TP53, RARA, RB1 14.76345 
BIOCARTA 
h_rarrxrPathway:Nucle
ar receptors 
coordinate the 
activities of chromatin 
remodeling complexes 
and coactivators to 
facilitate initiation of 
transcription in 
carcinoma cells 
0.013431 
NCOA2, RARA, NCOR2, 
POLR2A 
14.76345 
BIOCARTA 
h_telPathway:Telomer
es, Telomerase, 
Cellular Aging, and  
Immortality 
0.02238 BCL2, TP53, RB1, POLR2A 23.46293 
KEGG 
hsa05222:Small cell 
lung cancer 
0.026054 
BCL2, TP53, RB1, PTEN, 
PIK3R1, TRAF3 
25.86317 
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BIOCARTA 
h_pcafpathway:The 
information-processing 
pathway at the IFN-
beta enhancer 
0.02906 HMGB1, CREBBP, POLR2A 29.41808 
KEGG 
hsa05340:Primary 
immunodeficiency 
0.032244 
CD19, TAP1, IL2RG, 
RFXAP 
31.03271 
KEGG 
hsa05215:Prostate 
cancer 
0.032409 
BCL2, CREBBP, TP53, RB1, 
PTEN, PIK3R1 
31.16593 
KEGG hsa05214:Glioma 0.036878 
TP53, CAMK2B, RB1, 
PTEN, PIK3R1 
34.68509 
BIOCARTA 
h_carm-
erPathway:CARM1 and 
Regulation of the 
Estrogen Receptor 
0.053205 
CREBBP, SPEN, NCOR2, 
POLR2A 
47.58013 
BIOCARTA 
h_il4Pathway:IL 4 
signaling pathway 
0.053409 STAT6, IL4R, IL2RG 47.71387 
BIOCARTA 
h_egfr_smrtePathway:
Map Kinase 
Inactivation of SMRT 
Corepressor 
0.053409 MAP3K1, RARA, NCOR2 47.71387 
Table 4-9. Mutated genes classified in KEGG/BIOCARTA pathways. 
 
 
 
Figure 4-4. Domains/regions affected by mutations for MEF2B. 
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Sample ID Chr|Pos|VarAllele Gene MutType 
Var 
Freq 
CN 
FL-2 chr1|27106915|T ARID1A stopgain 0.055 NA 
tFL-2 chr1|27106915|T ARID1A stopgain 0.232 2 
FL-3-cus chr1|27023162|G ARID1A nonsynonymous 0.073 NA 
tFL-3-cus chr1|27023162|G ARID1A nonsynonymous 0.042 NA 
FL-27 chr1|27089478|T ARID1A stopgain_ 0.141 2 
tFL-27 chr1|27089478|T ARID1A stopgain 0.451 2 
FL-6 chr10|63759897|A ARID5B nonsynonymous 0.519 2 
tFL-6 chr10|63759897|A ARID5B nonsynonymous 0.222 2 
FL-6 chr10|63759918|G ARID5B nonsynonymous 0.494 2 
tFL-6 chr10|63759918|G ARID5B nonsynonymous 0.258 2 
FL-10 chr6|157528317|A ARID1B stopgain 0.413 2 
FL-10-cus chr6|157528317|A ARID1B stopgain 0.34 2 
tFL-10 chr6|157528317|A ARID1B stopgain 0.517 2 
tFL-10-cus chr6|157528317|A ARID1B stopgain 0.38 2 
FL-22 chr1|235420509|C ARID4B nonsynonymous 0.357 NA 
tFL-22 chr1|235420509|C ARID4B nonsynonymous 0.27 NA 
Table 4-10. Mutations in ARID1A, ARID1B, ARID4B and ARID5B. 
 
Gene Samples 
%  
Loss/double 
Loss 
% 
Double 
Loss 
% 
Gain/Amplification 
% 
Amplification 
ARID1A 
FL (n=198) 0.096 0.000 0.005 0.000 
tFL (n=79) 0.152 0.000 0.000 0.000 
ARID1B 
FL (n=198) 0.162 0.000 0.000 0.000 
tFL (n=79) 0.228 0.013 0.000 0.000 
CD69 
FL (n=198) 0.015 0.005 0.157 0.025 
tFL (n=79) 0.076 0.000 0.152 0.013 
Table 4-11. Frequency of CNAs affecting ARID1A, ARID1B and CD69 based on previously 
published data. 
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Figure 4-5. Abnormalities of the S1PR1 and S1PR2 pathway are associated with FL 
transformation. Black arrows and bar-headed lines indicate activation or inhibition, respectively; 
dotted lines indicate an indirect effect. Different color and shape of border lines were used to 
mark the types of mutations or copy changes observed in our case series (n=35), within which, 
80% of the cases carry at least one of the genetic abnormalities.  
 
 
 
 
 
 
 
 
 
 
 
 
110 
 
Sample 
ID 
Chr|Pos|VarAllele Gene MutType 
Var 
Freq 
CN 
tFL-22 chr19|10334805|T S1PR2 stopgain 0.223 NA 
FL-22 chr19|42398308|A ARHGEF1 nonsynonymous 0.31 NA 
tFL-22 chr19|42398308|A ARHGEF1 nonsynonymous 0.25 NA 
FL-22 chr19|42398565|+A ARHGEF1 frameshift_insertion 0.353 NA 
tFL-22 chr19|42398565|+A ARHGEF1 frameshift_insertion 0.202 NA 
FL-22 chr19|42406962|A ARHGEF1 nonsynonymous 0.3 NA 
tFL-22 chr19|42406962|A ARHGEF1 nonsynonymous 0.333 NA 
FL-29 chr17|63010412|T GNA13 nonsynonymous 0.199 2 
tFL-29 chr17|63010412|T GNA13 nonsynonymous 0.43 2 
FL-6 chr1|39322649|G RRAGC nonsynonymous 0.278 2 
tFL-6 chr1|39322649|G RRAGC nonsynonymous 0.234 2 
FL-8 chr1|39322697|A RRAGC nonsynonymous 0.34 NA 
tFL-8 chr1|39322697|A RRAGC nonsynonymous 0.446 NA 
tFL-4 chr10|89624275|T PTEN stopgain 0.333 1 
tFL-24 chr16|2104347|A TSC2 nonsynonymous 0.23 2 
tFL-9 chr5|67576825|A PIK3R1 nonsynonymous 0.318 2 
tFL-16 chr5|67591106|G PIK3R1 nonsynonymous 0.1 2 
Table 4-12. Mutations in S1PR2 pathway and PI3K/AKT/mTOR pathway genes.  
 
Samples %  Loss/double Loss % Gain/Amplification 
FL (n=198) 0.076 0.359 
tFL (n=79) 0.215 0.405 
Table 4-13. Frequency of CNAs affecting any of the following genes:GNA13, ARHGEF1, 
P2RY8,S1PR2, and/or CXCR4 on previously published data. 
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Sample 
Gene 
Symbol  
Chromosome 
Genomic 
position 
ref|variant 
Mutation 
type 
Data 
resource 
S4_FL RRAGC chr1 39322646 C|T missense Oko 
S4_tFL RRAGC chr1 39322646 C|T missense Oko 
S7_FL3 RRAGC chr1 39322723 G|T missense Oko 
23 RRAGC chr1 39322649 A|G missense Pas 
Table 4-14. Mutations in RRAGC in other sequencing studies. The first column (Sample ID) 
indicates the samples that the mutations were detected, the second column (Gene Symbol) 
indicates the genes of the mutations, the third column (Chromosome) indicates the 
chromosome of the mutations, the fourth column (Genomic position) indicates the position of 
the mutations, the fifth column (ref|variant) indicates the reference and variant of the 
mutations, the sixth column (Mutation type) indicates the mutation types, the seventh column 
(Data resource) indicates the datasets of the mutations were detected. 
 
H. Domains and regions affected by mutations 
B-cell receptor (BCR) signaling complex includes both CD79 and surface immunoglobulin. 
CD79 generates a signal when BCR recognize antigens. CD79B is one of the two distinct chains of 
CD79 and it has an ITAM, which is a conserved sequence of 4 amino acids. The ITAM plays an 
important role in signal transduction.  We detected 6 mutations in CD79B. One mutation was in 
the IG-like V-type domain. Three mutations were between the transmembrane domain and 
ITAM domain. 2 tFL-unique mutations were within ITAM domain. The other two studies also 
found 2 shared mutations in the ITAM domain. Figure 4-6 shows all the mutations. 
After antigen stimulation in normal B cells, the BCR sends signal to activate the NF-κB 
pathway, which among other effects promotes survival. CARD11 is a signaling scaffold protein 
that forms a complex with BCL10 and MALT1, which leads to K63-ubiquitination of MALT1 and 
eventually to the activation of the IKK complex, which activates the NF-κB pathway. We 
detected 8 mutations in CARD11 (Table 4-3). 2 of them were tFL-unique mutations, the rest 6 
were found in single tFL samples. The other two studies also found 4 shared mutations and 1 
tFL-unique mutation (Figure 4-3). 9 out of 12 mutations were within the coiled-coil domain, 3 of 
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them were within the caspase activation and recruitment domain (CARD), and no mutations 
were found in the inhibitory domain, PDZ domain, SRC homology 3 domain (SH3) or guanylate 
kinase-like domain (Figure 4-7). 
RRAGC is a protein that is encoded by the RRAGC gene. This protein is a monomeric guanine 
nucleotide-binding protein and forms a heterodimer with RRAGA or RRAGB. It is primarily 
localized in the cytoplasm. When RRAGC binds GTP or GDP, it acts as a switch for downstream 
pathways. As we mentioned in the previous section, we detected 2 shared mutations in our 
study (Table 4-12). 3 shared mutations and 1 FL-unique mutations were detected in the other 
two datasets (Table 4-14). All of the mutations were within P-loop containing nucleoside 
triphosphate hydrolase domain as depicted in Figure 4-8.  
 
 
Figure 4-6. Domains/regions affected by mutations for CD79B. The mutations from our case 
series have black outline, while those from the other two published datasets have gray outline. 
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Figure 4-7. Domains/regions affected by mutations for CARD11. The mutations from our case 
series have black outline, while those from the other two published datasets have gray outline. 
 
 
 
Figure 4-8. Domains/regions affected by mutations for RRAGC. Sites of GTP binding are noted. 
The mutations from our case series have black outline, while those from the other two 
published datasets have gray outline. 
 
I. Subclonal mutations 
Mutations present in small subclones in FL and which later became dominant clones in 
corresponding tFL may help to drive the transformation process. We investigated all our FL and 
tFL paired samples and revealed a number of genes in which the VAF increased in the tFL (Table 
4-15). Several of the genes that were identified as subclonal in the FL such as CARD11, CD79B, 
EZH2, FOXO1, HIST1H1E, and MYD88 are recurrently mutated in our dataset and likely 
important for disease progression. S1PR2, which is involved in germinal center B-cell 
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confinement46 was also detected at low VAF in the FL sample but emerged as clonal in the 
transformed sample. 
Sample 
ID  
# 
Variant 
Reads 
# 
Total 
Reads 
%VAF 
% 
Tumor 
content 
% 
Adjusted 
VAF 
CN chr|pos|var Gene 
FL-8 1 144 0.69% 88% 0.79% NA 
chr2|191064806|G C2orf88 
tFL-8 42 146 28.77% 79% 36.51% NA 
FL-8 1 116 0.86% 88% 0.98% NA 
chr1|220379264|G RAB3GAP2 
tFL-8 50 174 28.74% 79% 36.47% NA 
FL-23-1 6 614 1.00% 84% 1.19% 3 
chr7|2979501|G CARD11 
tFL-23 108 829 13.00% 26% 49.43% 3 
FL-23-2 7 711 0.99% 84% 1.18% NA 
chr7|2979501|G CARD11 
tFL-23 108 829 13.00% 26% 49.43% 3 
FL-23-1 12 1194 0.99% 84% 1.18% 3 
chr6|26156797|T HIST1H1E 
tFL-23 116 1052 10.99% 26% 41.79% 3 
FL-23-2 11 1161 0.99% 84% 1.18% NA 
chr6|26156797|T HIST1H1E 
tFL-23 116 1052 10.99% 26% 41.79% 3 
tFL-10 2 180 1.11% 90% 1.24% 5 
chr1|85736474|T BCL10 
FL-10 125 193 64.77% 81% 79.67% NA 
tFL-24 9 910 0.98% 77% 1.27% 2 
chr5|138260327|C CTNNA1 
FL-24-1 111 464 24.03% 92% 26.09% 2 
tFL-24 9 910 0.98% 77% 1.27% 2 
chr5|138260327|C CTNNA1 
FL-24-2 128 532 23.99% 92% 26.05% NA 
tFL-9 1 87 1.15% 84% 1.37% 1 
chr22|24530363|G CABIN1 
FL-9 23 150 15.33% 24% 64.14% 2 
FL-8 2 156 1.28% 88% 1.46% NA 
chr6|121562671|A TBC1D32 
tFL-8 43 152 28.29% 79% 35.90% NA 
FL-8 1 74 1.35% 88% 1.54% NA 
chr5|96507052|C RIOK2 
tFL-8 18 64 28.13% 79% 35.70% NA 
FL-11 1 131 0.76% 49% 1.54% 2 
chr7|148506437|A EZH2 
tFL-11 18 95 18.95% 27% 69.41% 2 
FL-22 1 109 0.92% 58% 1.59% NA 
chr1|233515277|G KIAA1804 
tFL-22 15 90 16.67% 43% 39.13% NA 
FL-11 1 121 0.83% 49% 1.69% 2 
chr5|79354080|A THBS4 
tFL-11 30 99 30.30% 27% 110.99% 2 
FL-22 2 150 1.33% 58% 2.29% NA 
chr19|10334805|T S1PR2 
tFL-22 29 130 22.31% 43% 52.37% NA 
FL-28 2 216 0.97% 36% 2.68% NA chr13|41240279|A FOXO1 
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tFL-28 27 182 14.98% 37% 40.38% 2 
FL-22 1 64 1.56% 58% 2.69% NA 
chr3|38182025|T MYD88 
tFL-22 7 49 14.29% 43% 33.54% NA 
FL-11 1 70 1.43% 49% 2.91% 2 
chr1|186036995|T HMCN1 
tFL-11 16 78 20.51% 27% 75.13% 2 
FL-11 1 69 1.45% 49% 2.95% 2 
chr1|178861391|T RALGPS2 
tFL-11 8 73 10.96% 27% 40.15% 2 
FL-11 2 119 1.68% 49% 3.41% 2 
chrX|53631710|C HUWE1 
tFL-11 16 85 18.82% 27% 68.94% 1 
FL-2 1 106 0.94% 26% 3.56% NA 
chr2|97370071|C FER1L5 
tFL-2 24 95 25.26% 32% 78.45% 2 
FL-9 1 113 0.88% 24% 3.68% 4 
chr18|47801358|T MBD1 
tFL-9 56 223 25.11% 84% 30.00% 6 
FL-3 2 167 1.20% 32% 3.79% 2 
chr8|139732980|C COL22A1 
tFL-3 8 65 12.31% 43% 28.56% 2 
FL-2 1 85 1.18% 26% 4.47% NA 
chr4|90035447|T TIGD2 
tFL-2 6 59 10.17% 32% 31.58% 1 
FL-11 2 85 2.35% 49% 4.78% 3 
chr18|66721328|A CCDC102B 
tFL-11 12 109 11.01% 27% 40.33% 7 
tFL-31 3 108 3.14% 58% 5.41% NA 
chr18|60985880|A BCL2 
FL-31 27 151 17.88% 32% 55.53% NA 
tFL-22 2 85 2.35% 43% 5.52% NA 
chr13|111372118|A ING1 
FL-22 13 77 16.88% 58% 29.10% NA 
FL-11 4 110 3.64% 49% 7.40% 2 
chr13|39262875|T FREM2 
tFL-11 21 85 24.71% 27% 90.51% 2 
FL-2 3 127 2.36% 26% 8.94% NA 
chr7|117431643|T CTTNBP2 
tFL-2 14 114 12.28% 32% 38.14% 4 
FL-3 2 53 3.77% 32% 11.89% 2 
chr19|38834308|T CATSPERG 
tFL-3 5 19 26.32% 43% 61.07% 2 
FL-2 6 191 3.14% 26% 11.89% NA 
chr2|210745783|G UNC80 
tFL-2 31 147 21.09% 32% 65.50% 2 
FL-3 3 67 4.48% 32% 14.13% 2 
chr17|62007128|T CD79B 
tFL-3 6 30 20.00% 43% 46.40% 2 
FL-2 2 53 3.77% 26% 14.28% NA 
chr10|53458823|A CSTF2T 
tFL-2 11 55 20.00% 32% 62.11% 0 
Table 4-15: Mutations present in subclones with increase VAF in tFL. Red indicates subclones, 
green indicates major clones. 
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J. Discussion 
The goal of our study is to understand which genetic events drive the indolent FL to 
aggressive tFL, so that we can identify which patients are in a high-risk group, determine the 
best treatment plan, and target the promising abnormalities for therapies. We performed WES 
on 12 paired FL and tFL samples and used a custom capture panel on 23 additional cases with 
deep sequencing. We identified recurrently mutated genes and pathways from the sequencing 
study, and integrated CNA information from our previous study. 
Our integrated data strongly suggests that the activation of NF-κB pathway is critically 
important for the transformation of some FL cases. We have identified ABC-like and GCB-like tFL 
as likely to be associated with certain genetic abnormalities.  For example, CARD11, MYD88, and 
TNFAIP3 are more frequently mutated in de novo ABC-DLBCL and are associated with NF-κB 
pathway activation. They are expected to have a similar influence on tFL. The corresponding 
CNA data indicated that some of the mutations cooperate with CNAs to generate homozygous 
alterations that amplify their functional consequences. Other studies reported that the ABC-like 
and GCB-like divergence may be present already at the FL stage; however, there is no evidence 
that the ABC-like FL is more likely to undergo transformation or have worse survival but the 
number of cases studied is low. 
Our pathway analysis found that the commonly targeted genes in transformation encode B-
cell transcription factors and proteins involved in cell cycle regulation, immune surveillance, JAK-
STAT activation, and the p53 pathway. These pathways highly overlap with the pathways we 
previously identified in CNAs.  
One of the characteristics of tFL is the loss of GC confinement. We detected mutations or CN 
losses in S1PR2, GNA13, ARHGEF1, P2RY8, CXCR4, and CD69. These genes are involved in the 
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S1PR1 and S1PR2 pathway, which is associated with FL transformation. The inactivation of the 
S1PR2 pathway or activation of the S1PR1 pathway promotes migration of B-cells out of the GC 
and activation of the AKT pathway. This may be a critical event in the change from a follicular to 
a diffuse state in the process of transformation.  
The activation of the AKT pathway likely provides a survival signal for the B-cells that move 
out of the GC and hence lose the supportive microenvironment of the GC. The concomitant 
activation of the mTOR pathway may enhance the effect of AKT activation. We identified 
mutations in several genes that are involved in mTOR pathway activation. RRAGC 
heterodimerizes with RRAGA or RRAGB and can recruit mTORC1 through RAPTOR to the 
lysosomal membrane, where mTORC1 can be activated by RHEB. Activity of the heterodimer is 
higher when GDP is bound to RRAGC. The switch 1 region of the RRAGC yeast ortholog Gtr2p 
undergoes a conformation change depending upon GTP or GDP binding; thus, mutations of this 
region may affect RRAGC activity and hence mTORC1 activation. TSC2 is a GTPase-activating 
protein (GAP) that inhibits mTORC1 activation by promoting the conversion of RHEB-GTP to 
RHEB-GDP. Additional genes that were mutated in PI3K/AKT/mTOR signaling pathway included 
PIK3R1, INPP5F and PTEN.. 
There are several mutated genes involved in the JAK-STAT pathway. The mutations in SOCS1 
(Figure 4-9) and STAT647 have been reported by other studies. STAT3 is another mutated gene 
that has not been discussed. We identified 4 mutations in STAT3, they all affected amino acids 
that are resolved within the STAT3 crystal structure. The K658N substitution within the SH2 
domain is identical to an activating mutation previously identified by other studies. According to 
the gain of function characteristic of this mutation, we would expect the tumor to shift toward 
ABC-tFL and our GEP data indicate that this case is unclassifiable. Another K340T substitution 
may act in an opposite way: it likely represents a loss of function mutation and may interfere 
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with binding to the target sequence. Because the mutant protein retains the ability to dimerize, 
it likely will have a dominant-negative effect. This mutation was found in a GCB-like tFL as it may 
act to block further differentiation. 
 
                
Figure 4-9. Domains/regions affected by mutations for SOCS1. 
 
Chromatin structure deregulation and disruption is important in the pathogenesis of FL and 
many mutations affecting chromatin modifiers have been identified. SWI/SNF family members, 
which are involved in chromatin remodeling, are often mutated in a variety of cancers. In our 
study, ARID1A and ARID1B were recurrently mutated and also identified in CN loss in tFL. 
Additional genes were mutated that affect chromatin organization and modification. For 
example, mutations in CREBBP and MLL2, which were highly recurrent, are likely to occur as 
early events in FL. in contrast. EZH2, another frequently mutated gene, which is mutated almost 
twice as frequently in tFL compared to FL, may tend to appear later in the disease and may 
promote transformation.  There is evidence of a positive feedback loop between EZH2 and MYC, 
via a micro-RNA network, and increase in MYC was largely confined to tFLs. The availability of 
specific inhibitors for EZH2 makes it a promising target for tFL treatment. 
MiR-142 mutation is a unique finding in the study. The mutations were detected within the 
seed sequence in 3 out of 12 tFL samples. We applied TargetScan 5.2 to mir-142 to identify 
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possible targets; it showed differences in the predicted targets between mutant and WT. All the 
mutations are expected to alter complementarity to target genes. CYLD, a negative regulator of 
NF-κB, was listed as a top predicted target for mutant mir-142-5p by TargetScan, and this 
mutation is a novel finding. One shared mutation affecting mir-142-3p is exactly the same as the 
one reported by another group42. They found that this mutation results in both gain and loss of 
function. Novel targets sites for the mutant miR in the ZEB2 3’ UTR may lead to its down-
regulation.  
There were only a few mutations appearing uniquely in tFLs. Therefore, the transformation 
likely occurs due to a combination of several genetic changes that cooperate together to push 
the FL to the transformation. A larger dataset is required to determine which combinations are 
important in transformation. 
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When an immune response occurs, B cells migrate within follicles and develop a germinal 
center with large proliferating cells. This event initiates massive clonal expansion, somatic 
hypermutation and class switch recombination. These events increase genomic instability and 
predispose GCB-cells to the development of lymphoma. Our sequencing study has 
demonstrated the genetic abnormalities that contribute to FL and tFL. While cancer has been 
viewed as the result of progressive accumulation of genetic and epigenetic abnormalities, it is 
known that B cell differentiation is regulated through the expression of transcription factors 
along with epigenetic modulation in the germinal center.  In our study, we have identified 
multiple mutated genes that may contribute to epigenetic alterations. For example, in EZH2 
(encoding a histone-lysine N-methyltransferase), the mutation usually occurs at only one 
position and is a gain-of-function mutation that enhances histone methylation at histone H3K27, 
an inhibitory mark. Mutation of MLL2 (lymphoid leukemia 2) was detected as loss–of-function 
and decreases histone methylation at histone H3K4, an activating mark. Certain genes can be 
turned off by both enhanced histone H3K27 methylation and decreased H3K4 methylation, 
including genes inhibiting cell proliferation and differentiation. TET2 (Tet methylcytosine 
dioxygenase 2) can convert 5-methylcytosine to 5-hydroxymethylcytosine and lead to eventually 
to DNA demethylation. All the information suggests that aberrant DNA methylation occurs 
simultaneously with genetic abnormalities in FL and tFL development. Aberrant DNA 
methylation in the right context of the genes, can lead to gene silencing, e.g. hypermethylation 
of CpG islands of DNA sequence in tumor cells could result in the silencing of tumor suppressors. 
Within the context of chromatin, gene activation or inactivation is highly dependent on the 
methylation in the tail lysine residues of histone proteins. Therefore, there is an interaction 
between DNA methylation and histone modification. These modifications follow different 
chemical reactions and have different groups of enzymes involved, but changes in one may 
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impact changes in the other. Histone modifications are actually more complex and include 
acetylation, phosphorylation, and ubiquitylation. In future studies, we can apply reduced 
representation bisulfite sequencing (RRBS) analysis to investigate genome-scale alterations in 
DNA methylation. We can also apply chromatin immunoprecipitation sequencing (ChIP-seq) 
for global analysis of histone modifications. ChIP-sequencing could help identify the genes 
affected by the mutation in histone modifying genes.  By correlating the results with our 
previous gene expression data, we can identify genes that are down-regulated by aberrant DNA 
methylation or chromatin modification and the pathways involved.  If we integrate our gene 
expression data, CNV data, epigenetic and somatic mutation data, we should be able to provide 
an illuminating insight into the genome, transcriptome, and epigenome of FL and tFL, 
demonstrate connections and interaction among them, and identify the mechanisms relevant to 
FL and tFL development. 
NGS has provided an opportunity to fully describe the spectrum of mutations that 
contribute to diseases. The majority of sequencing studies are focused on somatic mutations 
that are located in coding regions of the genome and on distinguishing driver mutations from 
passenger mutations among these somatic mutations. It is a very efficient strategy. In our study, 
we first concentrated on protein-coding regions, and then selected recurrently mutated genes 
for further analysis. However, we and others have noticed that most somatic mutations are 
actually located in non-coding regions which are often excluded from WES analysis, but may still 
play a role in the disease process. For example, mutation of the regulatory region of the TERT 
gene has been found in malignant melanoma and may be important in its pathogenesis. RNA 
has traditionally been considered as a messenger between DNA and protein but, recent studies 
indicate that RNA is involved in the regulation of genome organization and gene expression.  
Additionally, mRNA splice sites, UTR regulation elements, promoters, transcription factor (TF) 
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binding sites, enhancers and noncoding RNAs (ncRNAs) could be functionally important in the 
non-coding regions.  Among the non-coding regions, the majority of the genomes are actually 
transcribed into ncRNAs that include several families of small RNAs such as the microRNA family 
and the Piwi family of RNAs. More interestingly, there are long ncRNAs (lncRNAs) that appear to 
control various levels of gene expression and potentially are involved in human disease. It has 
been reported that lncRNA functions as the interface between DNA and specific chromatin 
remodeling activities. For example, the expression level of the lncRNA HOTAIR is used to predict 
metastasis and survival in breast cancer48. The increasing expression of the same lncRNA in 
epithelial cancer cells has also been reported to induce Polycomb repressive complex 2 (PRC2) 
and lead to alter histone H3K27 methylation and increase cancer invasiveness and metastasis48. 
As another example, lncRNAs recruit Polycomb group (PcG) complexes to target genes and 
regulate the activity of PcG protein49. lncRNA regulation is likely dependent on direct 
interactions with PcG proteins such as EZH2, SUZ12, and CBX . MALAT1 is another ncRNA whose 
expression is also associated with metastasis and affects survival in lung cancer50. All these 
studies suggest that lncRNAs participate in epigenome alterations and that they may play a vital 
role in disease. According to the ample evidence for important roles of ncRNA, we can extend 
our current study to non-coding regions especially ncRNAs and explore the abnormalities that 
might contribute to FL and tFL.  
WTS can be used for the analysis of ncRNA alone but a global analysis of non-coding regions 
would require WGS and the availability of corresponding normal DNA is critical. We will also 
have to develop a pipeline that is specifically designed for mutation identification in non-coding 
regions and for the analysis of large structural alteration. Instead of detecting nonsynonymous 
variants, we would focus on variants within ncRNAs, enhancers, and mRNA promoters and TF 
binding site. It has been reported that variants identified in TF binding site are related to cancer 
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progression51,52. We can also look into is how mutations in regulatory regions of the genome 
might play a role in the FL and tFL development. For example, the structural alteration and 
mutations in the first exon-intron region of BCL6 are common in B-cell lymphoma53. This less 
than 3 kb region has been shown to contain negative regulatory elements, and the first intron is 
found to be commonly deleted in B-cell lymphoma as a result of chromosomal rearrangements.  
Our current study is concentrated on recurrently mutated genes in coding regions, according to 
the above evidence, we can extend our study to mutations in regulatory regions that can 
downregulate transcription of important genes. 
miRNA s are  another potential target for investigation. Variants in miRNA sequence could 
alter binding specificity, therefore leading to the alterations of expression and translation of 
target mRNA54. We have found mutations in only one miRNA but a more extensive study is 
needed to assess the importance of miRNA mutation in FL/tFL. Similarly, mutations of critical 
miRNA binding sites on important genes should also be evaluated.  
Chromatin open or active regions are considered most likely to contain key regulatory 
elements55. Therefore, these regions can be potential targets for investigation as well. Since 
there may not be clear and uniform information about these regions, particularly in the cell type 
of interest, the challenge during pipeline design can be that the variants within these regions are 
more difficult to annotate and interpret than the variants within amino acid coding regions. The 
other challenge might be in locating databases to use. Since non-coding regions are not as well-
studied as coding regions, we probably will need to collect different databases from various 
resources and reformat them into a convenient format to apply to the pipeline. 
KMT2D(MLL2), CREBBP, BCL2, EZH2, MEF2B, TNFRSF14, CARD11 and CCND3 are the top 
recurrent genes in our study. Although none of them is unique to the transformation, the 
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functional study of these mutants could provide insight on how they contribute to the tumor 
development. 
In our sequencing study, the very limited number of frozen or fresh tissue samples has been 
a limitation. However, there are much larger numbers of formalin-fixed paraffin-embedded 
(FFPE) samples in tissue banks, and they are often well-characterized with histological, 
immunophenotypical and follow-up clinical data. We have set up robust pipelines for mutation 
detection in frozen/fresh samples and for reliable downstream analysis. We would like to apply 
them to FFPE samples. As it is commonly known that the DNA may be highly fragmented in FFPE 
samples and errors can introduced into sequencing due to formalin fixation, the challenge will 
be to improve the quality of DNA from FFPET and to remove the artifacts introduced by formalin 
fixation.  
For the experimental part, there are many available methods designed specifically for FFPE 
samples. For example, the QIAamp DNA FFPE Tissue Kit uses special lysis conditions to overcome 
inhibitory effects caused by formalin crosslinking of nucleic acids while releasing DNA from 
tissue sections. Another possible method for FFPE samples would be water-soluble bifunctional 
catalysts, which can enhance the removal and decrosslinking of adducts from RNA and DNA 
bases56. Also, our laboratory has developed a modified Qiagen protocol for extracting DNA from 
FFPE samples resulting in higher yield of high quality DNA.  
For the analysis part, we would like to add additional filtering steps to remove artifacts in our 
current pipelines.  Because there are many publications57,58 about common artifacts in FFPE 
samples, we should be able to apply their methods or adjust their methods to estimate the 
threshold VAF at which a variant can be trusted not to be artifactual. Our current pipeline will be 
robust enough to detect the majority of real variants. Our main focus will be on how to detect 
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true low frequency variants. We assume the artifacts tend to occur at certain locations instead 
of randomly57. In order to detect the hidden patterns, we will investigate the difference 
between the reliable artifacts and variants around their neighboring region, for example, the 
proportion of certain sequences, and the frequency of same variants. Statistical methods will be 
applied to measure the differences. 
In our machine learning prediction study, the SIFT score in the complex feature set 
improved the training model and provided noticeably better prediction. However, SIFT score 
cannot predict every single variant (SIFT can predict most of the variants and have the best AUC 
score compared to other related programs59), therefore, we sacrificed some of our training 
dataset, which might impair the performance of the training model. Also, we cannot predict the 
variants that do not have a SIFT score in the testing dataset or real dataset. To address this 
limitation, we would like to assign comparable scores to the variants that SIFT score is unable to 
predict based on its own theory. The rationale33 applied to SIFT score prediction is based on 
whether an amino acid substitution affects the protein structure. If the substituted amino acid 
doesn’t have a similar property, it tends to be predicted as deleterious. For example, if a 
position located in the regions contain only hydrophobic amino acids, the SIFT score would 
assume this position can only contain amino acids with a hydrophobic character. Therefore, if 
the amino acid changes to any other one with hydrophilic character, this change would tend to 
be predicted as deleterious. In contrast, if this amino acid changes to any other one with a 
hydrophobic character, the mutation would tend to be predicted as tolerated. SIFT score also 
presumes that the important amino acids are highly conserved, so if the amino acid changes at a 
very conserved position, the position would tend to be predicted as deleterious. We would like 
to apply the similar idea in assigning comparable scores to the variants that cannot be predicted 
by their SIFT score. For example, if the variant is a nonsense mutation and it results in a 
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truncated, incomplete, nonfunctional protein product, the consequence is similar or even worse 
than if the amino acid substitution occurs in a conserved region, and it would be assigned as 
deleterious. Conversely, if the variant is a missense mutation and the amino acid changes to 
another amino acid with a similar character, it would be assigned as benign. This concept was 
also taken into consideration in our filtering method to remove germline variants. 
In this machine learning prediction study, we selected the features that are strongly 
associated with the characters of somatic mutations to ensure the model gets trained with the 
most useful information. We would like to add more features to improve the model in the 
future. There are more features annotated by ANNOVAR that we can include in the model. The 
challenge is that not all of the features provide useful information for somatic mutation 
prediction; instead, some of them might even degrade the model. The solution is that when we 
consider adding a feature, we first understand the theory behind the feature, the connection 
between the new feature and somatic mutation, then the distribution of the new feature to 
avoid biasing the data, and most importantly, we will test the new features in the model to 
confirm the performance.  We would like to use forward selection, which tests the addition of 
each new feature that improves the model the most and repeat this process until none improve 
the model.  
We have identified recurrently mutated genes and important pathways that are affected by 
mutations and CNAs but there are no mutations or CNAs that were completely unique to tFL. It 
is quite clear that the transformation is the result of the transformation event in combination of 
certain existing genetic events. We need to have a larger dataset to figure out the genetic 
combinations that can cause transformation. We are going to use our custom capture panel and 
the pipelines we applied to it to extend the study. 
128 
 
 
 
 
 
 
 
CHAPTER VI 
CONCLUSIONS 
 
 
 
 
 
 
 
 
129 
 
In our study, we designed multiple reliable pipelines to identify mutations from samples 
sequenced by WES and by a custom capture approach and evaluated the sequencing 
performance in each sample.  
All the pipelines include the following: read quality control for all raw reads from the 
sequencers, read mapping against reference genome (alignment), mapping performance 
evaluation, duplicate ratio adjustment, variants calling, variant quality evaluation, variant depth 
evaluation, gene-related annotation, and database-related annotation. Each of these pipelines 
was constructed for use on particular sequencing types (WES vs. custom capture) and sample 
types (single vs. pairs vs. triplets) to make sure it takes full consideration of its corresponding 
features and expectations. All the variant calling pipelines were validated by Sanger sequencing 
to confirm their performance. Samples performed by two different sequencing platforms were 
carefully investigated to validate and compare their performance. 
In custom capture panel sequencing, the method we employed used restriction enzymes to 
fragment DNA samples.  A novel, statistically-based method was applied to estimate the 
duplicate ratio in samples with identical sequence reads that are generated by restriction 
enzymes. Simulation was performed for evaluation. This duplicate ratio estimation method 
enhances the statistical accuracy of variant frequency estimates and their changes from FL to tFL 
during clonal evolution. 
An innovative two-way filtering based method was applied to retrieve somatic mutations 
from samples without corresponding normal samples. It is ideal to have healthy tissue from the 
same patient so that we can exclude germline variants from somatic mutations, but such tissue 
is not always available. Our layer by layer filtering approach was designed based on the 
biological character of the disease and the mutations and employed multiple reliable databases 
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to select reliable somatic mutations that may contribute to the disease. We classified the 
variants into two tiers of confidence. To validate our method, we applied it to a dataset which 
has corresponding normal samples without using the data from the normal samples. Then we 
compared the filtered results with the true somatic mutations identified from the full set of data. 
The validation proves our method is reliable and can filter out most of germline variants with 
20.2% FDR. 
We are the first to introduce a machine learning approach in predicting somatic mutations 
from samples without corresponding normal samples. Five different robust machine learning 
models were trained on one dataset (training dataset) with known germline variants. Two 
different sets of features were applied during training. Then the trained models were applied to 
another dataset (testing dataset) also with corresponding normal samples. The prediction 
performance was evaluated by a set of statistical measures based on the comparison of 
predicted results and true results. Random forest turned out to be the best model for germline 
variants prediction based on a comprehensive consideration.  
We also designed an advanced survival analysis for CNV data. Compared to commonly used 
analysis, this advanced approach put different emphasis on survival curves based on the 
biological understanding of each CNA and brings more statistical power to the comparison test. 
The comprehensive output provides more flexibility for reviewers to retrieve information.  
By integrating the information on mutation and CNAs, we have identified recurrently 
mutated genes and important pathways that may contribute to FL and to its transformation. We 
have found recurrent mutations of miR-142, which is a novel finding in FL and tFL studies. We 
also detected a number of mutations that appear to be more prevalent in tFL. The genes most 
frequently mutated in tFL included TP53, KMT2D (MLL2), CREBBP, EZH2, BCL2, miR-142, and 
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MEF2B. Many recurrently mutated genes are involved in important pathways, such as 
epigenetic regulation, the JAK-STAT or the NF-κB pathways, immune surveillance, and cell cycle 
regulation. Some other recurrently mutated genes are transcription factors involved in B-cell 
development. An especially interesting pathway is the S1P-activated pathway, which likely 
regulates lymphoma cell migration and survival outside of follicles during transformation. We 
detected mutations and CNAs along this pathway. We found few genes that were mutated only 
in tFL samples; therefore, it must be a combination of different genetic and epigenetic events 
that cooperate to drive an indolent FL to an aggressive tFL. A larger dataset and statistical 
analysis will be required to sort out the necessary combination of abnormalities required for 
transformation. The custom capture panel and analytical and experimental methods we have 
developed for frozen as well as FFPET will allow us to study a large set of patient samples to 
further our understanding of cooperativity of mutants and mechanisms of transformation. 
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APPEDIX A: RECURRENT SOMATIC MUTATIONS IDENTIFIED IN WES AND CUSTOM CAPTURE 
PANEL SEQUENCING 
Sample 
ID 
Chromosome| Position 
|Altered-Base 
Gene Mutation Type 
Var 
Freq 
Class Platform 
FL-2 chr1|27106915|T ARID1A stopgain 6% shared WES 
tFL-2 chr1|27106915|T ARID1A stopgain 23% shared WES 
FL-1 chr18|60985508|T BCL2 missense 19% shared WES 
tFL-1 chr18|60985508|T BCL2 missense 35% shared WES 
FL-22 chr18|60985814|C BCL2 missense 12% shared WES 
tFL-22 chr18|60985814|C BCL2 missense 17% shared WES 
FL-6 chr18|60985889|A BCL2 missense 27% shared WES 
tFL-6 chr18|60985889|A BCL2 missense 27% shared WES 
FL-22 chr2|32693596|T BIRC6 stopgain 29% shared WES 
tFL-22 chr2|32693596|T BIRC6 stopgain 30% shared WES 
FL-6 chr17|65908884|-ACT BPTF 
non-frameshift 
deletion 
35% shared WES 
tFL-6 chr17|65908884|-ACT BPTF 
non-frameshift 
deletion 
40% shared WES 
FL-4 chr10|98742885|T C10orf12 stopgain 5% shared WES 
tFL-4 chr10|98742885|T C10orf12 stopgain 49% shared WES 
FL-11 chr10|98743591|A C10orf12 stopgain 8% shared WES 
tFL-11 chr10|98743591|A C10orf12 stopgain  26% shared WES 
FL-1 chr6|41903707|A CCND3 missense 46% shared WES 
tFL-1 chr6|41903707|A CCND3 missense 50% shared WES 
FL-3 chr17|62007128|T CD79B splicing 5% shared WES 
tFL-3 chr17|62007128|T CD79B splicing 20% shared WES 
FL-10 chr16|3786704|G CREBBP missense 48% shared WES 
tFL-10 chr16|3786704|G CREBBP missense 83% shared WES 
FL-22 chr16|3786706|G CREBBP missense 32% shared WES 
tFL-22 chr16|3786706|G CREBBP missense 26% shared WES 
FL-6 chr16|3786739|G CREBBP missense 31% shared WES 
tFL-6 chr16|3786739|G CREBBP missense 33% shared WES 
FL-12 chr16|3788605|G CREBBP missense 41% shared WES 
tFL-12 chr16|3788605|G CREBBP missense 51% shared WES 
FL-11 chr16|3788618|A CREBBP missense 20% shared WES 
tFL-11 chr16|3788618|A CREBBP missense 37% shared WES 
FL-12 chr16|3795311|-A CREBBP frameshift deletion 36% shared WES 
tFL-12 chr16|3795311|-A CREBBP frameshift deletion 49% shared WES 
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FL-5 chr16|3807881|A CREBBP stopgain 23% shared WES 
tFL-5 chr16|3807881|A CREBBP stopgain 53% shared WES 
FL-5 chr16|3807917|C CREBBP missense 21% shared WES 
tFL-5 chr16|3807917|C CREBBP missense 53% shared WES 
FL-5 chr16|3808030|C CREBBP missense 43% shared WES 
tFL-5 chr16|3808030|C CREBBP missense 32% shared WES 
FL-5 chr16|3808033|G CREBBP missense 41% shared WES 
tFL-5 chr16|3808033|G CREBBP missense 33% shared WES 
FL-5 chr16|3808046|G CREBBP missense 33% shared WES 
tFL-5 chr16|3808046|G CREBBP missense 44% shared WES 
FL-8 chr16|3828175|C CREBBP stopgain 45% shared WES 
tFL-8 chr16|3828175|C CREBBP stopgain 39% shared WES 
FL-8 chr16|3860683|T CREBBP missense 51% shared WES 
tFL-8 chr16|3860683|T CREBBP missense 40% shared WES 
FL-1 chrX|31854912|C DMD missense 23% shared WES 
tFL-1 chrX|31854912|C DMD missense 40% shared WES 
FL-6 chr1|184692957|T EDEM3 missense 33% shared WES 
tFL-6 chr1|184692957|T EDEM3 missense 24% shared WES 
FL-22 chr6|74229068|A EEF1A1 missense 29% shared WES 
tFL-22 chr6|74229068|A EEF1A1 missense 26% shared WES 
tFL-4 chr7|148508727|A EZH2 missense 23% shared WES 
tFL-6 chr7|148508727|A EZH2 missense 44% shared WES 
FL-1 chr7|148508728|T EZH2 missense 20% shared WES 
tFL-1 chr7|148508728|T EZH2 missense 42% shared WES 
FL-5 chr7|148508728|T EZH2 missense 26% shared WES 
tFL-5 chr7|148508728|T EZH2 missense 47% shared WES 
FL-9 chr11|18327713|T HPS5 missense 10% shared WES 
tFL-9 chr11|18327713|T HPS5 missense 37% shared WES 
FL-3 chr4|3134324|A HTT missense 14% shared WES 
tFL-3 chr4|3134324|A HTT missense 25% shared WES 
FL-5 chr16|85936784|G IRF8 missense 32% shared WES 
tFL-5 chr16|85936784|G IRF8 missense 56% shared WES 
FL-22 chr3|183210327|C KLHL6 missense 39% shared WES 
tFL-22 chr3|183210327|C KLHL6 missense 13% shared WES 
FL-5 chr12|49418731|A KMT2D(MLL2) splicing 32% shared WES 
tFL-5 chr12|49418731|A KMT2D(MLL2) splicing 40% shared WES 
FL-12 chr12|49426001|-C KMT2D(MLL2) frameshift deletion 44% shared WES 
tFL-12 chr12|49426001|-C KMT2D(MLL2) frameshift deletion 45% shared WES 
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FL-6 chr12|49427255|A KMT2D(MLL2) stopgain 52% shared WES 
tFL-6 chr12|49427255|A KMT2D(MLL2) stopgain 36% shared WES 
FL-2 chr12|49431070|C KMT2D(MLL2) missense 6% shared WES 
tFL-2 chr12|49431070|C KMT2D(MLL2) missense 27% shared WES 
FL-8 chr12|49431800|-G KMT2D(MLL2) frameshift deletion 55% shared WES 
tFL-8 chr12|49431800|-G KMT2D(MLL2) frameshift deletion 40% shared WES 
FL-6 chr12|49432396|A KMT2D(MLL2) stopgain 37% shared WES 
tFL-6 chr12|49432396|A KMT2D(MLL2) stopgain 31% shared WES 
FL-1 chr12|49433220|A KMT2D(MLL2) stopgain 56% shared WES 
tFL-1 chr12|49433220|A KMT2D(MLL2) stopgain 95% shared WES 
FL-10 chr12|49433524|-CT KMT2D(MLL2) frameshift deletion 76% shared WES 
tFL-10 chr12|49433524|-CT KMT2D(MLL2) frameshift deletion 81% shared WES 
FL-5 chr12|49438694|T KMT2D(MLL2) stopgain 49% shared WES 
tFL-5 chr12|49438694|T KMT2D(MLL2) stopgain 53% shared WES 
FL-3 chr15|42035019|A MGA missense 59% shared WES 
tFL-3 chr15|42035019|A MGA missense 54% shared WES 
FL-8 chr17|56408621|G MIR142 - 45% shared WES 
tFL-8 chr17|56408621|G MIR142 - 47% shared WES 
FL-11 chr17|56408657|G MIR142 - 9% shared WES 
tFL-11 chr17|56408657|G MIR142 - 21% shared WES 
FL-12 chr3|38182641|C MYD88 missense 40% shared WES 
tFL-12 chr3|38182641|C MYD88 missense 83% shared WES 
FL-6 chr1|39322649|G RRAGC missense 28% shared WES 
tFL-6 chr1|39322649|G RRAGC missense 23% shared WES 
FL-8 chr1|39322697|A RRAGC missense 34% shared WES 
tFL-8 chr1|39322697|A RRAGC missense 45% shared WES 
FL-3 chr20|48500446|A SLC9A8 missense 24% shared WES 
tFL-3 chr20|48500446|A SLC9A8 missense 22% shared WES 
FL-1 chr18|60985760|T BCL2 missense 5% 
FL-
unique 
WES 
FL-8 chr18|60985880|A BCL2 missense 24% 
FL-
unique 
WES 
FL-12 chr6|41903688|T CCND3 missense 31% 
FL-
unique 
WES 
FL-8 chr17|62007129|T CD79B splicing 45% 
FL-
unique 
WES 
FL-5 chrX|41200829|C DDX3X missense 36% 
FL-
unique 
WES 
FL-11 chr7|148508728|T EZH2 missense 3% 
FL-
unique 
WES 
FL-8 chr6|26056530|C HIST1H1C missense 34% 
FL-
unique 
WES 
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FL-8 chr6|26234591|G HIST1H1D missense 46% 
FL-
unique 
WES 
FL-12 chr17|16012098|T NCOR1 splicing 56% 
FL-
unique 
WES 
FL-8 chr21|43256276|C PRDM15 missense 31% 
FL-
unique 
WES 
FL-3 chr1|110882568|G RBM15 missense 57% 
FL-
unique 
WES 
FL-12 chr13|37394096|G RFXAP splicing 49% 
FL-
unique 
WES 
FL-6 chr1|2493172|A TNFRSF14 stopgain 67% 
FL-
unique 
WES 
tFL-4 chr18|60985405|G BCL2 missense 24% 
tFL-
unique 
WES 
tFL-4 chr18|60985411|C BCL2 missense 18% 
tFL-
unique 
WES 
tFL-2 chr7|2979495|G CARD11 missense 30% 
tFL-
unique 
WES 
tFL-12 chr6|41903688|G CCND3 missense 44% 
tFL-
unique 
WES 
tFL-8 chr6|41903710|G CCND3 missense 13% 
tFL-
unique 
WES 
tFL-22 chr6|41903755|A CCND3 stopgain 25% 
tFL-
unique 
WES 
tFL-8 chr17|62006836|T CD79B splicing 52% 
tFL-
unique 
WES 
tFL-2 chr16|3786206|C CREBBP splicing 33% 
tFL-
unique 
WES 
tFL-6 chrX|41205842|A DDX3X missense 43% 
tFL-
unique 
WES 
tFL-8 chr6|74228924|T EEF1A1 missense 37% 
tFL-
unique 
WES 
tFL-4 chr11|128391823|A ETS1 missense 41% 
tFL-
unique 
WES 
tFL-11 chr7|148506437|A EZH2 missense 19% 
tFL-
unique 
WES 
tFL-22 chr7|148508728|T EZH2 missense 30% 
tFL-
unique 
WES 
tFL-9 chr3|183273154|C KLHL6 stopgain 37% 
tFL-
unique 
WES 
tFL-4 chr12|49435906|-T KMT2D(MLL2) frameshift deletion 21% 
tFL-
unique 
WES 
tFL-4 chr12|49443750|-T KMT2D(MLL2) frameshift deletion 49% 
tFL-
unique 
WES 
tFL-22 chr3|38182025|T MYD88 missense 14% 
tFL-
unique 
WES 
tFL-9 chr5|67576825|A PIK3R1 missense 32% 
tFL-
unique 
WES 
tFL-2 chr21|43256634|C PRDM15 missense 11% 
tFL-
unique 
WES 
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tFL-2 chr1|110883003|T RBM15 missense 15% 
tFL-
unique 
WES 
tFL-5 chr17|78269544|C RNF213 missense 50% 
tFL-
unique 
WES 
tFL-6 chr20|48467300|-T SLC9A8 frameshift deletion 21% 
tFL-
unique 
WES 
tFL-6 chr1|16256410|+A SPEN frameshift insertion 37% 
tFL-
unique 
WES 
tFL-1 chr6|152456309|C SYNE1 missense 50% 
tFL-
unique 
WES 
tFL-22 chr17|7577097|A TP53 missense 18% 
tFL-
unique 
WES 
tFL-5 chr17|7577545|C TP53 missense 38% 
tFL-
unique 
WES 
tFL-5 chr17|7577598|A TP53 missense 56% 
tFL-
unique 
WES 
tFL-15 chr7|2984163|T CARD11 nonsynonymous 47% single custom 
tFL-15 chr7|148508728|G EZH2 nonsynonymous 46% single custom 
tFL-15 chr12|49433790|-G KMT2D(MLL2) frameshift_deletion 25% single custom 
tFL-15 chr16|3788617|T CREBBP nonsynonymous 33% single custom 
tFL-15 chr16|85942671|C IRF8 nonsynonymous 18% single custom 
tFL-15 chr17|40475318|G STAT3 nonsynonymous 29% single custom 
tFL-15 chr18|60985724|C BCL2 nonsynonymous 22% single custom 
tFL-15 chr19|11143994|A SMARCA4 nonsynonymous 30% single custom 
tFL-15 chr19|19260045|A MEF2B nonsynonymous 30% single custom 
tFL-16 chr5|67591106|G PIK3R1 nonsynonymous 10% single custom 
tFL-16 chr6|37138763|G PIM1 nonsynonymous 28% single custom 
tFL-16 chr12|49427447|A KMT2D(MLL2) stopgain 39% single custom 
tFL-19 chr3|38182641|C MYD88 missense 81% single custom 
tFL-19 chr5|35857093|A IL7R nonsynonymous 23% single custom 
tFL-19 chr6|37138423|C PIM1 nonsynonymous 36% single custom 
tFL-19 chr7|2977613|T CARD11 nonsynonymous 32% single custom 
tFL-19 chr12|49425693|-C KMT2D(MLL2) frameshift_deletion 54% single custom 
tFL-19 chr17|62006798|C CD79B nonsynonymous 44% single custom 
tFL-20 chr7|148508727|A EZH2 nonsynonymous 19% single custom 
tFL-20 chr12|49415846|A KMT2D(MLL2) stopgain 44% single custom 
tFL-20 chr12|49435698|G KMT2D(MLL2) splicing 43% single custom 
tFL-20 chr16|11349287|T SOCS1 nonsynonymous 38% single custom 
tFL-20 chr16|89857858|T FANCA nonsynonymous 33% single custom 
tFL-20 chr22|41556727|A EP300 splicing 49% single custom 
tFL-31 chr1|16265861|G SPEN nonsynonymous 37% single custom 
tFL-31 chr6|26056305|C HIST1H1C nonsynonymous 30% single custom 
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tFL-31 chr6|138192455|T TNFAIP3 stopgain 39% single custom 
tFL-31 chr12|49446429|T KMT2D(MLL2) stopgain 29% single custom 
tFL-31 chr13|41240211|A FOXO1 nonsynonymous 27% single custom 
tFL-31 chr16|3788618|A CREBBP nonsynonymous 38% single custom 
tFL-31 chr17|16046921|C NCOR1 nonsynonymous 31% single custom 
tFL-31 chr18|60985760|T BCL2 nonsynonymous 6% single custom 
tFL-31 chr18|60985880|A BCL2 nonsynonymous 3% single custom 
tFL-31 chrX|70613191|A TAF1 nonsynonymous 58% single custom 
tFL-32 chr1|2492152|G TNFRSF14 nonsynonymous 11% single custom 
tFL-32 chr5|35867526|G IL7R nonsynonymous 56% single custom 
tFL-32 chr17|7578286|G TP53 nonsynonymous 37% single custom 
tFL-32 chr17|40477033|C STAT3 nonsynonymous 36% single custom 
tFL-33 chr7|148508728|T EZH2 nonsynonymous 20% single custom 
tFL-33 chr17|40474427|G STAT3 nonsynonymous 20% single custom 
tFL-33 chr18|60985301|G BCL2 nonsynonymous 25% single custom 
tFL-33 chr18|60985626|T BCL2 nonsynonymous 19% single custom 
tFL-34 chr1|2488138|A TNFRSF14 stopgain 43% single custom 
tFL-34 chr4|153244046|G FBXW7 nonsynonymous 22% single custom 
tFL-34 chr7|2977614|A CARD11 nonsynonymous 28% single custom 
tFL-34 chr7|148508727|A EZH2 nonsynonymous 14% single custom 
tFL-34 chr7|148508745|C EZH2 nonsynonymous 14% single custom 
tFL-34 chr7|148508763|A EZH2 nonsynonymous 17% single custom 
tFL-34 chr12|49415647|T KMT2D(MLL2) stopgain 17% single custom 
tFL-34 chr12|49425098|A KMT2D(MLL2) stopgain 25% single custom 
tFL-34 chr16|3790421|T CREBBP nonsynonymous 20% single custom 
tFL-35 chr1|2492063|-C TNFRSF14 frameshift_deletion 78% single custom 
tFL-35 chr6|26234923|T HIST1H1D nonsynonymous 42% single custom 
tFL-35 chr7|148508727|G EZH2 nonsynonymous 36% single custom 
tFL-35 chr12|49432738|A KMT2D(MLL2) stopgain 87% single custom 
tFL-35 chr16|3790421|T CREBBP nonsynonymous 86% single custom 
tFL-36 chr6|27860754|C HIST1H2AM stopgain 15% single custom 
tFL-36 chr12|49425446|-CT KMT2D(MLL2) frameshift_deletion 43% single custom 
tFL-36 chr18|60985896|T BCL2 nonsynonymous 22% single custom 
tFL-37 chr7|148508728|T EZH2 nonsynonymous 27% single custom 
tFL-37 chr12|49431667|A KMT2D(MLL2) stopgain 47% single custom 
tFL-37 chr12|49434187|+T KMT2D(MLL2) frameshift_insertion 39% single custom 
tFL-37 chr16|3820888|+GTGCA CREBBP frameshift_insertion 45% single custom 
tFL-37 chr16|11348901|C SOCS1 nonsynonymous 24% single custom 
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tFL-37 chr18|60985286|T BCL2 nonsynonymous 24% single custom 
tFL-37 chr18|60985884|C BCL2 nonsynonymous 32% single custom 
tFL-37 chr19|19260045|A MEF2B nonsynonymous 53% single custom 
tFL-38 chr6|37138355|T PIM1 nonsynonymous 38% single custom 
tFL-38 chr12|49424074|T KMT2D(MLL2) nonsynonymous 16% single custom 
tFL-38 chr12|49435294|A KMT2D(MLL2) stopgain 76% single custom 
tFL-38 chr17|62007480|C CD79B nonsynonymous 36% single custom 
tFL-39 chr6|37139111|T PIM1 nonsynonymous 27% single custom 
tFL-39 chr6|41903710|G CCND3 nonsynonymous 44% single custom 
tFL-39 chr12|49435479|A KMT2D(MLL2) stopgain 34% single custom 
tFL-39 chr16|3788657|G CREBBP nonsynonymous 31% single custom 
tFL-40 chr1|155920754|A ARHGEF2 stopgain 49% single custom 
tFL-40 chr7|2985468|T CARD11 nonsynonymous 41% single custom 
tFL-40 chr15|45003764|A B2M stopgain 60% single custom 
tFL-40 chr18|60795973|A BCL2 nonsynonymous 37% single custom 
tFL-40 chr22|41566522|G EP300 nonsynonymous 20% single custom 
FL-3-
cus 
chr1|27023162|G ARID1A nonsynonymous 7% shared custom 
FL-3-
cus 
chr1|110882568|G RBM15 nonsynonymous 16% shared custom 
FL-3-
cus 
chr17|62007128|T CD79B splicing 14% shared custom 
FL-5-
cus 
chr7|148508728|T EZH2 nonsynonymous 32% shared custom 
FL-5-
cus 
chr12|49418731|A KMT2D(MLL2) splicing 40% shared custom 
FL-5-
cus 
chr12|49438694|T KMT2D(MLL2) stopgain 34% shared custom 
FL-5-
cus 
chr16|3807881|A CREBBP stopgain 37% shared custom 
FL-5-
cus 
chr16|3807917|C CREBBP nonsynonymous 39% shared custom 
FL-5-
cus 
chr16|3808030|C CREBBP nonsynonymous 38% shared custom 
FL-5-
cus 
chr16|3808033|G CREBBP nonsynonymous 38% shared custom 
FL-5-
cus 
chr16|3808046|G CREBBP nonsynonymous 38% shared custom 
FL-5-
cus 
chr16|11349099|C SOCS1 nonsynonymous 36% shared custom 
FL-5-
cus 
chr16|85936784|G IRF8 nonsynonymous 38% shared custom 
FL-30 chr12|49433524|-CT KMT2D(MLL2) frameshift_deletion 54% shared custom 
FL-30 chr16|3786704|G CREBBP nonsynonymous 35% shared custom 
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FL-23-1 chr16|3789578|A CREBBP splicing 40% shared custom 
FL-23-2 chr16|3789578|A CREBBP splicing 18% shared custom 
FL-24-1 chr6|90402481|G MDN1 nonsynonymous 23% shared custom 
FL-24-1 chr7|148508728|G EZH2 nonsynonymous 40% shared custom 
FL-24-2 chr7|148508728|G EZH2 nonsynonymous 38% shared custom 
FL-24-1 chr16|3788618|A CREBBP nonsynonymous 76% shared custom 
FL-24-2 chr16|3788618|A CREBBP nonsynonymous 79% shared custom 
tFL-24 chr16|3788618|A CREBBP nonsynonymous 66% shared custom 
FL-25-1 chr7|148508727|A EZH2 nonsynonymous 18% shared custom 
FL-25-2 chr7|148508727|A EZH2 nonsynonymous 10% shared custom 
tFL-25 chr7|148508727|A EZH2 nonsynonymous 10% shared custom 
FL-25-1 chr12|49428448|A KMT2D(MLL2) stopgain 61% shared custom 
FL-25-2 chr12|49428448|A KMT2D(MLL2) stopgain 66% shared custom 
FL-25-1 chr12|113496211|G DTX1 nonsynonymous 27% shared custom 
FL-25-2 chr12|113496211|G DTX1 nonsynonymous 31% shared custom 
FL-25-1 chr15|45003779|C B2M nonsynonymous 17% shared custom 
FL-25-2 chr15|45003779|C B2M nonsynonymous 26% shared custom 
FL-25-1 chr16|3900873|A CREBBP stopgain 21% shared custom 
FL-25-2 chr16|3900873|A CREBBP stopgain 31% shared custom 
FL-25-1 chr16|11349320|A SOCS1 stopgain 23% shared custom 
FL-25-2 chr16|11349320|A SOCS1 stopgain 33% shared custom 
FL-25-1 chr19|19257600|C MEF2B stopgain 28% shared custom 
FL-25-2 chr19|19257600|C MEF2B stopgain 29% shared custom 
FL-25-1 chr19|19260045|A MEF2B nonsynonymous 33% shared custom 
FL-25-2 chr19|19260045|A MEF2B nonsynonymous 35% shared custom 
FL-26-1 chr11|128332397|C ETS1 stopgain 27% shared custom 
FL-26-2 chr11|128332397|C ETS1 stopgain 22% shared custom 
FL-26-1 chr12|49426598|A KMT2D(MLL2) stopgain 23% shared custom 
FL-26-2 chr12|49426598|A KMT2D(MLL2) stopgain 24% shared custom 
FL-26-1 chr12|49433902|-AG KMT2D(MLL2) frameshift_deletion 53% shared custom 
FL-26-2 chr12|49433902|-AG KMT2D(MLL2) frameshift_deletion 47% shared custom 
FL-26-1 chr16|3781333|T CREBBP nonsynonymous 31% shared custom 
FL-26-2 chr16|3781333|T CREBBP nonsynonymous 34% shared custom 
FL-26-1 chr16|3831211|+C CREBBP frameshift_insertion 23% shared custom 
FL-26-1 chr18|60985883|T BCL2 nonsynonymous 26% shared custom 
FL-27 chr1|27089478|T ARID1A stopgain 14% shared custom 
FL-27 chr12|49424062|T KMT2D(MLL2) splicing 23% shared custom 
FL-27 chr16|3788618|A CREBBP nonsynonymous 21% shared custom 
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tFL-27 chr16|3788618|A CREBBP nonsynonymous 79% shared custom 
FL-27 chr18|60985760|T BCL2 nonsynonymous 26% shared custom 
tFL-27 chr18|60985760|T BCL2 nonsynonymous 41% shared custom 
FL-28 chr4|153332538|A FBXW7 nonsynonymous 14% shared custom 
FL-28 chr7|148508727|A EZH2 nonsynonymous 12% shared custom 
tFL-28 chr7|148508727|A EZH2 nonsynonymous 18% shared custom 
FL-29 chr18|60985529|G BCL2 nonsynonymous 13% shared custom 
FL-29 chr19|19260045|G MEF2B nonsynonymous 62% shared custom 
FL-31 chr1|16265861|G SPEN nonsynonymous 20% shared custom 
FL-31 chr12|49446429|T KMT2D(MLL2) stopgain 19% shared custom 
FL-31 chr13|41240211|A FOXO1 nonsynonymous 18% shared custom 
FL-31 chr16|3788618|A CREBBP nonsynonymous 14% shared custom 
FL-31 chr18|60985880|A BCL2 nonsynonymous 18% shared custom 
FL-5-
cus 
chrX|41200829|C DDX3X nonsynonymous 43% 
FL-
unique 
custom 
FL-24-2 chr6|90402481|G MDN1 nonsynonymous 22% 
FL-
unique 
custom 
FL-26-2 chr18|60985883|T BCL2 nonsynonymous 25% 
FL-
unique 
custom 
FL-27 chr6|134495706|G SGK1 nonsynonymous 15% 
FL-
unique 
custom 
FL-27 chr12|49427261|A KMT2D(MLL2) stopgain 14% 
FL-
unique 
custom 
FL-28 chr18|60985815|G BCL2 nonsynonymous 18% 
FL-
unique 
custom 
FL-29 chr12|49418462|C KMT2D(MLL2) stopgain 24% 
FL-
unique 
custom 
FL-31 chr12|92538182|T BTG1 nonsynonymous 11% 
FL-
unique 
custom 
tFL-3-
cus 
chr1|27023162|G ARID1A nonsynonymous 4% 
tFL-
unique 
custom 
tFL-3-
cus 
chr1|110882568|G RBM15 nonsynonymous 22% 
tFL-
unique 
custom 
tFL-3-
cus 
chr17|62007128|T CD79B splicing 20% 
tFL-
unique 
custom 
tFL-5-
cus 
chr7|148508728|T EZH2 nonsynonymous 37% 
tFL-
unique 
custom 
tFL-5-
cus 
chr12|49418731|A KMT2D(MLL2) splicing 47% 
tFL-
unique 
custom 
tFL-5-
cus 
chr12|49438694|T KMT2D(MLL2) stopgain 46% 
tFL-
unique 
custom 
tFL-5-
cus 
chr16|3807881|A CREBBP stopgain 40% 
tFL-
unique 
custom 
tFL-5-
cus 
chr16|3807917|C CREBBP nonsynonymous 42% 
tFL-
unique 
custom 
tFL-5- chr16|3808030|C CREBBP nonsynonymous 42% tFL- custom 
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cus unique 
tFL-5-
cus 
chr16|3808033|G CREBBP nonsynonymous 42% 
tFL-
unique 
custom 
tFL-5-
cus 
chr16|3808046|G CREBBP nonsynonymous 42% 
tFL-
unique 
custom 
tFL-5-
cus 
chr16|11349099|C SOCS1 nonsynonymous 40% 
tFL-
unique 
custom 
tFL-5-
cus 
chr16|85936784|G IRF8 nonsynonymous 40% 
tFL-
unique 
custom 
tFL-5-
cus 
chr17|7577545|C TP53 nonsynonymous 83% 
tFL-
unique 
custom 
tFL-5-
cus 
chr17|7577598|A TP53 nonsynonymous 11% 
tFL-
unique 
custom 
tFL-5-
cus 
chr17|78269544|C RNF213 nonsynonymous 34% 
tFL-
unique 
custom 
tFL-30 chr12|49433524|-CT KMT2D(MLL2) frameshift_deletion 83% 
tFL-
unique 
custom 
tFL-30 chr16|3786704|G CREBBP nonsynonymous 76% 
tFL-
unique 
custom 
tFL-23 chr3|38182032|G MYD88 nonsynonymous 19% 
tFL-
unique 
custom 
tFL-23 chr7|2979501|G CARD11 nonsynonymous 13% 
tFL-
unique 
custom 
tFL-23 chr16|3786704|T CREBBP nonsynonymous 15% 
tFL-
unique 
custom 
tFL-23 chr16|3789578|A CREBBP splicing 12% 
tFL-
unique 
custom 
tFL-24 chr7|148508728|G EZH2 nonsynonymous 33% 
tFL-
unique 
custom 
tFL-24 chr17|40485721|G STAT3 nonsynonymous 31% 
tFL-
unique 
custom 
tFL-25 chr12|49428448|A KMT2D(MLL2) stopgain 53% 
tFL-
unique 
custom 
tFL-25 chr12|113496211|G DTX1 nonsynonymous 26% 
tFL-
unique 
custom 
tFL-25 chr15|45003779|C B2M nonsynonymous 23% 
tFL-
unique 
custom 
tFL-25 chr16|3900873|A CREBBP stopgain 25% 
tFL-
unique 
custom 
tFL-25 chr16|11349320|A SOCS1 stopgain 26% 
tFL-
unique 
custom 
tFL-25 chr16|11349333|A SOCS1 nonsynonymous 26% 
tFL-
unique 
custom 
tFL-25 chr19|19257600|C MEF2B stopgain 23% 
tFL-
unique 
custom 
tFL-25 chr19|19260045|A MEF2B nonsynonymous 21% 
tFL-
unique 
custom 
tFL-26 chr11|128332397|C ETS1 stopgain 37% 
tFL-
unique 
custom 
tFL-26 chr12|49426598|A KMT2D(MLL2) stopgain 42% tFL- custom 
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unique 
tFL-26 chr12|49433902|-AG KMT2D(MLL2) frameshift_deletion 47% 
tFL-
unique 
custom 
tFL-26 chr16|3781333|T CREBBP nonsynonymous 40% 
tFL-
unique 
custom 
tFL-26 chr16|3831211|+C CREBBP frameshift_insertion 30% 
tFL-
unique 
custom 
tFL-26 chr16|11348935|T SOCS1 nonsynonymous 42% 
tFL-
unique 
custom 
tFL-26 chr19|19257993|A MEF2B splicing 81% 
tFL-
unique 
custom 
tFL-27 chr1|27089478|T ARID1A stopgain 45% 
tFL-
unique 
custom 
tFL-27 chr6|90453359|T MDN1 stopgain 36% 
tFL-
unique 
custom 
tFL-27 chr7|151873463|A KMT2C(MLL3) nonsynonymous 39% 
tFL-
unique 
custom 
tFL-27 chr12|49424062|T KMT2D(MLL2) splicing 32% 
tFL-
unique 
custom 
tFL-27 chr17|7578265|G TP53 nonsynonymous 63% 
tFL-
unique 
custom 
tFL-27 chr18|60985722|T BCL2 nonsynonymous 39% 
tFL-
unique 
custom 
tFL-28 chr2|73677838|G ALMS1 nonsynonymous 17% 
tFL-
unique 
custom 
tFL-28 chr4|153332538|A FBXW7 nonsynonymous 15% 
tFL-
unique 
custom 
tFL-28 chr6|134495724|C SGK1 nonsynonymous 13% 
tFL-
unique 
custom 
tFL-28 chr12|92539226|C BTG1 nonsynonymous 12% 
tFL-
unique 
custom 
tFL-28 chr13|41240279|A FOXO1 nonsynonymous 15% 
tFL-
unique 
custom 
tFL-29 chr7|148508727|A EZH2 nonsynonymous 28% 
tFL-
unique 
custom 
tFL-29 chr7|152027794|-C KMT2C(MLL3) frameshift_deletion 34% 
tFL-
unique 
custom 
tFL-29 chr12|49420082|A KMT2D(MLL2) nonsynonymous 50% 
tFL-
unique 
custom 
tFL-29 chr12|49420132|A KMT2D(MLL2) nonsynonymous 41% 
tFL-
unique 
custom 
tFL-29 chr17|7576571|C TP53 stopgain 47% 
tFL-
unique 
custom 
tFL-29 chr17|7577093|G TP53 nonsynonymous 51% 
tFL-
unique 
custom 
tFL-29 chr18|60985529|G BCL2 nonsynonymous 33% 
tFL-
unique 
custom 
tFL-29 chr19|19260045|G MEF2B nonsynonymous 97% 
tFL-
unique 
custom 
tFL-31 chr1|16265861|G SPEN nonsynonymous 37% tFL- custom 
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unique 
tFL-31 chr6|26056305|C HIST1H1C nonsynonymous 30% 
tFL-
unique 
custom 
tFL-31 chr6|138192455|T TNFAIP3 stopgain 39% 
tFL-
unique 
custom 
tFL-31 chr12|49446429|T KMT2D(MLL2) stopgain 29% 
tFL-
unique 
custom 
tFL-31 chr13|41240211|A FOXO1 nonsynonymous 27% 
tFL-
unique 
custom 
tFL-31 chr16|3788618|A CREBBP nonsynonymous 38% 
tFL-
unique 
custom 
tFL-31 chr17|16046921|C NCOR1 nonsynonymous 31% 
tFL-
unique 
custom 
tFL-31 chr18|60985760|T BCL2 nonsynonymous 6% 
tFL-
unique 
custom 
tFL-31 chr18|60985880|A BCL2 nonsynonymous 3% 
tFL-
unique 
custom 
tFL-31 chrX|70613191|A TAF1 nonsynonymous 58% 
tFL-
unique 
custom 
The first column (Sample ID) indicates the samples in which the mutations were detected. The 
second column (Chromosome| Position |Altered-Base) indicates the coordinates of the 
mutations. The third column indicates the genes altered by the mutations. The fourth column 
indicates the mutation type. The fifth column (Var Freq) indicates the variant frequencies of the 
mutations. The sixth column indicates the classes of the mutations. The last column indicates 
the platform used to detect the mutations. 
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APPENDIX B: INTEGRATED MUTATION AND CN INFORMATIN FOR TNFRSF14, CARD11, 
HIST1H1E, EZH2, KMT2D (MLL2), BCL2, TNFAIP3, SGK1, CREBBP, and TP53 
Sample ID Chr|Pos|VarAllele Gene MutType 
Var 
Freq 
CN 
FL-5 chr1|2493112|C TNFRSF14 nonsynonymous 0.667 NA 
FL-5-cus chr1|2493112|C TNFRSF14 nonsynonymous 0.81 NA 
tFL-5 chr1|2493112|C TNFRSF14 nonsynonymous 1 1 
tFL-5-cus chr1|2493112|C TNFRSF14 nonsynonymous 0.881 1 
FL-6 chr1|2493172|A TNFRSF14 stopgain 0.667 1 
FL-10 chr1|2493111|A TNFRSF14 splicing 0.409 2 
FL-10-cus chr1|2493111|A TNFRSF14 splicing 0.48 2 
tFL-10 chr1|2493111|A TNFRSF14 splicing 0.474 2 
tFL-10-cus chr1|2493111|A TNFRSF14 splicing 0.55 2 
tFL-15 chr1|2489802|A TNFRSF14 nonsynonymous 0.629 2 
tFL-32 chr1|2492152|G TNFRSF14 nonsynonymous 0.11 2 
tFL-34 chr1|2488138|A TNFRSF14 stopgain 0.431 2 
tFL-35 chr1|2492063|-C TNFRSF14 frameshift_deletion 0.78 1 
tFL-2 chr7|2979495|G CARD11 nonsynonymous 0.303 4 
tFL-15 chr7|2984163|T CARD11 nonsynonymous 0.47 3 
tFL-15 chr7|2979466|C CARD11 nonsynonymous 0.46 3 
tFL-19 chr7|2977613|T CARD11 nonsynonymous 0.32 2 
tFL-19 chr7|2979486|G CARD11 nonsynonymous 0.4 2 
tFL-23 chr7|2979501|G CARD11 nonsynonymous 0.13 3 
tFL-34 chr7|2977614|A CARD11 nonsynonymous 0.28 3 
tFL-40 chr7|2985468|T CARD11 nonsynonymous 0.41 2 
tFL-19 chr6|26156958|T HIST1H1E nonsynonymous 0.33 2 
tFL-19 chr6|26156976|C HIST1H1E nonsynonymous 0.32 2 
tFL-20 chr6|26156911|A HIST1H1E nonsynonymous 0.41 2 
tFL-23 chr6|26156797|T HIST1H1E nonsynonymous 0.11 3 
FL-25-1 chr6|26156787|C HIST1H1E nonsynonymous 0.2 2 
FL-25-2 chr6|26156787|C HIST1H1E nonsynonymous 0.301 NA 
tFL-25 chr6|26156787|C HIST1H1E nonsynonymous 0.24 2 
tFL-37 chr6|26156947|G HIST1H1E nonsynonymous 0.22 3 
tFL-38 chr6|26157271|G HIST1H1E nonsynonymous 0.3 3 
FL-1 chr7|148508728|T EZH2 nonsynonymous 0.204 2 
tFL-1 chr7|148508728|T EZH2 nonsynonymous 0.422 2 
tFL-4 chr7|148508727|A EZH2 nonsynonymous 0.228 3 
FL-5 chr7|148508728|T EZH2 nonsynonymous 0.262 NA 
FL-5-cus chr7|148508728|T EZH2 nonsynonymous 0.321 NA 
tFL-5 chr7|148508728|T EZH2 nonsynonymous 0.465 2 
154 
 
tFL-5-cus chr7|148508728|T EZH2 nonsynonymous 0.37 NA 
tFL-6 chr7|148508727|A EZH2 nonsynonymous 0.441 2 
tFL-11 chr7|148506437|A EZH2 nonsynonymous 0.189 2 
FL-11 chr7|148508728|T EZH2 nonsynonymous 0.034 2 
tFL-15 chr7|148508728|G EZH2 nonsynonymous 0.46 3 
tFL-20 chr7|148508727|A EZH2 nonsynonymous 0.19 3 
tFL-22 chr7|148508728|T EZH2 nonsynonymous 0.3 NA 
FL-24-1 chr7|148508728|G EZH2 nonsynonymous 0.4 2 
FL-24-2 chr7|148508728|G EZH2 nonsynonymous 0.38 NA 
tFL-24 chr7|148508728|G EZH2 nonsynonymous 0.331 2 
FL-25-1 chr7|148508727|A EZH2 nonsynonymous 0.18 3 
FL-25-2 chr7|148508727|A EZH2 nonsynonymous 0.1 NA 
tFL-25 chr7|148508727|A EZH2 nonsynonymous 0.1 3 
FL-28 chr7|148508727|A EZH2 nonsynonymous 0.12 NA 
tFL-28 chr7|148508727|A EZH2 nonsynonymous 0.18 3 
tFL-29 chr7|148508727|A EZH2 nonsynonymous 0.28 2 
tFL-33 chr7|148508728|T EZH2 nonsynonymous 0.2 3 
tFL-34 chr7|148508727|A EZH2 nonsynonymous 0.14 3 
tFL-34 chr7|148508745|C EZH2 nonsynonymous 0.14 3 
tFL-34 chr7|148508763|A EZH2 nonsynonymous 0.17 3 
tFL-35 chr7|148508727|G EZH2 nonsynonymous 0.36 2 
tFL-37 chr7|148508728|T EZH2 nonsynonymous 0.27 3 
FL-1 chr12|49433220|A KMT2D(MLL2) stopgain 0.559 2 
tFL-1 chr12|49433220|A KMT2D(MLL2) stopgain 0.951 2 
FL-2 chr12|49431070|C KMT2D(MLL2) nonsynonymous 0.062 NA 
tFL-2 chr12|49431070|C KMT2D(MLL2) nonsynonymous 0.271 2 
tFL-4 chr12|49435906|-T KMT2D(MLL2) frameshift_deletion 0.21 3 
tFL-4 chr12|49443750|-T KMT2D(MLL2) frameshift_deletion 0.493 3 
FL-5 chr12|49418731|A KMT2D(MLL2) splicing 0.317 NA 
FL-5-cus chr12|49418731|A KMT2D(MLL2) splicing 0.4 NA 
tFL-5 chr12|49418731|A KMT2D(MLL2) splicing 0.395 2 
tFL-5-cus chr12|49418731|A KMT2D(MLL2) splicing 0.47 NA 
FL-5 chr12|49438694|T KMT2D(MLL2) stopgain 0.486 NA 
FL-5-cus chr12|49438694|T KMT2D(MLL2) stopgain 0.34 NA 
tFL-5 chr12|49438694|T KMT2D(MLL2) stopgain 0.531 2 
tFL-5-cus chr12|49438694|T KMT2D(MLL2) stopgain 0.46 NA 
FL-6 chr12|49427255|A KMT2D(MLL2) stopgain 0.521 2 
tFL-6 chr12|49427255|A KMT2D(MLL2) stopgain 0.364 2 
FL-6 chr12|49432396|A KMT2D(MLL2) stopgain 0.367 2 
tFL-6 chr12|49432396|A KMT2D(MLL2) stopgain 0.308 2 
FL-8 chr12|49431800|-G KMT2D(MLL2) frameshift_deletion 0.545 NA 
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tFL-8 chr12|49431800|-G KMT2D(MLL2) frameshift_deletion 0.395 NA 
FL-9 chr12|49433087|T KMT2D(MLL2) nonsynonymous 0.504 2 
tFL-9 chr12|49433087|T KMT2D(MLL2) nonsynonymous 0.427 2 
FL-10 chr12|49433524|-CT KMT2D(MLL2) frameshift_deletion 0.764 2 
FL-30 chr12|49433524|-CT KMT2D(MLL2) frameshift_deletion 0.54 2 
tFL-10 chr12|49433524|-CT KMT2D(MLL2) frameshift_deletion 0.806 2 
tFL-30 chr12|49433524|-CT KMT2D(MLL2) frameshift_deletion 0.832 2 
FL-12 chr12|49426001|-C KMT2D(MLL2) frameshift_deletion 0.438 2 
tFL-12 chr12|49426001|-C KMT2D(MLL2) frameshift_deletion 0.449 2 
tFL-15 chr12|49433790|-G KMT2D(MLL2) frameshift_deletion 0.25 3 
tFL-16 chr12|49427447|A KMT2D(MLL2) stopgain 0.39 2 
tFL-19 chr12|49425693|-C KMT2D(MLL2) frameshift_deletion 0.54 2 
tFL-20 chr12|49415846|A KMT2D(MLL2) stopgain 0.44 2 
tFL-20 chr12|49435698|G KMT2D(MLL2) splicing 0.43 2 
FL-25-1 chr12|49428448|A KMT2D(MLL2) stopgain 0.61 2 
FL-25-2 chr12|49428448|A KMT2D(MLL2) stopgain 0.66 NA 
tFL-25 chr12|49428448|A KMT2D(MLL2) stopgain 0.53 2 
FL-26-1 chr12|49426598|A KMT2D(MLL2) stopgain 0.231 NA 
FL-26-2 chr12|49426598|A KMT2D(MLL2) stopgain 0.239 3 
tFL-26 chr12|49426598|A KMT2D(MLL2) stopgain 0.421 2 
FL-26-1 chr12|49433902|-AG KMT2D(MLL2) frameshift_deletion 0.531 NA 
FL-26-2 chr12|49433902|-AG KMT2D(MLL2) frameshift_deletion 0.47 3 
tFL-26 chr12|49433902|-AG KMT2D(MLL2) frameshift_deletion 0.47 2 
FL-27 chr12|49424062|T KMT2D(MLL2) splicing 0.23 2 
tFL-27 chr12|49424062|T KMT2D(MLL2) splicing 0.32 2 
FL-27 chr12|49427261|A KMT2D(MLL2) stopgain 0.14 2 
FL-29 chr12|49418462|C KMT2D(MLL2) stopgain 0.24 2 
tFL-29 chr12|49420082|A KMT2D(MLL2) nonsynonymous 0.501 2 
tFL-29 chr12|49420132|A KMT2D(MLL2) nonsynonymous 0.409 2 
FL-31 chr12|49446429|T KMT2D(MLL2) stopgain 0.19 NA 
tFL-31 chr12|49446429|T KMT2D(MLL2) stopgain 0.29 NA 
tFL-34 chr12|49415647|T KMT2D(MLL2) stopgain 0.17 2 
tFL-34 chr12|49425098|A KMT2D(MLL2) stopgain 0.25 2 
tFL-35 chr12|49432738|A KMT2D(MLL2) stopgain 0.87 2 
tFL-36 chr12|49425446|-CT KMT2D(MLL2) frameshift_deletion 0.43 2 
tFL-37 chr12|49431667|A KMT2D(MLL2) stopgain 0.47 2 
tFL-37 chr12|49434187|+T KMT2D(MLL2) frameshift_insertion 0.39 2 
tFL-38 chr12|49424074|T KMT2D(MLL2) nonsynonymous 0.16 4 
tFL-38 chr12|49435294|A KMT2D(MLL2) stopgain 0.76 4 
tFL-39 chr12|49435479|A KMT2D(MLL2) stopgain 0.34 3 
tFL-39 chr12|49435750|A KMT2D(MLL2) nonsynonymous 0.51 3 
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tFL-39 chr12|49435765|C KMT2D(MLL2) nonsynonymous 0.51 3 
FL-1 chr18|60985508|T BCL2 nonsynonymous 0.192 3 
tFL-1 chr18|60985508|T BCL2 nonsynonymous 0.353 3 
FL-1 chr18|60985760|T BCL2 nonsynonymous 0.05 3 
tFL-4 chr18|60985405|G BCL2 nonsynonymous 0.237 2 
tFL-4 chr18|60985411|C BCL2 nonsynonymous 0.179 2 
FL-6 chr18|60985889|A BCL2 nonsynonymous 0.267 2 
tFL-6 chr18|60985889|A BCL2 nonsynonymous 0.271 2 
FL-8 chr18|60985880|A BCL2 nonsynonymous 0.244 NA 
tFL-15 chr18|60985724|C BCL2 nonsynonymous 0.219 2 
tFL-20 chr18|60985443|G BCL2 nonsynonymous 0.42 2 
FL-22 chr18|60985814|C BCL2 nonsynonymous 0.121 NA 
tFL-22 chr18|60985814|C BCL2 nonsynonymous 0.169 NA 
FL-26-1 chr18|60985883|T BCL2 nonsynonymous 0.261 NA 
FL-26-2 chr18|60985883|T BCL2 nonsynonymous 0.251 2 
tFL-27 chr18|60985722|T BCL2 nonsynonymous 0.388 2 
FL-27 chr18|60985760|T BCL2 nonsynonymous 0.259 2 
tFL-27 chr18|60985760|T BCL2 nonsynonymous 0.411 2 
FL-28 chr18|60985815|G BCL2 nonsynonymous 0.181 NA 
FL-29 chr18|60985529|G BCL2 nonsynonymous 0.13 2 
tFL-29 chr18|60985529|G BCL2 nonsynonymous 0.331 2 
tFL-31 chr18|60985760|T BCL2 nonsynonymous 0.06 NA 
FL-31 chr18|60985880|A BCL2 nonsynonymous 0.179 NA 
tFL-31 chr18|60985880|A BCL2 nonsynonymous 0.031 NA 
tFL-33 chr18|60985301|G BCL2 nonsynonymous 0.25 2 
tFL-33 chr18|60985626|T BCL2 nonsynonymous 0.19 2 
tFL-36 chr18|60985896|T BCL2 nonsynonymous 0.22 2 
tFL-37 chr18|60985286|T BCL2 nonsynonymous 0.239 4 
tFL-37 chr18|60985884|C BCL2 nonsynonymous 0.32 4 
tFL-38 chr18|60985308|T BCL2 nonsynonymous 0.459 2 
tFL-40 chr18|60795973|A BCL2 nonsynonymous 0.37 2 
tFL-40 chr18|60985798|T BCL2 nonsynonymous 0.42 2 
FL-6 chr6|138200146|G TNFAIP3 nonsynonymous 0.471 0 
tFL-6 chr6|138200146|G TNFAIP3 nonsynonymous 0.542 2 
tFL-21 chr6|138200194|G TNFAIP3 nonsynonymous 0.141 2 
tFL-31 chr6|138192455|T TNFAIP3 stopgain 0.391 NA 
FL-27 chr6|134495706|G SGK1 nonsynonymous 0.15 1 
tFL-28 chr6|134495724|C SGK1 nonsynonymous 0.129 2 
tFL-2 chr16|3786206|C CREBBP splicing 0.33 2 
FL-5 chr16|3807881|A CREBBP stopgain 0.233 NA 
FL-5-cus chr16|3807881|A CREBBP stopgain 0.37 NA 
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tFL-5 chr16|3807881|A CREBBP stopgain 0.529 2 
tFL-5-cus chr16|3807881|A CREBBP stopgain 0.4 NA 
FL-5 chr16|3807917|C CREBBP nonsynonymous 0.213 NA 
FL-5-cus chr16|3807917|C CREBBP nonsynonymous 0.39 NA 
tFL-5 chr16|3807917|C CREBBP nonsynonymous 0.532 2 
tFL-5-cus chr16|3807917|C CREBBP nonsynonymous 0.42 NA 
FL-5 chr16|3808030|C CREBBP nonsynonymous 0.433 NA 
FL-5-cus chr16|3808030|C CREBBP nonsynonymous 0.38 NA 
tFL-5 chr16|3808030|C CREBBP nonsynonymous 0.316 2 
tFL-5-cus chr16|3808030|C CREBBP nonsynonymous 0.42 NA 
FL-5 chr16|3808033|G CREBBP nonsynonymous 0.414 NA 
FL-5-cus chr16|3808033|G CREBBP nonsynonymous 0.38 NA 
tFL-5 chr16|3808033|G CREBBP nonsynonymous 0.333 2 
tFL-5-cus chr16|3808033|G CREBBP nonsynonymous 0.42 NA 
FL-5 chr16|3808046|G CREBBP nonsynonymous 0.333 NA 
FL-5-cus chr16|3808046|G CREBBP nonsynonymous 0.38 NA 
tFL-5 chr16|3808046|G CREBBP nonsynonymous 0.438 2 
tFL-5-cus chr16|3808046|G CREBBP nonsynonymous 0.42 NA 
FL-6 chr16|3786739|G CREBBP nonsynonymous 0.306 2 
tFL-6 chr16|3786739|G CREBBP nonsynonymous 0.333 2 
FL-8 chr16|3828175|C CREBBP stopgain 0.449 NA 
tFL-8 chr16|3828175|C CREBBP stopgain 0.393 NA 
FL-8 chr16|3860683|T CREBBP nonsynonymous 0.512 NA 
tFL-8 chr16|3860683|T CREBBP nonsynonymous 0.396 NA 
FL-10 chr16|3786704|G CREBBP nonsynonymous 0.481 2 
FL-30 chr16|3786704|G CREBBP nonsynonymous 0.35 2 
tFL-10 chr16|3786704|G CREBBP nonsynonymous 0.828 1 
tFL-30 chr16|3786704|G CREBBP nonsynonymous 0.761 1 
FL-11 chr16|3788618|A CREBBP nonsynonymous 0.197 2 
tFL-11 chr16|3788618|A CREBBP nonsynonymous 0.373 2 
FL-12 chr16|3788605|G CREBBP nonsynonymous 0.413 2 
tFL-12 chr16|3788605|G CREBBP nonsynonymous 0.51 2 
FL-12 chr16|3795311|-A CREBBP frameshift_deletion 0.355 2 
tFL-12 chr16|3795311|-A CREBBP frameshift_deletion 0.49 2 
tFL-15 chr16|3788617|T CREBBP nonsynonymous 0.328 2 
FL-22 chr16|3786706|G CREBBP nonsynonymous 0.317 NA 
tFL-22 chr16|3786706|G CREBBP nonsynonymous 0.262 NA 
tFL-23 chr16|3786704|T CREBBP nonsynonymous 0.15 2 
FL-23-1 chr16|3789578|A CREBBP splicing 0.4 2 
FL-23-2 chr16|3789578|A CREBBP splicing 0.18 NA 
tFL-23 chr16|3789578|A CREBBP splicing 0.12 2 
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FL-24-1 chr16|3788618|A CREBBP nonsynonymous 0.761 2 
FL-24-2 chr16|3788618|A CREBBP nonsynonymous 0.789 NA 
tFL-24 chr16|3788618|A CREBBP nonsynonymous 0.661 2 
FL-25-1 chr16|3900873|A CREBBP stopgain 0.21 2 
FL-25-2 chr16|3900873|A CREBBP stopgain 0.31 NA 
tFL-25 chr16|3900873|A CREBBP stopgain 0.25 2 
FL-26-1 chr16|3781333|T CREBBP nonsynonymous 0.31 NA 
FL-26-2 chr16|3781333|T CREBBP nonsynonymous 0.34 2 
tFL-26 chr16|3781333|T CREBBP nonsynonymous 0.4 2 
FL-26-1 chr16|3831211|+C CREBBP frameshift_insertion 0.23 NA 
tFL-26 chr16|3831211|+C CREBBP frameshift_insertion 0.3 2 
FL-27 chr16|3788618|A CREBBP nonsynonymous 0.209 2 
tFL-27 chr16|3788618|A CREBBP nonsynonymous 0.791 2 
FL-31 chr16|3788618|A CREBBP nonsynonymous 0.141 NA 
tFL-31 chr16|3788618|A CREBBP nonsynonymous 0.377 NA 
tFL-34 chr16|3790421|T CREBBP nonsynonymous 0.2 2 
tFL-35 chr16|3790421|T CREBBP nonsynonymous 0.86 2 
tFL-37 chr16|3820888|+GTGCA CREBBP frameshift_insertion 0.45 2 
tFL-39 chr16|3788657|G CREBBP nonsynonymous 0.311 2 
tFL-5 chr17|7577545|C TP53 nonsynonymous 0.378 2 
tFL-5-cus chr17|7577545|C TP53 nonsynonymous 0.833 NA 
tFL-5 chr17|7577598|A TP53 nonsynonymous 0.56 2 
tFL-5-cus chr17|7577598|A TP53 nonsynonymous 0.107 NA 
tFL-22 chr17|7577097|A TP53 nonsynonymous 0.176 NA 
tFL-27 chr17|7578265|G TP53 nonsynonymous 0.63 1 
tFL-29 chr17|7576571|C TP53 stopgain 0.469 2 
tFL-29 chr17|7577093|G TP53 nonsynonymous 0.511 2 
tFL-32 chr17|7578286|G TP53 nonsynonymous 0.371 2 
The first column (Sample ID) indicates the sample in which the mutations were detected. The 
second column (Chromosome| Position |Altered-Base) indicates the coordinates of the 
mutation. The third column indicates the gene altered by the mutation. The fourth column 
indicates the mutation type. The fifth column indicates the variant frequency of the mutation. 
The sixth column indicates the CN estimated for this gene from our previous study; note that all 
CN>3 are shown as 4. NA is noted if we do not have the CN information. 
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APPENDIX C: MUTATIONS IDENTIFIED IN REGIONS OF COPY NUMBER ABNROMALITIES 
rCNA CNAband 
Frequency 
in FLs 
Frequency 
in FLs 
Recurrently mutated genes in our 
cases 
964 18q+ 35% 41%  BCL2 
965 18+ 31% 32%  BCL2 
122 
1p36.33-
p36.31- 
25% 24%  TNFRSF14 
799 7q+ 24% 39%  EZH2, MLL3 
798 7p+ 23% 38%  CARD11 
1012 Xq+ 23% 24%  TAF1 
1011 Xp+ 21% 23%  DMD, DDX3X, HUWE1 
800 7+ 21% 37%  CARD11, EZH2, MLL3 
1013 X+ 20% 19%  DMD, DDX3X, HUWE1, TAF1 
688 1q+ 16% 28%  ARHGEF2, EDEM3 
442 10q23.1-q25.1- 15% 14%  C10orf12 
953 17q+ 15% 13%  STAT3, MIR142, CD79B, BPTF, RNF213 
339 6q- 14% 15% 
 EEF1A1, MDN1, PRDM1, SGK1, 
TNFAIP3, SYNE1 
785 6p+ 14% 18% 
 HIST1H1C, HIST1H1E, HIST1H1D, 
HIST1H2AM, PIM1, CCND3, CUL7 
880 12q+ 13% 20%  MLL2, BTG1, DTX1 
993 21q+ 12% 20%  PRDM15 
711 2p+ 12% 8%  BIRC6, SPTBN1, ALMS1 
762 5p+ 12% 11%  IL7R 
994 21+ 12% 18%  PRDM15 
881 12+ 11% 15%  MLL2, BTG1, DTX1 
593 17p- 9% 18%  TP53, NCOR1 
882 12q12-q13.13+ 9% 10%  MLL2 
763 5q+ 9% 10%  PIK3R1 
304 6q23.3-q24.1- 8% 13%  TNFAIP3 
713 2+ 8% 5%  BIRC6, SPTBN1, ALMS1 
764 5+ 8% 8%  IL7R, PIK3R1 
585 17p13.3-p13.1- 7% 15%  TP53 
341 6q13-q15- 7% 6%  EEF1A1, MDN1 
856 11p+ 7% 16%  HPS5 
37 6q23.3- (x2) 6% 10%  TNFAIP3 
340 6q23.2-q25.1- 6% 10%  SGK1, TNFAIP3 
153 
1p36.33-
p36.12- 
6% 8%  TNFRSF14, SPEN 
857 11q+ 6% 15%  ETS1 
1191 18q+ (x2) 5% 6%  BCL2 
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935 16p+ 5% 8%  CREBBP, SOCS1 
124 1p36.11-p35.3- 5% 5%  ARID1A 
936 16q+ 5% 9%  IRF8, FANCA 
989 20q+ 5% 8%  TM9SF4, SLC9A8 
990 20+ 5% 8%  TM9SF4, SLC9A8 
422 10q24.1- 4% 11%  C10orf12 
543 15q21.1- 4% 11%  B2M 
444 11q24.3- 4% 3%  ETS1 
858 11+ 4% 13%  HPS5, ETS1 
937 16+ 4% 6%  CREBBP, SOCS1, IRF8, FANCA 
974 19p+ 4% 3%  DAZAP1, SMARCA4, MEF2B 
342 6q16.3-q22.33- 4% 4%  PRDM1 
1087 7q+ (x2) 4% 1%  EZH2, MLL3 
839 10q+ 4% 4%  C10orf12 
840 10+ 4% 4%  C10orf12 
976 19+ 4% 3%  DAZAP1, SMARCA4, MEF2B 
714 2p16.3-p14+ 3% 5%  SPTBN1 
769 6p21.2-p21.1+ 3% 1%  CCND3, CUL7 
1014 Xp21.1-p11.1+ 3% 5%  DDX3X, HUWE1 
1078 6p+ (x2) 3% 1% 
 HIST1H1C, HIST1H1E, HIST1H1D, 
HIST1H2AM, PIM1, CCND3, CUL7 
1227 Xq+ (x2) 3% 4%  TAF1 
558 15q- 3% 13%  MGA, B2M 
665 Xp- 3% 4%  DMD, DDX3X, HUWE1 
666 Xq- 3% 5%  TAF1 
733 3q+ 3% 10%  KLHL6 
564 16p13.3- 3% 5%  CREBBP 
787 7p22.3-p21.3+ 3% 8%  CARD11 
966 
18q21.2-
q21.33+ 
3% 4%  BCL2 
1002 22q+ 3% 1%  IGLL5, EP300 
1027 1q+ (x2) 3% 3%  ARHGEF2, EDEM3 
1086 7p+ (x2) 3% 6%  CARD11 
1192 18+ (x2) 3% 0%  BCL2 
1226 Xp+ (x2) 3% 5%  DMD, DDX3X, HUWE1 
605 18q21.33-q23- 3% 4%  BCL2 
667 X- 3% 4%  DMD, DDX3X, HUWE1, TAF1 
732 3p+ 3% 8%  MYD88 
734 3+ 3% 6%  MYD88, KLHL6 
952 17p+ 3% 3%  TP53, NCOR1 
954 17+ 3% 3% 
 TP53, NCOR1, STAT3, MIR142, CD79B, 
BPTF, RNF213 
161 
 
312 6q21- 2% 5%  PRDM1 
1088 7+ (x2) 2% 1%  CARD11, EZH2, MLL3 
1143 12q+ (x2) 2% 0%  MLL2, BTG1, DTX1 
1228 X+ (x2) 2% 3%  DMD, DDX3X, HUWE1, TAF1 
515 13q- 2% 3%  RFXAP, FOXO1 
687 1p+ 2% 1% 
 TNFRSF14, SPEN, ARID1A, RRAGC, 
RBM15 
689 1+ 2% 1% TNFRSF14 
735 3q26.1-q29+ 2% 3%  KLHL6 
898 13q+ 2% 5%  RFXAP, FOXO1 
1042 2p21-p14+ (x2) 2% 1%  SPTBN1 
1122 11p+ (x2) 2% 1%  HPS5 
1144 12+ (x2) 2% 0%  MLL2, BTG1, DTX1 
1203 21q+ (x2) 2% 1%  PRDM15 
1204 21+ (x2) 2% 0%  PRDM15 
561 15q11.2-q21.1- 2% 0%  MGA, B2M 
583 16q- 2% 4%  IRF8, FANCA 
668 Xp22.33-p21.1- 2% 1%  DMD 
801 7p22.3-p21.1+ 2% 1%  CARD11 
919 15q+ 2% 5%  MGA, B2M 
946 17p12-p11.2+ 2% 1%  NCOR1 
968 19p13.3+ 2% 3%  DAZAP1 
1065 5p+ (x2) 1% 3%  IL7R 
1075 
6p21.32-p12.2+ 
(x2) 
1% 0%  PIM1, CCND3, CUL7 
1182 
17p12-p11.2+ 
(x2) 
1% 0%  NCOR1 
119 Xp- (x2) 1% 0%  DMD, DDX3X, HUWE1 
1215 
Xp11.22-q11.1+ 
(x2) 
1% 3%  HUWE1 
1223 Xp11.4+ (x2) 1% 0%  DDX3X 
1229 
Xp11.23-q11.1+ 
(x2) 
1% 1%  HUWE1 
152 1p- 1% 5% 
 TNFRSF14, SPEN, ARID1A, RRAGC, 
RBM15 
223 3q27.1- 1% 1%  KLHL6 
269 4p- 1% 9%  HTT 
343 6p22.2-p21.33- 1% 1% 
 HIST1H1C, HIST1H1E, HIST1H1D, 
HIST1H2AM 
470 11q23.3-q25- 1% 3%  ETS1 
581 16q24.1-q24.3- 1% 0%  FANCA 
653 22q- 1% 1%  IGLL5, EP300 
765 5p11-q13.3+ 1% 0%  PIK3R1 
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854 11q24.3+ 1% 0%  ETS1 
872 12q13.12+ 1% 3%  MLL2 
955 17q22-q24.1+ 1% 1%  MIR142, CD79B 
1007 Xp21.2-p21.1+ 1% 3%  DMD 
1022 
1p36.33-
p36.32+ (x2) 
1% 1%  TNFRSF14 
1066 5q+ (x2) 1% 0%  PIK3R1 
1067 5+ (x2) 1% 0%  IL7R, PIK3R1 
1082 
7p22.3-p22.1+ 
(x2) 
1% 1%  CARD11 
1089 
7p22.3-p21.1+ 
(x2) 
1% 3%  CARD11 
1138 
12q13.12-
q13.13+ (x2) 
1% 1%  MLL2 
1173 16p+ (x2) 1% 0%  CREBBP, SOCS1 
1174 16q+ (x2) 1% 0%  IRF8, FANCA 
1175 16+ (x2) 1% 0%  CREBBP, SOCS1, IRF8, FANCA 
1185 17q+ (x2) 1% 0%  STAT3, MIR142, CD79B, BPTF, RNF213 
120 Xq- (x2) 1% 0%  TAF1 
121 X- (x2) 1% 0%  DMD, DDX3X, HUWE1, TAF1 
154 1p21.1-p12- 1% 5%  RBM15 
155 1q21.1-q23.3- 1% 1%  ARHGEF2 
236 3p- 1% 1%  MYD88 
270 4q- 1% 8%  FBXW7 
271 4- 1% 8%  HTT, FBXW7 
332 6p21.1- 1% 1%  CCND3 
333 6p21.1-p12.3- 1% 1%  CUL7 
469 11q- 1% 0%  ETS1 
493 
12q23.3-
q24.31- 
1% 1%  DTX1 
557 15q15.1-q15.3- 1% 1%  MGA 
562 15q13.1-q22.2- 1% 1%  MGA, B2M 
582 16p- 1% 0%  CREBBP, SOCS1 
619 19p- 1% 1%  DAZAP1, SMARCA4, MEF2B 
621 19- 1% 0%  DAZAP1, SMARCA4, MEF2B 
951 17q22-q24.2+ 1% 1%  CD79B 
985 20q13.13+ 1% 1%  SLC9A8 
100 17p- (x2) 0% 1%  TP53, NCOR1 
1051 3p+ (x2) 0% 1%  MYD88 
1052 3q+ (x2) 0% 1%  KLHL6 
1053 3+ (x2) 0% 1%  MYD88, KLHL6 
1079 
6p25.3-p21.33+ 
(x2) 
0% 3% 
 HIST1H1C, HIST1H1E, HIST1H1D, 
HIST1H2AM 
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108 19p- (x2) 0% 1%  DAZAP1, SMARCA4, MEF2B 
193 2p- 0% 1%  BIRC6, SPTBN1, ALMS1 
237 3q- 0% 3%  KLHL6 
238 3- 0% 1%  MYD88, KLHL6 
274 4p16.3-p15.2- 0% 3%  HTT 
441 10q- 0% 1%  C10orf12 
594 17q- 0% 3%  STAT3, MIR142, CD79B, BPTF, RNF213 
595 17- 0% 3% 
 TP53, NCOR1, STAT3, MIR142, CD79B, 
BPTF, RNF213 
637 20q- 0% 1%  TM9SF4, SLC9A8 
752 4p+ 0% 1%  HTT 
753 4q+ 0% 1%  FBXW7 
754 4+ 0% 1%  HTT, FBXW7 
805 7q33-q36.3+ 0% 3%  EZH2, MLL3 
895 13q13.2-q13.3+ 0% 3%  RFXAP 
 
 
 
 
 
